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Abstract
Abstract
In recent years, polyphosphoinositides, particularly phosphatidylinositol-
4,5-bisphosphate (PI(4,5)P2) and phosphatidylinositol-3,4,5-trisphosphate 
(PI(3,4,5)P3), have become increasingly important due to the discovery that these 
lipids, rather than just having calcium or growth factor signalling functions, play 
key roles in a wide range of other important cellular processes. For this reason, 
their generation and control is tightly regulated by a growing group of enzymes 
that produce them, degrade them or depend on their presence to function.
One of the main enzymes involved in PI(4,5)P2 production is Type I 
phosphatidylinositol 4-phosphate 5-kinase (PI(4)P5K), which generates it by 
phosphorylation of PI(4)P. PI(4,5)P2 is in the central fork of phosphoinositide 
cascades, from where several second messengers are generated. Its production by 
Type I PI(4)P5K is regulated, amongst others, by members of the small GTP 
binding protein family of ADP-ribosylation factors or ARFs. Part of my thesis has 
concentrated on determining the isoform selectivity between ARFs and lipid 
kinases, and the finding that ARF6, the most divergent isoform of the six known 
ARFs, is the preferred regulator. Previous studies have always defended the 
indiscriminate activation by both ARF1 and ARF6. This is the first time that a 
clear preference for ARF6 is proved in vitro and supported in permeabilised cell- 
systems.
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Abstract
The activity of Type I PI(4)P5K has been known to be influenced by the 
presence of certain lipids, which either activate it, phosphatidylserine and 
phosphatidic acid, or inhibit it, as it happens by its own product, PI(4,5)P2.1 have 
found that another important cell signalling lipid, diacylglycerol, is also capable 
of activating the lipid kinase.
Finally, one of the functions of PI(4,5)P2 is the generation of the second 
messenger PI(3,4,5)P3, by the subsequent phosphorylation of the inositol ring by 
phosphoinositide 3-kinases (PI3Ks). This lipid is involved in a very large number 
of crucial events in the cell, such as cell migration, cell survival and phagocytosis, 
amongst others. For the first time, I have found that ARF proteins are also 
involved in the generation of PIP3, by activating one of the four known isoforms 
of PI3K, namely pllOy.
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Introduction
1.1 PHOSPHOINOSITIDES
Eukaryotic cells and their internal organelles such as the endoplasmic 
reticulum, the nucleus or the mitochondria, are surrounded by dynamic 
structures called membranes. These structures are active barriers which delimit 
and compartmentalise the cell and its interior, they can move, its components are 
degraded and resynthesised and they have their own identity and specific 
composition depending on the cell type and organelle. The main components of 
membranes are lipids, primarily phospholipids, cholesterol and sphingolipids. 
But other organic structures add complexity to the lipid bilayer, especially 
proteins and carbohydrates.
But as well as having such crucial structural function, membranes and 
more precisely some of the lipids that compose the bilayer, have other more 
complex and not less vital functions such as being part of the signalling network 
of the cell. From the moment that an external signal arrives to the outer surface of 
the cell until the ultimate stages where the cell responds for example by 
secreting, dividing or locomoting towards or away from a signal, these lipids are 
involved in the transduction of the signalling cascades. Their presence, 
generation and degradation are tightly controlled and myriads of different 
proteins and enzymes depend on them to interact with and transfer onwards the 
message to produce the ultimate biological effect. Some of these lipids are the 
source of second messengers or they are second messengers themselves, i.e. 
diffusible low-weight molecules which relay a signal within the cell. Defects in 
their metabolism can lead to disorders and serious diseases such as cancer.
One of these very important groups of lipids are phosphoinositides (Pis). 
Pis are found in unicellular eukaryotic organisms and thus must have appeared 
quite early in evolutionary terms. They are found in low abundance if compared
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with the rest of phospholipids, between 5 and 10% of total membrane lipids. 
Nevertheless, recognition of their importance has been growing over the last 20 
years since the discovery that they were the origin of the key second messengers 
diacylglycerol (DAG), inositol-1,4,5-trisphosphate (IP3) and phosphatidylinositol-
3,4,5-trisphosphate (PIP3). On the whole, these phospholipids are connected to 
two basic cell physiological events, namely membrane fusion/vesicular transport 
and signal transduction by hormones or neurotransmitters into the cell.
Structure
The structure of the
o
phosphatidylinositol (PI) v/W W W V Ac -° - jHi
molecule is a simple one and no vv\*A s^=,A »/v\c-o-ai ^
more complicated than that of i-
Other phospholipids. It is Figure i.l Structure off the molecule I-
, , , . - stearoyl, 2-arachydonoyl, sn-Glycero-3-
composed of the typical [Phosphoinositol-4,5-bisphosphate]
phospholipid diacylglycerol
backbone, the two acyl chains bound to carbons 1' and 2' of the diacylglycerol, 
and the phosphate group bound to carbon 3' and to the inositol ring forming a 
phosphodiester bond, as seen in Figure 1.1. However, the position and number 
of phosphate groups added to the 5 free hydroxyl groups of the inositol ring 
allows for up to 37 different theoretical conformations. In living cells however, 
only positions 3 , 4 '  and 5' of the inositol ring have been found to be reversibly 
phosphorylated by the combined action of various kinases and phosphatases and 
therefore, 8 different phosphoinositides can be found in cellular membranes. The 
most common phosphoinositide is PI, which constitutes at least 80% of total
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phosphoinositides. PI(4)P and PI(4,5)P2 are next, but they are still only 0.5% of 
total lipids in cellular membranes. The other 5 are PI(3)P, PI(5)P, PI(3,4)P2, 
PI(3,5)P2 and PI(3,4,5)P2 (Rameh and Cantley, 1999; Anderson et al., 1999). The 
last three are especially scarce in cellular membranes, but their levels can rise 
suddenly upon stimulation (Vanhaesebroeck et al., 2001). Figure 1.2 shows the 
different enzymes involved in the sequential phosphorylation and hydrolysis of 
the different phosphate groups that takes place in mammalian cells (Payrastre et 
al., 2001; Takenawa and Itoh, 2001; Abel et al., 2001; Vanhaesebroeck et al., 2001).
R I4K , P IPK  I, II
P I P K I PI3K IPI4K
»
4Pase. Saclp Synaptojanm PTEN
PI(5)P
MTMR, Saclp
I, III
8CIP. Pharttn, Synaptojanin
PI P I P P IP P I P
Figure 1.2 Pathways of phosphoinositides synthesis and interconversion.
The figure shows the pathways for the biosynthesis of the eight existent phosphoinositides and the 
majority of known kinases and phosphatases involved in their generation. Some of the pathways have 
only be proven to take place in vitro but not in vivo.
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General Localisation
Phosphoinositides are found in practically all eukaryotic endomembranes 
(see Table 1.1). Nonetheless, the distribution of Pis in general on the plasma 
membrane is asymmetrical, for it is only on its inner leaflet that these 
phospholipids can be found as individual freely diffusing molecules, like 
phosphatidylserine and the majority of phosphatidylethanolamine (Verkleij and 
Post, 2000).
Yeast Cell (Saccharomyces cerevisiae)
Phospholipid Plasma Mb. ER Vacuole Mitochondrium
PC IB 50 51 40
PE 22 24 21 27
PS 36 9 4 3
PI 19 12 20 15
Mammalian Cell (rat liver)
Phospholipid Plasma Mb. ER Lysosome Golgi Mitochondrium
PC 40 60 48 51 44
PE 24 23 17 21 34
PS 9 2 3 6 1
PI 8 10 6 12 5
Plant Cell (cauliflower, castor and mung bean)
Phospholipid P.Mb. Microsome Chloroplast Peroxisome Tonoplast Mitochond.
PC 47 47 55 54 47 44
PE 35 31 6 29 32 34
PS 8 2 n.d. 2 5 n.d.
PI 5 14 14 10 II 7
Table I . I Lipid composition of subcellular fractions of yeast, mammalian and plant cells.
The table shows the percentage of the four major constituents of living membranes of eukaryotic cells 
against total amount of phospholipids (Daum and Vance, 1997).
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Moreover, the Pl-distribution on the plasma membrane seems to be 
enriched in certain domains known as lipid rafts or caveolae. These 
microdomains have reduced lateral mobility, a chemical composition distinct 
from the rest of the membrane, high in sphingolipids and cholesterol, and 
variable thickness (Binder et al., 2003). They are surface areas abundant in 
molecules involved in intracellular signal transduction, for instance, G-protein 
coupled receptors, Src family tyrosine kinases, and endothelial nitric oxide 
synthase (eNOS) (Smart et al., 1999). An agonist-sensitive pool of Pis, namely 
PI(4)P, PI(4,5)P2 and PI(3,4,5)P3 as well as PA, has been described in these lipid 
microdomains (Pike and Casey, 1996; Liu Y. et al., 1998; Waugh et al., 1998; Bodin 
et al., 2001), although in the case of PI(4,5)P2 at least, this is a controversial 
statement (Watt et al., 2002). The inner leaflet of rafts is enriched in saturated 
phosphoinositides with structural function. However, Pis have almost 
exclusively polyunsaturated acyl chains, 30-80% composed of a stearoyl and 
arachidonoyl fatty acyl pairing in mammalian cells (Mahadevappa and Holub, 
1982; Holbrook et al., 1992). Hence Pis, which are quantitatively minor lipids in 
these microdomains, are not backbone components of rafts but rather signalling 
molecules capable of rapidly interacting and recruiting specific effectors to 
generate a signal.
Functional pools of Pis can also be found in intracellular membranes 
together with their metabolising enzymes. Examples of this can be seen in yeast 
vacuoles, the enzyme VPS35 (yeast PI3K) and the phosphoinositide PI(3)P 
(Odorizzi et al., 2000); the trans-golgi network and PI3K-C2a in mammalian cells 
(Domin et al., 2000), as well as PI4K III and PI(4)P5K, which are recruited to the 
Golgi through an ARF1-dependent mechanism to generate PI(4)P and PI(4,5)P2
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(Godi et al, 1999). PI(3)P and PI(3,5)P2 are selectively concentrated on early and 
late endosomes respectively (Odorizzi et al., 2000; Birkeland and Stenmark, 2004).
Phosphoinositides are also present in the membrane of the nucleus, and 
they go through similar synthesis and hydrolysis processes as they do in the 
other membranes. However, there is another pool of phosphoinositides within 
the nucleus that does not form part of the lipid bilayer and whose metabolism is 
regulated independently from that present elsewhere in the cell. Although these 
Pis generate second messengers such as DAG and IP3, it is becoming increasingly 
clear that in the nucleus Pis may act by themselves to influence pre-mRNA 
splicing and chromatin structure (Martelli et al., 2004). For instance, PI(4,5)P2 has 
been detected in subnuclear domains containing pre-mRNA processing factors 
identified as nuclear speckles, and the absence of membranes in these structures 
suggests that nuclear Pis are actually presented to their metabolising enzymes in 
a non-membranous form, probably bound to proteins (Boronenkov et al., 1998; 
Anderson et al, 1998).
Discrete Localization and Function
Pis are not distributed at random in the cell. Each stereoisomer has a 
unique distribution within cellular membranes and its localisation is spatially 
and temporally controlled, as well as having particular and specific functions 
(Odorizzi et al, 2000). Those Pis directly involved in membrane traffic are 
represented in Figure 1.3.
23
Introduction
Regulated 
exocytosis j
Phagocytosis
VII
SG
PGC
XII
Ph-ly
—  Ptdlns(4)P,
— Ptd!ns(3)P
— PUJIns{4.5)P?
Go®
Complex
Figure 1.3 Phosphoinositide composition of subcellular membranes of the endocytic and 
exocytic pathways.
The numbers represent the different steps involved in each one of the processes. CP -  coated pits', EE -  
early endosome; RE -  recycling endosome; MVB/LE -  multivesicular body/late endosome; Ly -  lysosome; Ph 
-  phagosomes; Ph-ly -  phagolysosome; SG -  secretory granule; PGC -  post-Golgi carrier (De Matteis and 
Godi, 2004).
PI(3)P
Phosphatidylinositol-3-phosphate is principally found in the cytoplasmic 
leaflet of endosomes and of phagosomes, being the most abundant 
phosphoinositide in these internal membranes, around 4% of total lipids. This 
lipid is probably generated on the surface of early endosomes and not on the 
incoming vesicles and this difference may be used to give directionality to the 
fusion reaction and to recruit the endosomal sorting machinery (Roth, 2004). 
Thus, a possible role of PI(3)P would be to identify the destination membrane for 
fusion of incoming vesicles to give directionality to the fusion reaction (Rubino et
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al., 2000). Consistent with this, PI3KIII generates PI(3)P on phagosomes only after 
they have budded off from the plasma membrane, and this is required for them 
to fuse with lysosomes (Vieira et al, 2001).
PI(3)P is also involved in receptor signalling and microbial killing through 
the recruitment and activation of a number of effector proteins. These effectors 
interact with this lipid via their PX domain, which is mainly PI(3)P-binding 
although it also binds PI(3,4)P2 and PI(4,5)P2, and FYVE domains, which bind 
PI(3)P exclusively (Birkeland and Stenmark, 2004).
Other functions include serving as precursor for the synthesis of PI(3,4)P2 
and PI(3,5)P2 by PIPKs I and II (Rameh et al, 1997; Zhang et al, 1997; Tolias et al, 
1998a).
PI(4)P
Phosphatidylinositol-4-phosphate is one of the most abundant Pis, 
constituting 93% of total cellular monophosphate derivatives of 
phosphatidylinositol (PIP) in NIH3T3 cells, against 5% of PI(3)P and 2% of PI(5)P 
(Rameh et al, 1997). It is particularly abundant in the Golgi, where it accounts for 
the majority of present Pis, around 5% of total lipids (Roth, 2004). PI(4)P is the 
main precursor of PI(4,5)P2 synthesis. In yeast, membrane traffic through the 
Golgi requires PI(4)P generated by Pik4 and does not require PI(4,5)P2 (Audhya 
et al, 2000). In mammalian cells, PI(4)P functions in maintaining Golgi structure 
both directly and through conversion to PI(4,5)P2, probably by recruiting 
cytoskeleton to Golgi membranes, by targeting the AP-1 adaptor protein 
complex, and by maintaining the flux of membrane moving through the 
organelle (Wang et al, 2003).
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PI(5)P
Phosphatidylinositol-5-phosphate has been one of the last Pis to be 
discovered and due to its low levels and difficulties on determining its presence 
and relative abundance, its functions are still not absolutely clear. However, 
there is now enough preliminary evidence to confirm that it is a signalling 
molecule in its own right. Its levels have been reported to increase in platelets in 
response to thrombin stimulation (Morris et al., 2000), and to decrease in mouse 
3T3-L1 fibroblasts and adipocytes upon hypo-osmotic shock (Sbrissa et al., 2002). 
PI(5)P has also been reported to exist and function in the nucleus (Clarke et al., 
2001). The PHD finger of the tumour suppressor ING2, a motif common in many 
chromatin-regulatory proteins, specifically interacts with PI(5)P and was 
proposed to function as a nuclear PI(5)P receptor to regulate nuclear responses to 
DNA damage (Gozani et al., 2003). Finally PI(5)P has also been identified as a 
novel key intermediate for insulin signalling in F-actin remodelling and GLUT4 
translocation (Sbrissa et al., 2004).
PI(3.4)P2
Phosphatidylinositol-3,4-bisphosphate is mostly found in the plasma 
membrane, but it is also present in multivesicular bodies and in the nuclear 
envelope (Watt et al., 2004). This bisphosphate derivative of phosphatidylinositol 
(PIP2) is generated in cells by two opposing pathways: D5 dephosphorylation of 
PI(3,4,5)P3 by SHIP1 and SHIP2 (Leslie et al., 2001) and D3 phosphorylation of 
PI(4)P by Class II PI3K (Rameh and Cantley, 1999) or D4 phosphorylation of 
PI(3)P. In an integrin-signalling pathway in platelets, PI(3,4)P2 was found to be 
generated from PI(3)P by an unidentified phosphoinositide 4-kinase 
independently of PI(3,4,5)P3 (Banfic et al., 1998), and also upon induction of
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peroxide-induced oxidative stress (Gray et al, 1999; van der Kaay et al, 1999). 
PI(3,4)P2 seems to be involved in the activation pathway of PKB/Akt. Both PKB 
and PDK1 (a kinase which phosphorylates PKB on Thr308 to fully activate it) 
bind to PI(3,4)P2 and PI(3,4,5)P3 with similar affinities in vitro, albeit it is not clear 
which one of the two is involved in their activation in vivo. A third undetermined 
kinase, termed PDK2, has been reported to also bind to PI(3,4)P2 and hence 
phosphorylates PKB on Ser473 and activate it in conjunction with PDK1 (Scheid 
et al, 2002). PI(3,4)P2 levels have also been found to rise due to oxidative stress, 
with the consequent activation of PKB (van der Kaay et al, 1999).
PI(3,5)P2
Phosphatidylinositol-3,5-bisphosphate was first discovered in yeast 
subjected to osmotic shock and then detected in mammalian cells (Dove et al, 
1997; Whiteford et al, 1997). Fabl in yeast and PIKfyve in mammals are the 
PI(3)P5Ks in charge of the production of PI(3,5)P2. The invagination of 
multivesicular endosomes (MVE) and late endosomes requires the production of 
PI(3,5)P2 (Odorizzi et al, 1998, 2000). PI(3)P, and presumably PI(3,5)P2, 
incorporated into the internal vesicles of MVEs is hydrolysed when these vesicles 
are transferred to the lumen of lysosomes or the yeast vacuole (Wurmser and 
Emr, 1998). This PI is also involved of the recruitment of myotubularin to the late 
endosomal compartment, and it is involved in epidermal growth factor receptor 
trafficking from late endosome to lysosome (Tsujita et al, 2004).
PI(4,5)P2
Phosphatidylinositol-4,5-bisphosphate has been shown to be maintained 
at relatively constant levels in cells (McLaughlin et al, 2002), but some agonists 
for cell surface receptors such as growth factors and components of the
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extracellular matrix cause rapid but modest changes in cellular PI(4,5)P2 content 
(Auger et al, 1989; Weemink et al, 2000). This lipid second messenger is mainly 
found in the plasma membrane (Balia T. and Vamai, 2002; Meyer and Teruel, 
2003) but it is also present in several other cellular organelles such as the 
endoplasmic reticulum, the nuclear envelope or the Golgi apparatus (Watt et al, 
2002; Balia and Vamai, 2002). Since the discovery that PI(4,5)P2 was the precursor 
of the second messengers DAG and IP3 some twenty years ago, a plethora of 
different functions have been discovered which imply that this particular 
polyphosphoinositide is involved in membrane traffic, the arrangement of the 
actin cytoskeleton and several other processes which are summarised hereafter.
Precursor of Second Messengers. Hydrolysis of PI(4,5)P2 by the phospholipase C 
family, on the perception of suitable stimulus, generates the two second 
messengers DAG and IP3. DAG is involved in the activation of protein kinase C 
(PKC), via binding to its Cl domain. PKC actively participates in a diversity of 
signalling pathways that control cell proliferation, differentiation, survival, 
transformation and apoptosis (see PKC section). Nonetheless, DAG also 
participates in the activation of several other proteins containing the same 
binding domain, such as RasGRPl, DGKa, p and y, Muncl3-1, PKD and others 
(Brose and Rosenmund, 2003). IP3 is responsible for a transient increase in 
intracellular free Ca2+ (Nishizuka et al, 1986; Berridge and Irvine, 1989).
Another very important second messenger is PI(3,4,5)P3 which is generated in 
response to extracellular signals by Class I PI3Ks by D3-phosphorylation of 
PI(4,5)P2 (Hawkins and Jackson, 1992; Rameh and Cantley, 1999).
Regulation of the Actin Cytoskeleton. Actin remodelling is directly or indirectly 
involved in many vital cell functions, such as maintenance of modulation of cell 
shape, motility, cytokinesis, the formation of filopodia, lamellipodia, membrane
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ruffles and phagosomes, endo and exocytosis, mRNA localization and growth 
regulation (Doughman et al., 2003a). The actin cytoskeleton has also been 
implicated as both a target and a mediator of signal transduction initiated 
through receptor tyrosine kinases and extracellular matrix-integrin systems 
(Hsuan et al., 1998). The activities of many factors involved in regulating the 
dynamics of actin filaments are controlled by PI(4,5)P2. PI(4,5)P2 causes the 
dissociation of G-actin from actin-monomer-binding proteins, as well as the 
uncapping of the actin filament barbed ends; in addition, it enhances both actin 
filament crosslinking and the linkage of actin filaments to the plasma membrane 
and modulates the activity of some of these proteins by inducing conformational 
changes or regulating their interaction with other cytoskeletal or membrane 
proteins (Sechi and Wehland, 2000). The most important ones are:
a. Profilin. This protein functions by sequestering actin monomers as a complex 
termed profilactin. PI(4,5)P2 disrupts this interaction, allowing for actin 
polymerisation at sites of high PI(4,5)P2 concentration. It also binds PI(3,4)P2 
and PI(3,4,5)P3 (Lassing and Lindberg, 1988; Lu et al, 1996).
b. Gelsolin. PI(4,5)P2 has also been proposed to promote actin polymerisation by 
interfering with the binding of capping proteins to filament ends. The actin 
severing/capping protein gelsolin is displaced from the barbed ends of actin 
filaments by the phosphoinositide, permitting rapid actin polymerisation 
(Hartwig et al., 1995; Barkalow et al., 1996). Gelsolin belongs to a Ca2+- 
regulated family of F-actin/binding proteins, which includes villin, severin, 
CapG and scinderin. These proteins are also known to be regulated by PIPs 
and PIP2 by an antagonistic mechanism to Ca2+ (Hsuan et al., 1998).
c. Vinculin. Involved in focal adhesions, PI(4,5)P2 disrupts the existing 
intramolecular interaction between the head and tail domains of vinculin,
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resulting in the exposure of its actin, a-actinin, talin, paxillin, VASP, ponsin, 
vinexin and PKC binding sites (Bailly, 2003). Past studies have revealed that 
vinculin plays a central role in mechanical coupling of integrins to the 
cytoskeleton, as well as in the control of cytoskeletal mechanics, cell shape, 
protrusion amplitude and cell motility. Vinculin could be the long-sought 
missing link that bridges the adhesion scaffold and the actin polymerisation 
machinery in the focal complexes, thus specifically targeting actin 
polymerisation to the leading edge of the cell to sustain lamellipodia 
extension (Critchley, 2000).
A clear example for the involvement of PI(4,5)P2 in focal adhesions is the 
specific localisation of PI(4)P5Ky to these structures, where it binds to the 
FERM domain of talin, as P-integrin does by mediation of PI(4,5)P2. Talin is a 
component of focal adhesions that couples p-integrin cytodomains to F-actin, 
as well as providing a scaffold for signalling proteins (di Paolo et al, 2002; 
Ling et al, 2002; Barsukov et al, 2003).
d. WASP/N-WASP and ERM Proteins. WASP, and its more widely expressed 
homologue N-WASP, have emerged as central node proteins that regulate 
actin polymerization in response to multiple upstream signals. PI(4,5)P2 
provokes conformational changes in the protein that in synergy with Cdc42, 
induce actin assembly. This output activity of N-WASP is mediated through 
the actin-related protein 2/3 (Arp2/3) complex, a seven-protein complex 
capable of stimulating actin filament nucleation (Sechi and Wehland, 2000; 
Prehoda and Lim, 2002). ERM proteins act in a very similar way to WASP 
proteins, where interaction with PI(4,5)P2 also activates the protein by 
inducing conformational changes and localises it to the plasma membrane. 
They also work in synergy with a small G protein, Rho, which influences the
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phosphorylation state, activation and localisation of ERM proteins at the 
plasma membrane. ERM proteins interact with membrane components such 
as CD44, CD43 and intercellular adhesion proteins (ICAMs). Because of their 
ability to bind F-actin in vitro, ERM proteins have been considered bona fide 
candidates for mediators of interactions between the actin cytoskeleton and 
the plasma membrane (Sechi and Wehland, 2000).
Exocytosis. PI(4,5)P2 has been found to be necessary for Ca2+-dependent
regulated exocytosis both in neuro-endocrine cells and in haematopoietic cells.
a. Neuro-endocrine cells. There are two types of vesicles in these mammalian 
cells which store neurotransmitters, chemical mediators and peptide 
hormones: dense core secretory granules and synaptic vesicles. PITPa and 
PI(4)P5Ky have been purified as cytosolic factors that can prime the cells for 
subsequent stimulation with Ca2+ and successive exocytosis of the first type of 
granules, in conjunction with a secretory granule-resident PI4K (Hay et al., 
1995; Wiedemann et al., 1996). Two proteins that contain two Ca2+-binding C2 
domains, synaptotagmin and rabphilin 3A, an effector of the small GTPase 
Rab3A, can bind PI(4,5)P2 in a Ca2+-dependent manner, and it is envisaged 
that this interaction, along with interaction with SNARE molecules involved 
in the docking/fusion process, are responsible for the exocytosis of synaptic 
vesicles (Cockcroft and de Matteis, 2001).
b. Haematopoietic cells. Cells of the immune system are capable of secreting 
proteins, cytokines and histamine readily upon detection of infectious agents. 
Degranulation in mast cells and neutrophils is dependent not only on a rise of 
intracellular levels of Ca2+ but also on the presence of a small G protein, 
identified as ARF (Fensome et al., 1996; Way et al., 2000) or Rab3D (Roa et al, 
1997; Tuvim et al., 1999). ARF, and also PITP, seem to trigger secretion by
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increasing the levels of PI(4,5)P2, both directly by activating PI(4)P5K and 
indirectly by activating PLD, which in turn produces PA, a reported in vitro 
activator of Type I PI(4)P5Ks (Cockcroft and de Matteis, 2001).
Endocytosis. Clathrin-mediated endocytosis is the major pathway for selective 
internalization of plasma membrane receptors and their bound ligands. Both the 
coat assembly and the endocytic vesicle release depend on PI(4,5)P2. The adaptor 
proteins AP2 and API80, which are needed for clathrin assembly, both bind 
PI(4,5)P2, as well as other clathrin adaptors such as epsin, H ipl/H iplR  and 
ARH/Dab. Some adaptors also bind to PI(3,4,5)P3 (Wenk and de Camilli, 2004). 
Other proteins involved in such process are the large GTPase dynamin, which 
also binds PI(4,5)P2 and AP2 and provides the machinery for the fission of the 
vesicle and the membrane (Schmid et al., 1998), and the 5-phosphatase 
synaptojanin 1, which dephosphorylates PI(4,5)P2 (and PI(3,4,5)P3) and also binds 
AP2 and clathrin and interacts via its COOH-terminal targeting domain with 
several proteins with direct or indirect roles in endocytosis (Wenk and de 
Camilli, 2004).
Control of the Golgi Complex. The amount of PI(4,5)P2 in the Golgi is nine fold 
lower than at the plasma membrane (Watt et al, 2002). None of the PI(4)P5Ks 
have ever been visualised in this cellular compartment, but there is evidence of 
an associated PI(4)P5K activity associated which elevates PI(4,5)P2 levels (Godi et 
al, 1999; Jones D.H. et al, 2000; Siddhanta et al, 2000). There are three proposed 
functions for PI(4,5)P2 in the Golgi complex that seem to be mediated by the 
control of spectrin and actin machineries: ER-to-Golgi transport (Godi et al, 
1998), formation and release of post-Golgi transport intermediates and a role in 
maintaining its structural integrity and function (Siddhanta et al, 2000; Sweeney 
et al, 2002). PI(4,5)P2 might also be involved in the membrane fission process by
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means of dynamin or PLD, producer of the fission-promoting lipid PA (Kozlov, 
2001). What is clear is that the control of PI(4,5)P2 levels in the Golgi are under 
the control of ARF proteins, which recruit PI4K(3 and PI(4)P5K to the Golgi 
membrane. Furthermore, ARF activates PI(4)P5Ks directly and indirectly 
through the activation of PLD, whose activity is PI(4,5)P2-dependent and whose 
catalytic product, PA, is in turn an activator of PI(4)P5Ks. ARF itself can interact 
with PI(4,5)P2 (Terui et al.f 1994; Randazzo et al., 1997) and PA (Manifava et al,
2001). Moreover, some ARF-GEFs and GAPs are capable of interacting with 
PI(4,5)P2 and PI(3,4,5)P3. All these enzymes acting together would provide an 
extremely powerful spatially and temporally controlled mechanism to increase 
PI(4,5)P2 levels rapidly in selected membrane domains (de Matteis et al, 2002).
Other functions. PI(4,5)P2 regulates the direction of the axonal transport of 
mitochondria (de Vos et al., 2003). PI(4,5)P2 generation in the nucleus by both 
Type I and II PIPKs is linked to regulation of gene expression, pre-mRNA 
processing and mRNA export (Boronenkov et al., 1998; Anderson et al., 1999; 
York et al., 1999).
PI(3,4,S)P}
Phosphatidylinositol-3,4,5-trisphosphate is produced by phosphorylation 
of PI(4,5)P2 by Class I PI3Ks (Heath et al., 2003). PI(3,4,5)P3 is transiently 
generated in response to stimuli and is mostly found at the plasma membrane 
(Cantley, 2002). The generation of this second messenger triggers a plethora of 
functions, most of which are summarised under the Class I PI3K functions 
section.
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1.2 PHOSPHOINOSITIDE KINASES
There are three families of phosphoinositide kinases that phosphorylate 
the inositol ring in the three different positions that can be found in nature: 3-, 4- 
and 5-kinases.
Phosphoinositide 3-Kinases -  PI3Ks
Phosphatidylinositol 3-kinases are responsible for the addition of a 
phosphate group to the D3 position of the inositol ring, generating PI(3)P, 
PI(3,4)P2, PI(3,5)P2 and PI(3,4,5)P3. They all share a catalytic core with PI4Ks and 
the protein kinases target of rapamycin (TOR, also known as FRAP), ATM (the 
gene product mutated in the human disorder ataxia telangiectasia) and the 
catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) (Wymann and 
Pirola, 1998; Vanhaesebroeck et al., 2001). They are divided in three classes, as 
seen on Table 1.2.
Class I PI3Ks
There are four different isoforms divided in two subclasses, IA and IB. 
They are all heterodimers composed of a so-called p i 10 catalytic subunit and a 
regulatory subunit, p85, p55 or p50 in the case of IA and plOl in the case of IB.
Members. Class IA is composed of three different isoforms of the p i 10 catalytic 
subunit, a, p and 5. Class IB is composed of one sole isoform, pllOy, which was 
cloned in 1995 by Stoyanov et al There are at least 7 regulatory subunits 
generated by expression and alternative splicing of three different genes, namely 
p85a (p55a and p50a), p85p, and p55y for class IA enzymes (Wymann et al,
2003). Class IB has one regulatory subunit, plOl, with no similarity to any other 
known protein (Stephens et al, 1997).
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PI3K
Class Enzyme 
pllOa
pi top 
pi 105 
IB pi lOy 
PI3K-C2a
PI3K-C2y
PI3KIII
MW
123(110)
123(119)
119(115)
120(110)
170/210
PI3K-C23 '80
171
101
Regulatory
subunits
p85a
p55a
p50a
p85p
p55y
plOl
pISO
Localisation
Cytosol 
Plasma Membrane
Clathrin-coated pits 
Plasma Membrane 
Microsomal Fractions 
Nucleus
Golgi and Endosomes
Substrate-^Product
P I(4,5)P2-> P I(3 ,4 ,5 )P j
PI-*PI(3)P  
PI(4)P-*PI(3,4)P2 
PI(5)P->PI(3,5)P2 (only class IA)
PI->PI(3)P
PI(4)P-*PI(3,4)P2 
PI(4,5)P2->PI(3,4,5)P3 
(only in the presence of PS)
PI->PI(3)P
Table 1.2  PI3K isoforms and properties.
The table shows the 3 different subfamilies of PI3Ks and the catalytic and regulatory subunits within 
each one. The molecular weight (MW) represents the predicted value in kDa of the different catalytic 
subunits, and in parentheses the observed value from SDS-PAGE migration studies. The first 
substrate->product pair in bold corresponds to  the observed specificity in vivo; the rest are from in vitro 
studies with no proof of them occurring in living cells.
Substrates. Class IA enzymes are able to phosphorylate PI, PI(4)P, PI(5)P and 
PI(4,5)P2 in vitro (Rameh et al, 1997; Fruman et al, 1998). p i 10y phosphorylates 
the same substrates in vitro except for PI(5)P. However, when these kinases are 
stimulated in vivo by either surface receptors or Ras, only increases in PI(3,4)P2 
and PI(3,4,5)P3 are registered, and PI(3,4)P2 is thought to be the product of a 5- 
phosphatase acting on PI(3,4,5)P3 rather than that of a direct phosphorylation 
reaction (Carpenter and Cantley, 1990).
Expression, pi 10a and pllOP are ubiquitously expressed in mammalian tissues, 
where pll05 is predominantly found in leukocytes (Vanhaesebroeck et al, 1997). 
pllOy is expressed highly in cells of haematopoietic origin and is present at low
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concentrations in endothelia, smooth muscle cells and cardiomyocytes (Wymann 
et al., 2003).
Localisation. They are thought to be mainly cytosolic under basal conditions, 
although they become membrane associated upon stimulation (Guillam et al, 
1999; Brock et al., 2003).
Structure. All Class I PI3Ks catalytic subunits contain an internal C2 domain, a 
Ras-binding domain, a PI kinase accessory/helical domain and a catalytic kinase 
domain, as illustrated in Figure 1.4. Class IA enzymes also contain a p85-binding 
domain. The Class IB enzyme has an adaptor-binding site for p i01 and two Py
CATALYTIC SUBUNITS
C lass IA 
pi 10a/p/8 
C lass IB 
pi lOy 
O a s s l l  
PI3K-C2a/p/y
C lass III 
Vps34p analog
REGULATORY SUBUNITS
C lass IA
p85a/p Q r. 
C lass IB
plOl  -------
C lass III 
pi 50
5 ™myr
PI3K Catalytic Core 
Helical 
C2 Domain 
RBD
p85B/AdB Domain
PX Domain 
Py Interaction Site
SH3 Domain 
Proline-rich 
Rho GAP Domain 
|  SH2 Domain 
p85B/AdB Domain
Figure 1.4  Diagrammatic representation of the domain structure of PI3K isozymes.
The catalytic subunits of Class I enzymes are com posed of p85-binding/adaptor-binding domain (Class 
IA/IB), Ras-binding domain (RBD), PKC homology domain 2 (C2), PI3K accessory domain and catalytic 
core domain which interacts directly with ATP, PI(4,5)P2 and wortmannin. pi IOy has tw o additional Py 
interaction sites. Class II enzymes lack an AdB site but possess additional phox (PX) and C2 domains. 
Class III enzymes share the PI3K catalytic and accessory domains, as well as one C2 domain. The Class 
IA regulatory subunits possess one Src homology 3 (SH3) and tw o Src homology 2 (SH2) domains, in 
addition to  a Rho-GAP domain and tw o proline rich regions. The Class IB regulatory subunit, plOl ,  has 
no resemblance to  any other know protein structure. The Class III regulatory subunit has a PI3K 
catalytic core, a WD-40 domain and an N-terminal myristate.
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Activation loop
Kinase Domain 
C-lobe
Helical
N-terminal linker Domain
C2 Domain
Kinase Domain 
N-lobe
ATP
Figure 1.5  Crystallographic structure of p 11 Oy.
Crystal structure of pi I Oy (porcine p 11 Oy with ATP; PDB code IE8X), w here the different domains 
have been coloured for clarity as in Figure 1.4: Red -  Kinase Domain N-lobe, Yellow -  Kinase Domain 
C-lobe, Black -  Activation loop, Purple -  Ras Binding Domain, Green -  Helical Domain, Blue -  C2 
Domain.
interaction sites.
Class IA catalytic subunits p85a and p and p55y are all composed of two 
SH2 domains, a pi 10-binding domain and a proline reach domain. Additionally, 
the p85 subunits contain another proline rich domain, an SH3 domain and a Rac- 
binding domain (Deane and Fruman, 2004).
The structure of pllOy has been resolved with the exclusion of the N- 
terminal regions that bind the adaptor protein pi 01 as seen in Figure 1.5. Its 
structure is very similar to that of protein kinases, although the nucleotide- 
binding loop is different in that it lacks the consensus glycine-rich GxGxxG 
sequence motif (Walker et al, 1999). The structure of pllOy together with the
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small G protein Ras has also been resolved (not shown), showing that this 
interaction takes place through the Ras-binding domain as well as the C-terminal 
lobe of pllOy. The interaction occurs with the switch 1 and 2 regions of Ras and 
causes an allosteric activation of PI3K (Pacold et al, 2000).
Function. The generation of PI(3,4,5)P3 upon reception of different stimuli is 
responsible for the recruitment to the plasma membrane and activation of 
enzymes involved in multiple cellular functions. Some of these proteins, which 
bind the polyphosphoinositide through their PH domain, include protein kinase 
B (PKB/Akt), phosphoinositide-dependent kinase 1 (PDK1), guanine nucleotide 
exchange factors (GEFs), protein tyrosine kinases of the Tec family such as 
Bruton's tyrosine kinase (BTK), PLCy and many more. Each one of these enzymes 
is responsible of triggering multiple cellular responses. Activation of PKB/Akt 
implies binding to this polyphosphoinositide and subsequent phosphorylation of 
the enzyme by PDK1 on Thr 308. Maximal activation requires phosphorylation of 
Ser473 by an activity called PDK2, the nature of which is controversial. PKB has a 
broad range of substrates (Brazil and Hemmings, 2001). Activation of PKB and 
PDK results in the counteraction of apoptosis so promoting cell survival. They 
also regulate the activity of the nutrient sensor TOR, which together with PDK1 
promote transcription, translation, and glucose uptake, all necessary for cell 
growth prior to cell division (Wymann et al, 2003). Proliferation is also 
controlled by PKB-dependent inactivation of glycogen synthase kinase 3p (GSK- 
3p), which leads to a rise in cyclin D1 and entry into the cell cycle. Motility is 
also dependent on the recruitment of GEFs for different small G proteins onto the 
plasma membrane by binding to PI(3,4,5)P3; these in turn recruit the GTPases, 
such as Rac and Cdc42, which are involved in the rearrangement of the actin 
cytoskeleton and migration. All these signals provide the mechanisms that
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render cells tumourigenic and malignant, making their understanding a key 
factor in the fight against cancer (Vivanco and Sawyers, 2002). PI(3,4,5)P3 
generation is also crucial in immunological responses; translocation of Tec family 
kinases such as Btk or phospholipases like PLCy, is instrumental in increasing the 
generation of DAG. In turn, DAG activates PKCs, which along with a rise in 
intracellular calcium concentration due to IP3, together induce clonal-selection 
processes in B and T cells and also mediate degranulation in mast cells and other 
granulocytes (Fruman and Cantley, 2002). This is a clear demonstration of the 
type of signalling crosstalk that inositol lipid metabolism controls in mammalian 
cells.
Each p i 10 isoform has specific unique functions within the cells. For instance, 
pllOy is essential in neutrophil and lymphocyte function, as deduced from 
knock-out approaches in mice (Cantrell, 2001). Mice lacking p85a are not viable 
but p85a-lacking B cells are functionally deficient whereas T cells seem 
completely normal. In macrophages, p i 10a is required for mitogenic responses 
triggered by colony-stimulating factor 1 (CFS-1), whereas pllOp and 8 are 
necessary for CSF-1 induced modulation of actin dynamics (Vanhaesebroeck et 
al, 1999).
PI 3-kinase also exhibits protein kinase activity which is involved in activation of 
the MAPK cascade (Bondeva et al., 1998).
Regulation. The activation of Class IA PI3Ks is dependent on the recruitment of 
the catalytic subunit p i 10 by the adaptor subunit p85. The adaptor subunit is in 
turn recruited by binding of its SH2 domains onto tyrosine-phosphorylated 
residues with consensus pYxxM, downstream of receptor tyrosine kinases or 
RTKs, their substrates or associated adaptor proteins. This recruitment gives 
pllO access to its lipid substrate (Gillham et al, 1999); and the contact of p85 with
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the tyrosine-phosphorylated receptor induces a conformational change of p85 
that results in dishinibition of pllO enzymatic activity (Yu et al., 1999).
On the other hand, the sole Class IB enzymatic complex, plOl/pllOy, is recruited 
to the plasma membrane through interaction with the py-subunits of 
heterotrimeric G proteins. These subunits are dissociated from the heterotrimer 
upon activation of G protein-coupled receptors, p i01 is thought to be responsible 
for the recruitment of pllOy upon release of Py-subunits (Brock et al, 2003). 
Interaction with GTP-bound Ras is proposed to induce conformational changes 
and membrane reorientation of the lipid kinase in relation to its substrate, further 
increasing its activity. Although p i01 and Ras contribute to PI3Ky activation, the 
sequence of actions and the quantitative contribution of PI3Ky-interacting 
proteins in physiological processes need further elucidation. PI3Ky-py-pl01-Ras 
interaction leads to massive production of PtdIns(3,4,5)P3 (Wymann et al, 2003).
Class II PI3Ks
Members. So far three members of this subfamily of PI3Ks have been identified, 
PI3K-C2 (Class IIPI3K) a, p and y.
Substrates. In vitro substrates include PI and PI(4)P, and PI(4,5)P2 exclusively in 
the presence of PS (Domin et al, 1997).
Expression. The a  and p isoforms are ubiquitously expressed; PI3K-C2y is found 
in hepatocytes, and a N-terminal truncated form was found in lung and a certain 
haematopoietic cell line (Misawa et al, 1998).
Localisation. Class II enzymes are mostly associated with the plasma membrane 
and with the low-density microsomal fraction (Vanhaesebroeck et al, 1999). 
PI3K-C2a has been reported to localise in clathrin-coated structures at the 
plasma membrane and TGN (Domin et al, 2000; Gaidarov et al, 2001) and also in
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the nucleus together with PI3K-C2(3 (Didichenko and Thelen, 2001; Sindic et al., 
2001).
Structure. Class II PI3Ks are large, 170-210 kDa, monomeric enzymes containing 
an internal C2 domain, Ras-binding domain, PI kinase homology domain and 
kinase domain, which are highly similar (45-50%) to those in Class IB 
(MacDougall et al, 1995). These PI3Ks also have another C2 domain and PX 
domain in their N-terminus (Fruman et al., 1998). This C2 domain can bind in 
vitro to phospholipids in a Ca2+-independent manner. The N-terminal regions 
contain a Ras binding domain, although there is no evidence of binding to this 
small G protein (MacDougall et al., 1995).
Function. Despite much investigation this is not clear.
Regulation. Their activity and location are thought to be regulated by 
extracellular stimuli; indeed, increases in lipid kinase activity from PI3K 
immunoprecipitates have been seen to be induced upon stimulation with insulin, 
epidermal growth factor, platelet-derived growth factor, integrin binding and 
chemokines (Vanhaesebroeck et al., 2001).
Class III PI3Ks
Members. Only one isoform of this class has been found, present from yeast to 
mammals. It is the homolog of the yeast Vps34p (Odorizzi et al, 2000).
Substrates. The only substrate it can phosphorylate is PI to generate PI(3)P in 
vivo.
Localisation. It is localised to endocytic vesicles (Stephens et al, 2002).
Structure. Like class II enzymes, they contain the internal C2 domain, PI3K 
catalytic core and helical domain.
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Function. This kinase is involved in protein and vesicle trafficking, as well as 
trafficking processes unique to immune cells, especially phagocytosis (Stephens 
et al., 2002).
Regulation. Both yeast and mammalian isoforms are regulated by interaction 
with a serine/threonine kinase and Vpsl5p or p i50 respectively, which are N- 
terminal myristoylated. This serves as a mechanism for targeting the lipid kinase 
to membranes (Panaretou et al, 1997). The constant levels of PI(3)P in cells 
suggest for a control mechanism of this class of PI3Ks independent of cellular 
stimulation, being most probably constitutively activated (Vanhaesebroeck et al.,
2001).
Phosphoinositide 4-Kinases - Pi4Ks
Phosphatidylinositol 4-kinases add a phosphate group to the D4 position 
of the inositol ring, directly generating PI(4)P. There are several PI4K isoforms 
(Table 1.3) whose activity must be strictly regulated, as other phosphoinositide 
kinases depend on the availability of the D4-phospho-stereoisomer to generate 
other Pis, mainly PI(4,5)P2 and PI(3,4,5)P3 (Fruman et al, 1998).
PI4K
Enzyme MW Yeastortholog Localisation
Substrate-*
Product Biochemical Properties
PI4Ka
II 55 PIK2(LSB6)
Endosomes
PI-*PI(4)P
- Inhibited by Adenosine and Ca2+
- Low Km for ATP and PI
PI4K P P.Mb./Golgi/ER - Wortmannin insensitive
PMKa
III
230 STT4 ER
PI-*PI(4)P
- Insensitive to Adenosine and Ca2+
-High Km for ATP and PI
- Sensitive to wortmannin ICso50- lOOnM
PI4K P 93 P1KI Golgi LY294002ICso 50-l00pM
Table 1.3 PI4K isoforms and properties.
The table shows the 2 different subfamilies of PKKs, their molecular weight (MW) in kDa, cellular 
localisation, phosphorylating-substrate and product and biochemical properties.
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Type II PI4Ka
Type II PI4Ks are the major contributors to cellular PI(4)P in response to 
extracellular signal transduction (Fruman et al, 1998). They are membrane 
associated enzymes inhibited by adenosine (K i < 50 pM) and Ca2+, that exhibit 
lower Km values for ATP and PI and which are insensitive to wortmannin and 
LY294002 (Balia T., 1998; Fruman et al., 1998). The single yeast homolog of 
mammalian PI4KIIs is PIK2 (LSB6) (Shelton et al., 2003).
Type II PI4Ka is membrane associated through a palmitoylation site in the 
centre of the 55 kDa protein (Barylko et al., 2001). It is located at the Golgi and at 
synaptic membranes (Guo et al, 2003; Wang et al, 2003). The enzymes product, 
PI(4)P, as well as serving as a precursor of PI(4,5)P2, is involved in membrane 
traffic from the fnws-Golgi network as it is required for membrane transport to 
the plasma membrane (Wang et al, 2003), and in the exo-endocytic cycle of 
synaptic vesicles (Guo et al, 2003). Some of this activity is thought to arise 
because API-containing clathrin coats recognise and bind PI(4)P.
Type IIP14K0
Type II PI4Kphas a high degree of similarity with type Ila in its C- 
terminal catalytic domain, but greater divergence in its N-terminus (Balia A. et 
al, 2002). This isoform is cytosolic and is recruited primarily to the plasma 
membrane and activated by Racl-GTP, although it can also be found at the Golgi 
and ER. PI4KIIp is activated strongly by membrane association to stimulate 
PI(4,5)P2 synthesis at the plasma membrane (Wei et al, 2002).
Type III PI4Ka/STT4
In yeast, mutants of STT4 do not affect the secretory pathway but disrupt 
actin remodelling. The mammalian isozymes contain a PH domain for
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membrane binding (Wong and Cantley, 1994) and several domains for protein- 
protein interaction and nucleic acid binding domains. Potential phosphorylation 
sites in PI4KIIIa suggest regulatory function of PKA, PKC, caseine kinase II and 
protein tyrosine kinases (Gehrmann et al, 1999).
Type III PI4KJ9/PIKI
In yeast, PI(4)P generated by this inositide kinase has been proposed to be 
involved in secretory pathway trafficking (Balia T. et al., 1998) and in Golgi to 
plasma membrane transport (Walch-Solimena and Novick, 1999). PIK1 is not 
sensitive to wortmannin. Both mammalian and yeast isozymes behave as soluble 
proteins; hence, their membrane association must be tightly regulated. Indeed, 
PI4KIIIp has been localised to the Golgi where is recruited by the GTPase ARF 
(Godi et al, 1999).
Phosphatidylinositol Phosphate Kinases -  PIPKs
Three different subfamilies of phosphatidylinositol x-phosphate y-kinases 
have been reported and they have been grouped by the similarity of their 
conserved kinase domains. Initially, all the kinases in this group were thought to 
use PI(4)P as a substrate to generate the important second messenger and 
promoter of second messengers PI(4,5)P2. However, later studies have 
demonstrated that even though they share homology in their catalytic domains, 
they use different substrates to generate PIP2 and they have diverse localisation 
and functions within cells.
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Enzyme 
PI(4)P5K a
PI(4)P5K P
PI(4)P5K y
PI(5)P4K a
PI(5)P4K p
PI(5)P4Ky
PIKfyve
MW 
56/61/62 (68)
61/57(68)
69/72/75
(87/90/-)
47(53)
235
Yeast
MSS4
FAB I
PIPK
Localisation
Plasma Mb. 
Nucleus 
Golgi 
Focal adhesions
Cytosol
Nucleus
ER
Actin cytoskeleton 
Late endosomes
Substrate->Product
PI (4)P-*P I (4 ,5) P2
PI-*PI(5)P  
PI(3)P->PI(3.4)P2 
PI(3)P-*PI(3,5)P2 
PI (3)P -*PI (3,4.5)P} 
PI(3,4)P-»PI(3,4,5)P3
PI(5)P->P I(4,5)P2
P I(3 )P -pPI(3.4)P2
PI(3)P-*PI(3,4,5)P3
PI(3)P->P I(3,5)P2
PI-*PI(5)P
Functions
- Actin reorganisation
- Secretion
- Endocytosis: receptor- 
mediated and trafficking
- Apoptosis
- Ion channel regulation
- Uncertain
- Membrane trafficking
Table 1.4  PIPK isoforms and properties.
The table shows the three types of PIPKs with the different isoforms within each group. The molecular 
weight (MW) represents the predicted value in kDa of the different existent splice variants, and in 
parentheses the observed value from SDS-PAGE migration studies. The first substrate->product pair in 
bold corresponds to  the observed specificity in vivo; the rest are from in vitro studies with no proof of 
them occurring in cells.
Type I PI(4)P5Ks -  Genuine PI(4)P5Ks
These kinases were the ones that originally gave name to the whole 
family.
Substrates. Out of the three subfamilies known to date, Type I PI(4)P5Ks are the 
only ones that genuinely use PI(4)P as a substrate to produce PI(4,5)P2 in vivo. 
However, they seem to be more promiscuous in vitro, where at least 5 different 
phosphorylation reactions using different substrates have been reported as seen 
in Table 1.4 (Hinchliffe et al, 1998a). The only other one of those reactions that 
has been detected in vivo is the phosphorylation of PI(3,4)P2 to generate 
PI(3,4,5)P3 by Type I PI(4)P5K in cells exposed to oxidative stress (Halstead et al,
2001).
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M embers. The subfamily is composed of three different isoforms and several 
splice variants of each one of them. PI(4)P5Ka and p were first cloned by Ishihara 
et al. (1996) from a cDNA library of the murine pancreatic p-cell line MIN6, and 
later the same group cloned the y isoform (1998) using the same cDNA library. 
There are three splice variants of the human a  isoform (which corresponds to 
murine PI(4)P5KP due to a long-standing divergence in nomenclature that has 
never been corrected), namely ai, 012 and 0 3 , all with slightly different molecular 
weights, and two of the human p isoform (murine PI(4)P5Ka), pi and p2 (Loijens 
et al., 1996b; Carvajal et al, 1996). Three different splice variants of PI(4)P5Ky 
(also murine PI(4)P5Ky) have been reported so far: PI(4)P5Ky661, PI(4)P5Ky635 
and PI(4)P5Ky688 (Ishihara et al, 1998; Giudici et al, 2004). Recently, a PI(4)P5K 
homolog with no apparent kinase activity has been identified and named PIPKH. 
It heterodimerises with other PI(4)P5Ks, acting as a scaffold to localise and 
regulate PI(4)P5Ks and the synthesis of PI(3,4,5)P3; its presence provokes 8-fold 
increases in total PI(3,4,5)P3 without significantly altering PI(4,5)P2 levels (Chang 
et al., 2004).
Expression. Type I PI(4)P5Ks are found in plants, yeast and mammalian cells. 
PI(4)P5Ka is mainly expressed in skeletal muscle, and it is also present in heart, 
placenta, kidney and pancreas. Low levels were reported in brain, liver and lung. 
PI(4)P5KP is also present in most tissues examined except for liver. It is especially 
abundant in heart and moderately expressed in brain and pancreas (Loijens and 
Anderson, 1996a). PI(4)P5Ky661 is widely expressed, being most preferentially 
found in kidney, lung and, in higher amounts, in brain (Ishihara et al., 1998; 
Wenk et al., 2001). PI(4)P5Ky635 is less broadly distributed and is hardly 
detectable in brain and testis, whereas the PI(4)P5Ky688 transcript is exclusively
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detected in brain (Giudici et al, 2004). PIPKH is expressed at relatively high 
levels in brain and testis (Chang et al., 2004).
Localisation. Type I PI(4)P5Ks are principally localised at the plasma membrane, 
in the Golgi, in the nucleus and at focal adhesions. Moreover, their subcellular 
distribution seems to vary depending on the isoform. Endogenous human 
PI(4)P5Ka (mouse (3) can be found in the nucleus where it associates with nuclear 
speckles (Boronenkov et al, 1998), in membrane ruffles, dependent upon 
association with Rac and/or ARF6 (Honda et al., 1999; Doughman et al., 2003b), 
and on the plasma membrane during phagocytosis (Botelho et al., 2000; 
Coppolino et al., 2002). Human PI(4)P5Kp (mouse a) is present in a vesicular 
perinuclear region (Doughman et al., 2003a). PI(4)P5Ky661 is targeted to focal 
adhesions by its 26-amino acid C-terminus. PI(4)P5Ky635 is also located at the 
plasma membrane but not in these specialised adherence domains, for it lacks 
the extreme 26 amino acids of its N-terminus which are required for such 
interaction (di Paolo et al., 2002; Ling et al., 2002).
Structure. PI3Kinases and PI4Kinases share some statistically significant 
sequence similarity, but PIPKinases do not have any strong sequence homology 
with the other two groups of PI kinases (Heath et al., 2003). Nevertheless, the 
crystallisation of Type II PI(4)P5Kp (or PI(5)P4Kp) and mutation analysis have 
revealed that they share some structural features with other kinases, such as 
activation loops and putative nucleotide binding sites with conserved catalytic 
residues that bind ATP and Mg2+; all this implies that there is a common 
phosphotransfer mechanism and that structurally, the phosphoinositide kinases 
all belong to a superfamily (Ishihara et al., 1998; Rao et al., 1998; Kunz et al., 2000,
2002). The activation loop of Type I and II PIPKs has a dual role in substrate 
specificity and in promoting membrane association. Using site-directed
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mutagenesis studies, Kunz et al. (2002) demonstrated that a single amino acid 
change was capable of swapping the stereo-specific substrate recognition of the 
type I and II PIPKs, as well as their subcellular membrane targeting. This means 
they can swap between utilising PI(4)P or PI(5)P to generate PI(4,5)P2. Recently, 
Arioka et al (2004) have shown how the presence of dibasic residues at the C- 
terminal end of the kinase homology domain, particularly the dibasic Arg-Lys 
sequence, is necessary and sufficient for the proper localization and cellular 
function of PIP5Ks. These residues are conserved among mammalian as well as 
invertebrate PIP5K family members, but not in the type II PIPKs that are not 
targeted to the plasma membrane.
The kinase domain of PI(4)P5Ks is comprised of around 400 amino acids located 
centrally and with 70-80% similarity amongst the three proteins, 40% identity
Homo sapiens 
PI(4)P5K
Homo sapiens
PI(5)P4K
Saccharomyces cerevisiae 
Mss4p
Saccharomyces cerevisiae 
Fab Ip
Arabidopsis thaliana 
PI(4)P5K
Figure 1.6 Diagrammatic representation of the kinase homology domain of PIPKs of 
Homo sapiens, Saccharomyces cerevisiae and Arabidopsis thaliana.
The kinase homology domain of PIPKs is represented in blue. The kinase domain, except in Fab Ip 
homologs, is separated by an insert region, represented in white.. The activation loop is part of the 
second half of the sequence of the homology domain. Although statistically there is no great global 
similarity with other kinases, there are local similarities in the conserved sequence motifs characteristic 
of protein (and lipid) kinases . For example, glycine-rich motif (GXSGS) G-Loop in the homologs 
resembles the same phosphate-binding loop of protein kinases and other ATP-binding proteins.
G-Loop Activation Loop
lnSCrt I ---
405
z i t m -
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Figure 1.7 Alignment of amino acid sequences for PIPKs of different species.
Identical residues are in red and similar are in blue. The abbreviations used and the GenBank protein 
accession numbers are as follows. PI(4)P5Kor. Type I phosphatidyl inositol 4-phosphate 5-kinase a 
Homo sapiens (AAC509I0); PI(5)P4Kor. Type II phosphatidyl inositol 4-phosphate 5-kinase a Homo 
sapiens (AAC509I0) PIKfyve: Type III phosphatidylinositol 4-phosphate 5-kinase Homo sapiens 
(P53807); Mss4p: Mss4p Saccharomyces cerevisiae (NP 010494); PPKI: Pip Kinase protein I 
Caenorhabditis elegans (AAB54I30); Arabidopsis: phosphatidylinositol 4-phosphate 5-kinase Arabidopsis 
thaliana (AAB82658). The tw o fragments of the Kinase Homology domain are coloured in blue, and 
the insert lies in between the tw o sequences. Fragments in green correspond to  regions of identity 
(structural regions are labelled). Alignment was generated by ClustalW (www.ebi.ac.uk/clustalw) and 
the printing of the multiple alignment output was performed by Boxshade 
(www.ch.embnet.org/software/ BOX_form.html). Domain determination was generated using CDD 
(Marchler-Bauer et al., 2003).
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only between the N-terminus of ip and Iy and 67% overall between a  and p (see 
Figures 1.6 and 1.7). The kinase core domain shares only 40% identity with 
PIPKIIa (Ishihara et al, 1998).
Function. The functions of PI(4)P5K enzymes are directly linked to those of 
P(4,5)P2. The controlled local generation of PI(4,5)P2 in places of actin 
remodelling, endocytosis, exocytosis, phagocytosis, focal adhesions, ion 
channels, and others is generally dependent on the recruitment and activation of 
Type I PI(4)P5Ks. In the case of actin dynamics and vesicular trafficking, there 
are several studies that demonstrate that there is a direct link between the two 
processes, and both are modulated by Type I PI(4)P5K isoforms (Doughman et 
al., 2003a). Early studies by Hay et al. (1995) identified Type I PI(4)P5K as one of 
the proteins necessary for regulated exocytosis, and thus, its immunodepletion 
resulted in both a decrease in vesicle priming and PI(4,5)P2 synthesis. Type I 
PI(4)P5Ks also play a role in endosomal vesicle trafficking (Galiano et al., 2002), 
and an early role in internalisation during receptor-mediated endocytosis. 
Different studies have shown that the truncation of the N-terminus of PI(4)P5K, 
which is equivalent to using a kinase-dead mutant, results in the blockage of 
endocytosis, allowing colony stimulating factor-1 receptor or the EGFR to remain 
at the plasma membrane. This occurs by blockade of the recruitment of clathrin 
light chain and dynamin to the plasma membrane (Cochet et al., 1991; Davis et 
al., 1997; Barbieri et al., 2001). PI(4)P5K is also involved in neurite remodelling in 
response to a number of diverse stimuli (van Horck et al., 2002; Yamazaki et al.,
2002) and regulation of axonal elongation and branching downstream of ARF6 
and ARNO (Hemandez-Deviez et al., 2004), amongst several other functions.
Regulation. The activity of Type I PI(4)P5Ks can be regulated by different factors, 
summarised in Figure 1.8.
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Figure 1.8  Regulation of PI(4)P5K enzymes by lipids, protein-protein interaction 
and de/phosphorylation mechanisms.
Phosphoinositide phosphatases have been excluded for simplicity.
a. Lipids. Type I PI(4)P5Ks are activated by PS (Cochet and Chambaz, 1986) and 
PA in vitro (Moritz et al., 1992; Jenkins et al, 1994; Ishihara et al, 1996, 1998) 
and inhibited by its own product PI(4,5)P2 (Moritz et al, 1992). The extent of 
the activation, which varies between 2-fold and 20-fold, is extremely 
dependent on the composition of the lipid vesicles and the origin of the lipid 
kinase; so much indeed that in the presence of PC these effects can be 
completely abolished (Jones D.H. et al, 2000). However, no direct activation 
in vivo has ever been demonstrated. There are contradictory reports that give 
evidence of this regulation (Ameson et al, 1999; Jones D.R. et al, 2000; 
O'Luanaigh et al, 2002; Skippen et al, 2002) or absence of such an activation
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in living cells (Godi et al., 1999; Jones D.H. et al., 2000). Generally, these 
reports are based on the measurement of changes in PI(4,5)P2 levels subject to 
the activation or inactivation of a PA-generating enzyme in cells, 
phospholipase D (PLD). Type I PI(4)P5Ks have also been found to be 
inhibited by arachidonic acid in rat submandibular gland cells (Chung and 
Fleming, 95).
b. Protein-protein Interaction. PI(4)P5Ks have been shown to interact with several 
different proteins that regulate their localisation or activation. They interact 
with the cytoplasmic tails of the EGFR (epidermal growth factor receptor) 
and thus regulate its internalisation (Cochet et al., 1991). A Type I PI(4)P5K 
associates with autophosphorylated PKD/PKCp (protein kinase D/protein 
kinase p), and this association may facilitate localisation of the PIPK to the 
Golgi membrane (Nishikawa et al., 1998). PLD is also capable of associating 
and recruiting PI(4)P5Ka, providing a local source of the critical PLD- 
activator PI(4,5)P2 (Divecha et al, 2000). Another lipid kinase which has been 
reported to associate with PI(4)P5K is DGK£ (diacylglycerol kinase Q. They 
both co-localise with actin in lamellipodial protrusions, supporting the idea 
that a DGK can generate PA in order to locally activate PI(4)P5K and thus 
increase PI(4,5)P2 levels, which in turn control actin polymerisation (Luo et al,
2004). PI(4)P5Ky661 interacts with and becomes strongly activated by talin, a 
principal component of focal adhesion plaques that is also present in neurons, 
suggesting a direct involvement of the PI(4)P5K in cell adhesion and synaptic 
junctions (di Paolo et al, 2002; Ling et al, 2002). BTK (Bruton's tyrosine 
kinase), a member of the Tec family of cytoplasmic protein tyrosine kinases, 
associates with PI(4)P5Ks upon B cell receptor activation, bringing PI(4)P5K 
to the plasma membrane as a means of generating local PI(4,5)P2 synthesis.
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This protein-protein interaction allows BTK to stimulate the production of the 
substrate required by both its upstream activator, PI3K, and its downstream 
target, PLCy2 (Saito et al, 2003).
As Type II PIPKs do, Type I PI(4)P5Ks also form dimers, and possibly 
oligomeric protein complexes thanks to the presence of two independent 
dimerisation domains found within murine Type I PI(4)P5Kp (Galiano et al.,
2002).
Finally, a crucial method of regulation of Type I PI(4)P5Ks is interaction with 
small G proteins. This type of regulation will be described separately in 
section d.
c. Phosphorylation. There is ample evidence of regulation of Type I PI(4)P5Ks by 
phosphorylation by different protein kinases, which overall has an inhibitory 
effect on their activity. In Schizosaccharomyces pombe, a Type I-like PIPK was 
shown to be phosphorylated and inhibited in vitro by the casein kinase I 
homologue Ckil and overexpression of this kinase reduces the cellular levels 
of PI(4,5)P2 (Vancurova et al., 1999). Autophosphorylation of Type I PIPKs 
has been demonstrated to be another way of downregulating their activity. 
Itoh et al. (2000) showed how in the presence of ATP and Mg2+ (and specially 
enhanced by the presence of PI), PI(4)P5K(3 autophosphorylates on serine 
residues and subsequent phosphatase treatment is able to increase its 5- 
kinase activity. LPA stimulation of Type I PI(4)P5Ks has been shown to 
directly correlate with PPl-mediated dephosphorylation of the enzyme upon 
PKC activation (Park et al., 2001). These authors also suggested that PKA 
might be responsible for the initial phosphorylation event, as treatment of 3T3 
cells with the PKA inhibitor, H89, but not with other protein kinase 
inhibitors, was able to reduce the resting phosphorylation of P(4)P5Kp. Wenk
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et al. (2001) have also reported that the major neuronal PI(4)P5Ky isoform 
undergoes dephosphorylation upon depolarisation of synaptosomes, which 
induces an increase in phosphoinositide turnover, although no correlating 
change in activity has been shown. PI(4)P5Ky661 also becomes tyrosine 
phosphorylated by FAK (focal adhesion associated kinase) signalling, 
increasing both its activity and its association with talin, although it is not 
clear whether the increase in activity is due directly to the phosphorylation or 
indirectly to the increased association with talin (Ling et al, 2002).
d. Small G proteins. Members of the Rho family of small G proteins, particularly 
Rho and Rac, and also members of the ARF family are involved in actin 
dynamics and vesicle trafficking, and so is PI(4,5)P2, by modulating signal 
transduction pathways and the activity of multiple actin-binding proteins. 
Therefore, a correlation between action of these small G proteins and PIPK 
activity exists and evidence shows that their direct interaction modulates the 
intracellular targeting of PI(4)P5Ks as a way of controlling the spatial 
production of PI(4,5)P2.
Rho, a small G protein involved in the assembly of actin stress fibres and 
focal adhesion (Ridley and Hall, 1992), has been shown to interact with all 
three isoforms of PI(4)P5K in a GTP-independent manner and promote 
PI(4,5)P2 synthesis in cells (Ren et al, 1996; Weemink et al, 2004). The 
activation of PI(4)P5K by Rho seems to be dependent upon the Rho effector 
ROCK (Rho kinase), independently of phosphorylation (Oude Weemink et 
al, 2000; van Horck et al, 2002; Yamazaki et al, 2002; Weemink et al, 2004) 
and it seems conceivable that the effect of Rho on PI(4)P5K rather than 
directly activating the kinase is its recruitment to specific cellular 
compartments (Chatah et al, 2001; Weemink et al, 2004). Both Rho and ROCK
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are responsible for the recruitment of the lipid kinase and regulation of the 
assembly of the actin cytoskeleton upon thrombin-stimulation in platelets 
(Yang et al, 2004). In contrast, there is one report in the literature where the 
activation of PI(4)P5K by Rho is independent of ROCK (Matsui et al, 1999). 
Rac, mediator of growth factor-induced membrane ruffling and lamellipodia 
formation, has also been found to interact with all PI(4)P5K isoforms in a 
GTP-independent manner and promote PI(4,5)P2 synthesis in cells (Tolias et 
al, 1995, 1998a, 1998b, 2000; Weemink et al, 2004). Moreover, Tolias and 
colleagues found that PI(4)P5K associated with the small GTPase in 
conjunction with a DGK, possibly the C, isoform, forming a lipid kinase 
signalling complex. The apparent independence of the activation state of both 
Rac and Rho (GTP- or GDP-bound) during association with PI(4)P5K, points 
at a binding-region outside the switch regions that normally undergo 
conformational rearrangements upon nucleotide changes. Indeed, in the case 
of Rac this region is located in the C-terminus and is necessary and sufficient 
for binding to both lipid kinases (Tolias et al, 1998b). As with Rho, it seems 
likely that the effect of Rac on the lipid kinase has more to do with 
localisation than with activation (Tolias et al, 2000b; Weemink et al, 2004). 
Cdc42 has also been reported to stimulate the production of PI(4,5)P2 in cells, 
but no direct physical interaction takes place between the two proteins 
(Weemik et al, 2004).
ARF proteins are another family of small G proteins that interact and activate 
PI(4)P5Ks. As these GTPases are the main focus of this thesis, an in depth 
revision of their characteristics and properties will be carried out on the 
following section. Regarding their interaction with Type I PI(4)P5Ks, there 
was evidence of the influence of ARF proteins in the generation of PI(4,5)P2 in
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cells before the finding that ARF specifically stimulated PI(4)P5K activity 
(Fensome et al., 1996; Martin et al., 1996; Godi et al., 1999). In 1999, Honda et al. 
demonstrated that ARF was capable of activating PI(4)P5Ka in the presence 
of PA, observation that has later been corrected, for the presence of the 
anionic lipid is not required (Jones D.H. et al., 2000). In some cases, the 
cellular increase in PI(4,5)P2 synthesis seems to occur by the coordinated 
activation of both PI(4)P5K and PLD (Honda et al., 1999; Skippen et al., 2002; 
O'Luanaigh et al., 2002), which is also activated by ARF proteins, generating a 
positive feedback loop since each enzymes product is an activator of the other 
one (Jenkins et al., 1994; Powner and Wakelam, 2002). However, in other 
examples it has been shown that the PA generated by PLD does not influence 
the activation of PI(4)P5K by ARF (Jones D.H. et al., Godi et al, 1999; 
Lawrence et al., 2003). Hence, this still remains a contentious subject that has 
not been resolved. Moreover, Type I PI(4)P5K has been proven to function 
and be recruited to plasma or endosomal membranes downstream of ARF6 
(Honda et al., 1999; Brown et al., 2001; Krauss et al., 2003; Aikawa and Martin,
2003) or of an unidentified ARF to Golgi membranes (Godi et al., 1999). In the 
case of membrane ruffling induced by EGF stimulation, the generation of 
PI(4,5)P2 at the plasma membrane is essential and ARF6 seems to be 
responsible for the co-translocation of PI(4)P5K(3 and PLD2 both by Racl- 
dependent and independent mechanisms; nevertheless, a Racl-dependent 
ARF6-independent pathway also seems to be required for the membrane 
ruffling to occur (Honda et al., 1999). In terms of the association of ARF and 
PI(4)P5Ks, two contradictory reports state that either ARF6, exclusively in the 
GTP-bound form (using the constitutively active mutant ARF6(Q67L)), pulls 
down PI(4)P5Ky from rat brain lysates but not GDP-bound ARF6
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(ARF6(T27N) mutant) or GTP-bound ARF1 (ARF1(Q71L) mutant) (Krauss et 
al, 2003). Conversely, HA-tagged PI(4)P5Ky pulled down wild type ARF6, 
ARF6(Q67L) or ARF6(N122I) (another GTP-binding deficient mutant) equally 
from cotransfected PCI 2 cells lysates, and even more effectively after 
provoking an intracellular Ca2+ influx with the consequent PKC activation 
and the apparent dephosphorylation of the lipid kinase (Aikawa and Martin,
2003). This study concluded that interactions between ARF6 and PI(4)P5Ky 
appear to be governed principally by the phosphorylation state of PI(4)P5Ky 
rather than the guanine nucleotide-bound state of ARF6.
Type II PI(4)P5Ks -  PI(5)P4Ks
Substrates. Initially these enzymes were thought to be PI(4)P5Kinases, but later 
on Rameh et al. (1997) showed that the real substrate was not PI(4)P but PI(5)P, 
and therefore Type II PI(4)P5Ks were truly PI(5)P4Ks. In vitro, they are also 
capable of using PI(3)P as a substrate to generate PI(3,4)P2 and PI(3,4,5)P3 
(Hinchliffe et al, 1998a). It is unclear at present whether PI(5)P or PI(3)P is the 
main physiological substrate of Type II PIPKs, although a PI(3)P4Kinase activity 
in human platelets, though still unidentified, has been shown not to be a Type II 
PIPK (Banfic et al, 1998).
Members. As with Type I enzymes, there are three isozymes in this subfamily. 
The human Type Ila was first cloned in 1995 (Boronenkov and Anderson, 1995; 
Divecha et al, 1995), whereas the (3 isoform was identified through a yeast 2- 
hybrid screen with the juxtamembrane region of the p55 tumour necrosis factor- 
a  receptor (Castellino et al, 1997). The rat y isoform was cloned by Itoh et al 
(1998).
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Expression. This subfamily of PIPKinases is only found in metazoans. PI(5)P4Ka 
is found ubiquitously although the highest levels of expression are in brain 
(Boronenkov and Anderson, 1995). PI(5)P4Kp can be found in all tissues but its 
levels are specially higher in skeletal muscle, and again in brain and heart 
(Castellino et al., 1997). The y isoform is predominantly expressed in kidney, with 
low expression in almost all other tissues (Itoh et al., 1998).
Localisation. Both PI(5)P4Ka and p are cytosolic enzymes, and the p isoform can 
also be found in the nucleus (Heath et al., 2003). PI(5)P4Ky localises 
predominantly in the endoplasmic reticulum (Itoh et al, 1998).
Structure. In 1998, Rao et al. crystallised and resolved the structure of PI(5)P4Kp 
at 3A, the only member of the PIPKinases whose structure has been determined. 
As depicted on Figure 1.9, this isoform forms a disc-shaped homodimer, through 
interactions of its N-terminus, and its structure suggests that an electrostatic 
mechanism is involved in membrane targeting.
The three isoforms share 60% sequence similarity in their kinase domains. Apart 
from forming homodimers as seen in the determination of the structure of 
PI(5)P4Pp, PI(5)P4Pa has been also shown to form heterodimers with all three 
isoforms of Type I PI(4)P5K, causing its relocation to the plasma membrane 
(Hinchliffe et al, 2002).
Function. The function of these PIPKinases is poorly understood. Type II PIPKp 
interacts with the p55 TNF receptor in mammalian cells and thus may play a role 
in TNFa-mediated signalling (Castellino et al, 1997). Since PI(4)P levels in cells 
far exceed those of PI(5)P (Rameh et al, 1997), the activity of PI(5)P4K would be 
unlikely to make a major contribution to bulk levels of PI(4,5)P2. Hinchliffe et al. 
(1999b) hypothesised three possible functions for Type II PIPKs. The first is that 
they act as PI(3)P4Ks to produce PI(3,4)P2. The second is that they are present to
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Figure 1.9
Crystallographic 
structure of a 
human PI(5)P4KP 
dimer (PDB
I BO I).
Sagittal and normal 
projections relative 
to  the presumed 
plane of the 
membrane. The 
flattened interface of 
the dimer (inferior 
surface of bottom 
projection/front) to 
interact with
membranes (the 
membrane would be 
underneath the 3D 
structure). The 
bottom view is the 
same but turned 
upside down.
clear PI(5)P by transforming it into PI(4,5)P2. And the third possibility is that they 
are responsible for the control of a specific pool of PI(4,5)P2 by being involved in 
a minor production pathway.
Type II PIPK has been shown to participate in MgATP-dependent, Ca2+-triggered 
a-granule secretion from platelets, its translocation to the plasma membrane 
being mediated by PKC (Rozenvayn and Flaumenhaft, 2001, 2003).
Regulation. Unlike Type I PI(4)P5Ks, Type II PIPKs are not stimulated by PA 
(Loijens et al., 1996a) or regulated by any small G protein (Hinchliffe et al, 1998a). 
One mode of regulation seems to be by phosphorylation of the lipid kinase by 
different protein kinases, including casein kinase II and two other
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serine/threonine kinases (Hinchliffe et al., 1998b, 1999a, 2000; Huang et al, 2001). 
There is also evidence of the degradation of Type II PIPKs by the 
calcium/stimulated protease calpain in thrombin/stimulated platelets (Hinchliffe 
et al., 1999b). A PI(5)P4K also associates with autophosphorylated PKCp as 
PI(4)P5K does (Nishikawa et al., 1998) and in platelets, PKC mediates the 
translocation of Type II PI(5)P4K that potentially leads to the recruitment of 
PI(4,5)P2-binding proteins, implying a direct involvement of the Type II PIPKs in 
Ca2+-induced platelet a-granule secretion (Rozenvayn and Flaumenhaft, 2001,
2003).
Type III PI(4)P5Ks -  PI(3)P5Ks
Substrates. From complementation studies using yeast cells lacking Fablp, 
which has been shown to be a PI(3)P5K responsible for vacuole morphology 
(Cooke et al., 1998), it is known that transfection of the yeast cells with PIKfyve 
and not Type I PIPKs can restore basal PI(3,5)P2 synthesis (McEwen et al., 1999). 
PIKfyve is also involved in the synthesis of PI(5)P in a osmotic response pathway 
in mammalian cells (Sbrissa et al., 2002).
Members. The sole member of this subfamily of PIPKs was cloned in 1999 by 
Shisheva et al. from a murine adipocyte cDNA library, and it has been termed 
p235, in reference to its molecular weight, or PIKfyve, due to the presence of an 
N-terminal zinc-binding FYVE finger.
Expression. Studies at the protein level reveal a widespread distribution among 
cells and tissues. Differentiated 3T3-L1 adipocytes in culture express the highest 
protein levels among the cells examined (Shisheva, 2001).
Localisation. The mammalian Type III PIPKs localise to vesicles of the late 
endocytic pathway, through interaction of their FYVE domain with PI(3)P.
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However, other molecular factors placed at post-endosomal compartments must 
also determine PIKfyve localization, because PIKfyve is undetectable on 
recycling or early endosomes (Shisheva, 2001).
Structure. Mouse and human PIKfyve harbor several evolutionarily conserved 
domains with functional significance, including a Zn2+/PI(3)P~binding FYVE 
finger, a DEP domain of unknown function found in signaling proteins that 
contain a PH domain, a chaperonin-like region found in proteins implicated in 
actin and tubulin folding, and a putative catalytic domain found in PI4Ks and 
PIP5Ks. In fact, PIKfyve belongs to an evolutionary ancient gene family 
represented by a single-copy gene identified thus far in S. pombe, S. cerevisiae, C. 
elegans, A. thaliana, D. melanogaster, M. musculus and H. sapiens (Shisheva et al, 
1999), as PI(4)P5Ks do.
Function. These PI(3)P5Ks play a role in membrane trafficking and their 
enzymatic activity is required to maintain cell morphology by regulating late 
endocytic membrane homeostasis (Shisheva et al, 1999; Ikonomov et al, 2002; 
Sbrissa et al, 2002).
Regulation. PIKfyve possesses a protein kinase activity and so it is capable of 
trans- and autophosphorylation, resulting in inhibition of its 5-kinase activity 
(Sbrissa et al, 2000).
61
Introduction
1.3 ADP-RIBOSYLATION FACTORS
ARF proteins are part of the Ras superfamily of small G proteins. This 
superfamily is composed of the Rho, Rab, ARF and Ras subfamilies, together 
with the closely related Ga subfamily. Each one of these subfamilies can in turn 
be divided into several branches; the ARF subfamily is subdivided into ARF 
proteins, ARP (ARF-related proteins), ARL (ARF-like proteins) and ARD 
proteins (ARF-domain proteins), as well as a another group of proteins distantly 
related to ARF, Sar or Sara proteins. The ARF subfamily comprises at least 30 
different members in mammals, 13 in C. elegans and 12 in D. Melanogaster, 
indicating that this is a highly conserved family of proteins in eukaryotes with a 
high degree of expansion (Colicelli, 2004).
ARFs were initially named after their activity as cofactors for cholera 
toxin-catalysed adenosine diphosphate-ribosylation of the heterotrimeric G 
protein Gas (Kahn and Gilman, 1986).
Members
To date, 6 different ARF proteins have been identified in mammals, 
termed ARF1 through 6, and are classified in three different classes according to 
their amino acid sequence similarity. Class I comprises ARFs 1, 2 and 3, Class II 
ARF4 and ARF5 and Class III only ARF6 (Moss and Vaughan, 1995). See Figure 
1.10 for a sequence alignment of 2 human isoforms and all the mouse isoforms.
Expression and Localisation
The levels of expression vary depending on the isoform, ARF1 and ARF3 
being expressed 3 to 10-fold above those of ARF4-6. All isoforms are expressed in 
all tissues (Cavenagh et al., 1996). ARF1 has higher levels of expression in kidney,
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fr iPTIG FN V El
ARF1 human 1 MGNIFANLFKGLFGKKEMRILMVGLDAAGKTTILYKLKLGEIVTTIPTIGFNVETVEYKN
ARF1 mouse 1 MGNIFANLFKGLFGKKEMRILMVGLDAAGKTTILYKLKLGEIVTTIPTIGFNVETVEYKN
ARF2 mouse 1 MGN VFEKLFKSLFGKKEMRILMVGLDAAGKTTILYKLKLGEIVTTIPTIGFNVETVEYKN
ARF3 mouse 1 MGNIFGNLLKSLIGKKEMRILMVGLDAAGKTTILYKLKLGEIVTTIPTIGFNVETVEYKN
ARF4 mouse 1 MGLTISSLFSRLFGKKQMRILMVGLDAAGKTTILYKLKLGEIVTTIPTIGFNVETVEYKN
ARF5 mouse 1 MGLTVSALFSRI FGKKQMR ILMVGLDAAGKTTILYKLKLGEIVTTI PT IGFNVETVEYKN
ARF6 mouse 1 MG KVLSKIFGNKEMRILMLGLDAAGKTTILYKLKLGQSVTTIPTVGFNVETVTYKN
ARF6 human 1 MG KVLSKI FWNKEMRILMLGLDAAGKTTI LYKLKLGQSVTT I PTVGFNVETVTYKN
ARF1 human 61 ISFTVWDVGGQDKIRPLWRHYFQNTQGLIFVVDSNDRERVNEAREELMRMLAEDELRDAV 
ARF1 mouse 61 ISFTVWDVGGQDKIRPLWRHYFQNTQGLIFWDSNDRERVNEAREELMRMLAEDELRDAV 
ARF2 mouse 61 ISFTVWDVGGQDKIRPLWRHYFQNTQGLIFVVDSNDRERVNEAREELTRMLAEDELRDAV 
ARF3 mouse 61 ISFTVWDVGGQDKIRPLWRHYFQNTQGLIFWDSNDRERVNEAREELMRMLAEDELRDAV 
ARF4 mouse 61 ICFTVWDVGGQDKIRPLWRHYFQNTQGLIFWDSNDRERIQEGAAVLQKMLLEDELQDAV 
ARF5 mouse 61 ICFTVWDVGGQDKIRPLWRHYFQNTQGLIFVVDSNDRERVQESADELQKMLQEDELRDAV 
ARF6 mouse 57 VKFNVWDVGGQDKIRPLWRHYYTGTQGLIFVVDCADRDRIDEARQELHRIINDREMRDAI 
ARF6 human 57 VKFNVWDVGGQDKIRPLWRHYYTGTQGLIFWDCADRDRIDEARQELHRIINDREMRDAI
ARF1 human 121 LLV FANKQDLPNAMNAAEITDKLGLHS LRHRNWYIQATCATSGDGLYEGLDWLSNQLRNQK 
ARF1 mouse 121 LLVFANKQDLPNAMNAAEITDKLGLHSLRHRNWYIQATCATSGDGLYEGLDWLSNQLRNQK 
ARF2 mouse 121 LLVFVNKQDLPNAMNAAEITDKLGLHSLRQRNWYIQATCATSGDGLYEGLDWLSNQLKNQK 
ARF3 mouse 121 LLVFANKQDLPNAMNAAEITDKLGLHSLRHRNWYIQATCATSGDGLYEGLDWLANQLKNKK 
ARF4 mouse 121 LLLFANKQDLPNAMAISEMTDKLGLQSLRNRTWYVQATCATQGTGLYEGLDWLSNELSKR- 
ARF5 mouse 121 LLVFANKQDMPNAMPVSELTDKLGLQHLRSRTWYVQATCATQGTGLYDGLDWLSHELSKR- 
ARF6 mouse 117 I LI FANKQDLPDAMKPHEIQEKLGLTRIRDRNW YVQPSCATSGDGLYEGLTWLTSNYKS—  
ARF6 human 117 I LI FANKQDLPDAMKPHE I QEKLGLTRI RDRNW YVQPSCATSGDGLYEGLTWLTSNYKS--
Figure 1. 10 Alignment of amino acid sequences for mammalian ARFs.
Identical residues are in red and similar are in blue. The GenBank protein accession numbers of all 
ADP-ribosylation factors are as follows. ARF I human (CAI23120); ARF I mouse (JC4945); ARF2 mouse 
(JC4946); ARF3 mouse ( JC4947); ARF4 mouse (JC4948); ARF5 mouse (JC4949); ARF6 mouse QC4950); 
ARF6 human (AAV3867I). The consensus sequences of the Switch I region appears above the 
alignment in blue and the Switch II region appears in orange. The site of N-terminal myristoylation 
after co-translational removal of methionine is indicated above the alignment in green. Alignment was 
generated by ClustalW (www.ebi.ac.uk/dustalw) and the printing of the multiple alignment output 
was performed by Boxshade (www.ch.embnet.org/software/BOX_form.html).
liver and placenta; ARF3 in kidney; ARF6 in heart, substantia nigra, kidney, and 
especially high in ovary (Cavenagh et al., 1996; Lebeda et al, 2003).
Within cells, the distribution of the different isoforms seems to be 
compartmentalised. ARF proteins, with the exception of ARF6, are 
predominantly cytosolic and they become bound to membranes upon activation, 
i.e., GTP-binding. ARF1, ARF2 and ARF3 are mainly cytosolic and are localised 
at the perinuclear regions corresponding to the Golgi and the ER; ARF1 can also 
be found in the nucleus. ARF4 and ARF5 are mainly cytosolic, whereas ARF6 is 
predominantly found bound to the plasma membrane when GTP-bound,
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especially in membrane ruffles, or in endosomes when GDP-bound (Peters et al, 
1995; Hosaka et al., 1996; Cavenagh et al, 1996; personal unpublished data), 
although the membrane-bound/cytosolic ratio is variable and dependent on cell 
type (Yang et al, 1998).
Structure
The amino acid primary structure of ARF proteins of different species has 
been conserved throughout evolution. Like other small G proteins, they bind 
GTP to become active and hydrolyse it to become GDP-bound and inactive. Like 
some other small G proteins, ARF proteins are routinely post-translationally 
modified. In the case of ARF proteins, this occurs at the N-terminal glycine 
residue (G2 which becomes G1 once the initiating methionine is removed) with 
the saturated fatty acid myristate. This modification has been shown to be critical 
for at least three reasons: firstly, myristoylation increases the nucleotide 
exchange on ARFs (Franco et al, 1995); secondly, it contributes to the recruitment 
of ARFs to natural or artificial membranes (Franco et al, 1996); and finally, 
myristoylation has been demonstrated to be essential for ARF interaction with 
regulator and effector proteins (Brown et al, 1993; Massenburg et al, 1994).
Single crystal X-ray diffraction analysis of ARF1 (Amor et al, 1994; 
Greasley et al, 1995; Goldberg, 1998) and ARF6 (Menetrey et al, 2000; Pasqualato 
et al, 2001) in several forms have revealed important functional regions, depicted 
in Figure 1.11. Indeed, the overall structure of the ARF molecule consists of seven 
p-strands, six a-helices and twelve connecting loops arranged in the classical Ras 
fold. As noted, the feature that distinguishes ARFs from the other Ras family 
GTP-binding proteins is the N-terminus. This region is an extension of up to 14
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ARF I-GDP ARFI-GTP
Switch
Switch 2
ARF6-GDP
N -helix C-helix
ARF6-GTP
Figure I. I I Crystal structures of ARF I -GDP, ARF I -GTP, ARF6-GDP and ARF6-GTP.
Same projection of ARF I complexed with GDP (bovine GDP-ARFI; PDB code IRRF), with GTP 
(mouse GTP-[AI7]ARFI; PDB code I03Y), ARF6 with GDP (human GDP-ARF6; PDB code I EOS) and 
with GTP (human GTPyS-ARF6; PDB code IHFV). The sequence in blue represents the Switch I 
region and in orange represents the  Switch 2 region. The grey sphere represents a Mg2+ ion.
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residues as shown for ARF1 (Greasley et al., 1995) and forms an a-helix that is 
tightly packed against the core domain of ARF when it is bound to GDP. Upon 
GTP-binding, this myristoylated a-helix is though to be mechanically displaced 
into the solvent and orient to interact with the membrane. Interestingly, sequence 
differences amongst ARFs mainly occur near the N-terminus since the alignment 
of the mammalian ARFs shows that the N-terminus of ARF6 is shorter than that 
of the other ARFs by four residues. This observation indicates a possible 
differential affinity interaction with downstream effector proteins and 
membranes. In addition to the N-terminal helix, two highly flexible regions 
defining, or close to, the acceptor site for the y-phosphate of GTP have been 
identified. These two regions have been named Switch 1, from residues 45-54, 
and Switch 2, from residues 70-80 of ARF1 (Goldberg, 1998) in accord with the 
known structure-function relationships of other member of the Ras superfamily. 
Close to the binding site for guanine nucleotides lies a Mg2+ ion. This ligand also 
constitutes another significant feature in the ARF molecule and is thought to 
stabilise the binding of GTP by the switch regions. Consequently, since these two 
switch regions undergo major rearrangements on GTP+-+GDP exchange they 
probably form, along with the N-terminus, the major sites for the interaction of 
ARF proteins with their cellular regulator and effectors. Specifically, upon 
guanine nucleotide exchange, the switch regions are thought to restructure, 
inducing the movement of one loop (between p2 and p3 strands), which 
displaces the N-terminal helix from its buried position against the protein core. 
As a result, the N-terminus exposes its attached myristate tail, which 
subsequently inserts into the membrane bilayer. Furthermore, the amino acid 
sequences for switch 1 and switch 2 regions are surprisingly almost identical 
among the ARF proteins, suggesting that they may have the same conformation
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and that they may not be readily distinguishable by the various regulatory and 
effector proteins that interact with them. It is worth noting that sequence 
differences between the most distantly related ARF isoforms, ARF1 and ARF6, 
occur outside the switch regions.
Thus minor differences found in the N-terminus region and the switch 
regions must presumably account for all of the reported differences in the 
localisation and function of ARF1 and ARF6. It should be noted that since these 
two isoforms of ARF are the most extensively studied, especially where side-by- 
side comparisons are attempted there is a significant bias in the literature.
Function
All ARF proteins are soluble proteins that become membrane bound upon 
GTP binding. This allows them to colocalise and interact with their effector 
proteins. Amongst their main functions are:
M em b ra n e  Traffic
Class I ARFs appear to control a variety of vesicle transport and fusion 
steps, which may include budding, transport, and fusion steps in the Golgi, in 
the ER, and in the endocytotic pathway. ARF1 was originally studied for its 
function on the Golgi where it localised and also for being responsible for the 
assembly of coat proteins on membranes (Randazzo et ah, 2000). Later, ARF1 has 
also been implicated in ER-to-Golgi and intra-Golgi transport, transport from the 
TGN, subsequent endosomal trafficking and the generation and exocytosis of 
synaptic vesicles and nascent secretory vesicles (Donaldson and Jackson, 2000).
ARF6 on the other hand affects membrane traffic in the cell periphery, in 
the endosomal-plasma membrane system. It is involved in endosomal recycling 
to the plasma membrane, receptor mediated endocytosis, regulated secretion,
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biogenesis and release of synaptic vesicles (Zheng and Bobich, 2004) and 
phagocytosis, amongst others (Randazzo et al., 2000; Donaldson and Jackson, 
2000).
Actin C ytoskeleton
ARF1 has also been shown to affect the actin cytoskeleton associated with 
the Golgi apparatus, by recruiting actin and a Golgi-specific isoform of spectrin, 
independently of COPI recruitment (Godi et al., 1998; Fucini et al., 2000).
ARF6 has been demonstrated to regulate the formation of membrane 
ruffles or ARF specific protrusions (Radhakrishna et al., 1999; Honda et al., 1999; 
Boshans et al, 2000); expression of a dominant-negative mutant of ARF6 has been 
shown to inhibit cell spreading of HeLa cells (Song et al., 1998).
E ffector Lipid M etabo lisin g  E nzym es
ARF proteins influence the activity of certain lipid metabolising roles in 
the cellular functions described above. These are PLD and PI(4)P5K. ARF1 and 
ARF3 were both found to be activators of PLD1 (Brown et al., 1993; Cockcroft et 
al., 1994), and so were the other ARFs (Massenburg et al., 1994). This activation 
was potently increased by the presence of the myristoyl group and the N- 
terminus (Brown et al., 1993, 1995; Massenburg et al., 1994; Zhang et al., 1995). 
ARF-dependent PLD activity has been detected in plasma membrane, nucleus, 
Golgi and cytosol (Exton, 1999). The activation of this phospholipase by ARF can 
be influenced by the participation of several PLD-stimulatory molecules such as 
PKC, Rho-family GTPases, Ca2+, tyrosine kinases and phosphoinositides (Singer 
et al., 1995, 1996; Hammond et al., 1997; Exton, 1997, 1999; Houle and Bourgoin, 
1999; Zhang Y. et al., 1999).
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Figure 1.12 Cyclical 
activation and
inactivation of ARF 
proteins.
Replacement of the GDP 
molecule bound to  the 
inactive cytosolic ARF 
protein with GTP, aided by 
an ARF-GEF, releases the 
hydrophobic N-terminus 
and the myristate group 
bound to  it, allowing for 
the molecule to  bind to 
membranes. Inactivation of 
the GTP-ase and its release 
from membranes is
catalysed by an ARF-GAP 
that prom otes the
hydrolysis of the GTP 
molecule.
The activation of PI(4)P5Kinases by ARF has already been commented on 
the Regulation of PI(4)P5K by Small G Proteins section (pages 55-57).
ARFs have also been seen to be involved in the recruitment of PI4KIIIp to 
Golgi membranes (Godi et al., 1999).
Regulation
ARF proteins are regulated by two types of proteins, ARF guanine 
nucleotide exchange factors/proteins (GEFs/GEPs), and ARF GTPase activating 
proteins (GAPs), as shown in Figure 1.12. The first promote a fast and effective 
activation of ARFs through the displacement of GDP and replacement with GTP; 
the second activate the hydrolysis of bound GTP to GDP (Donaldson and 
Jackson, 2000).
ARF-GEFs are divided in two major classes, the large (>100 kDa) ARF- 
GEFs and the smaller (<100 kDa) ARF-GEFs, on the basis of sequence similarity, 
functional differences and sensitivity to the fungal metabolite Brefeldin A. ARF 
activation takes place after both the GEF and its target ARF have been localised
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to membranes. To do so, the small GEFs are recruited to target membranes via 
their PH domain, which binds polyphosphoinositides, particularly PIP2 and PIP3 
(Jackson and Casanova, 2000). The large ARF-GEFs lack the PH domain, but they 
have other fragments of their sequence with membrane-targeting information; 
otherwise, they must rely on other proteins to mediate membrane recruitment 
(Donaldson and Jackson, 2000).
Some of the most recently discovered ARF-GAPs are multi-domain 
proteins that were identified as binding partners of signalling molecules. They all 
have a GAP domain which includes a Zinc finger motif and some also have PH 
domains for localisation (Donaldson and Jackson, 2000).
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1.4 PROTEIN KINASE C
Protein kinase C (PKC) is a multifunctional enzyme that phosphorylates 
serine and threonine residues in many target proteins. Nishizuka and colleagues 
were the first to identify it as a protein kinase that phosphorylated histone and 
protamine in bovine cerebellum (Takai et al, 1977; Inoue et al, 1977). The PKC 
family is the largest serine/threonine-specific kinase family known to which 
many cellular responses have been credited (Parker et al.f 1992).
Members
The PKC family is represented in all eukaryotes and in Homo sapiens 
comprises several isoforms that have been divided into three subgroups, 
differing on their cofactor requirements and structure (Dempsey et al., 2000). The 
conventional isoforms, cPKCs, (PKCa, PKCpi and PKCPn and PKCy) are DAG 
and phospholipid sensitive and Ca2+ responsive. The novel isoforms, nPKCs, 
(PKC8, PKCe, PKCr| and PKC0) are DAG sensitive but Ca2+ insensitive. The 
atypical isoforms, aPKCs, (PKC£ and PKCiA) do not respond to either Ca2+ or 
DAG (Parker and Murray-Rust, 2004). An extra two isoforms, PKCp/PKD 
(Valverde et al., 1994) and PKCv (Hayashi et al., 1999), both of which are DAG 
sensitive, have also been identified and could be considered members of a fourth 
subgroup.
Expression and Localisation
The expression and distribution of PKC isoforms varies markedly 
between cells and tissues (Nishizuka, 1988). Some isoforms such as PKCa, pi, pn, 
8, e and are ubiquitously expressed whereas others seem to be restricted to 
certain tissues; e.g. PKCy is mainly restricted to the central nervous system and
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spinal chord, PKCr| is strongly expressed in lung and PKC9 in skeletal muscle 
(Liu W.S. and Heckman, 1998; Webb et al., 2000).
With the exception of PKCp, which is a transmembrane protein located at 
the Golgi (Prestle et al., 1996), PKC enzymes are cytosolic proteins which are 
recruited to membranes upon stimulation. PKC action can be localised to 
multiple compartments, including the plasma membrane, (recycling) endosomes, 
the Golgi and the nucleus. Location is determined in part by the scaffolds but 
also by targeting information intrinsic to individual isoforms; for example, 
nuclear localisation/export sequences (NLS/NES) (Parker and Murray-Rust, 
2004).
Structure
The general structure of a PKC molecule consists of a catalytic and a 
regulatory region found at the C- and N-termini respectively, as illustrated in 
Figure 1.13. Both regions are composed of a number of conserved domains 
interspersed with regions of lower homology. These domains are a kinase 
domain, a C2 or C2-like (in the case of novel PKCs) domain, a Cl domain, a 
pseudosubstrate domain and a PB1 (Phox and Bern 1) domain in the case of 
atypical PKCs. The kinase domains are closely related and form part of the AGC 
kinase superfamily. PKCp and PKCv family members (not included in the 
structure figure) have distinct kinase domains but some related regulatory 
properties. cPKCs respond to Ca2+ through an archetypal C2 domain; nPKCs 
contain a C2-related domain that does not retain Ca2+-coordinating residues. The 
Cl domain of cPKCs and nPKCs contain two cysteine-rich regions and serve 
them to bind DAG and phorbol esters. In contrast, aPKCs have altered Cl 
domains and are not DAG sensitive; regulation occurs in part through the N-
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terminal PB1 domain (Liu W.S. and Heckman, 1998; Parker and Murray-Rust, 
2004).
Structures for Cl, C2 and PB1 domains have been determined (Figure 
1.13), and kinase domain models based on the highly related PKA have been 
built (not shown).
C o n ve n tio n a l
PKCa/PKCp/PKCy
N o v e l
PKC5/PKCe/PKCiyPKCG
A ty p ic a l
PKCC/PKCi/X
REGULATORY CATALYTIC
r
/
Figure 1.13 Diagrammatic representation of the domain 
structure of PKC isozymes.
The C I , C2 (or C2-like in the case of novel PKCs) pseudosubstrate 
domain, and PBI domains are represented with different colours. The 
crystallographic structures of the Cl domain of rat PKCy (PBD 
ITBO), C2 domain of rat PKC8 (PBD IBDY) and PBI domain of 
human PKCi (PBD IVD2) are also included. Domain determination 
was generated using CDD (Marchler-Bauer et al., 2003).
|  Kinase Domain 
|  C2 or C2-like Domain 
JJ Cl Domain 
Pseudosubstrate 
|  PBI Domain
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Function
Since its discovery, much interest has been shown in PKC and its role in 
signal transduction. Development, differentiation, proliferation and 
carcinogenesis are all crucial processes for which PKC has been implicated 
(Webb et ah, 2000), as well as others such as receptor desensitization, modulation 
of membrane structure events, regulation of transcription, mediation of immune 
responses and learning and memory among many others (Newton, 1995). In the 
case of PKCa, the most widely expressed of all isoforms and possibly the most 
studied, its functions vary from opposing roles such as proliferation and 
differentiation to apoptosis, cell migration to adhesion, and this isoform is in 
addition involved in processes such as tumorigenesis, cardiac hypertrophy and 
angiogenesis (Nakashima, 2002). At lest in part and exclusively in those cases 
where certain isoforms are expressed only in particular tissues, the requirements 
for other individual isoforms can be revealed by the non-redundant properties 
manifest in the mouse knockout phenotypes. PKCp mouse knockout has 
defective B-cell signalling; PKCy, defective CNS functions; PKC5, defective B-cell 
tolerance; PKCe, defective innate immunity and hypersensitivity to ethanol and 
PKC<£, defective NFkB transcriptional activation (Parker and Murray-Rust, 2004).
Regulation
The function of protein kinase C is regulated by two equally important 
mechanisms.
First, the enzyme is rendered catalytically competent by 
phosphorylations that correctly align residues for catalysis and localise protein 
kinase C to the cytosol. PKC isoforms, like many other kinases, are 
phosphorylated at an activation-loop C-terminal serine/threonine residue, in the
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sequence TFCGTP by PDK1. This is followed by an additional phosphorylation, 
probably PDK-mediated, or autophosphorylation at a more C-terminal 
serine/threonine residue in the sequence FSY/FTY. Nineteen amino acids N- 
terminal to this phosphorylation motif is another autophosphorylation site, the 
so called TP site (Bomancin and Parker, 1996; 1997; Stempka et al, 1997; Li et al, 
1997). The PDK1-dependent, activation-loop phosphorylation occurs in 
conjunction with C-terminal phosphorylations to lock the kinase domains in 
their active conformations; there remains some debate as to the order and 
requirements for these phosphorylations.
The second mechanism involves translocation from the cytosol to binding 
domains at cell membranes. Specific anchoring proteins immobilized at 
particular intracellular sites localise the kinase to its site of action. These proteins 
include receptors for activated C-kinase (RACKS), adducins, annexins and other 
cytoskeletal proteins. Following an increase in intracellular calcium levels, cPKCs 
interact with the cell membrane in an inactive, but conformationally distinct 
form. DAG facilitates penetration of these isozymes into the cell membrane. 
When attached, the affinity of PKC for calcium is increased such that activation 
of the enzyme is achieved, depending on its phosphorylation status. For nPKCs 
isoforms, no equivalent mechanism promoting interaction with DAG has been 
elucidated. For cPKCs, the initial recruitment event is the Ca2+-sensitive step. For 
aPKC isoforms activation can be driven in part by interaction with the Cdc42- 
CTP-Par6 complex, which binds the PBI domain (Parker and Murray-Rust,
2004). Phosphatidylserine is the membrane lipid anchor for both cPKCs and 
nPKCs, although other membrane phospholipids may ultimately link 
extracellular signals to intracellular events through PKC (Newton, 1995).
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The main objective of this thesis was to investigate some of the aspects of 
the control of enzymes involved in polyphosphoinositide metabolism.
Initially, I aimed to determine whether some specificity of interaction 
between different isoforms of ARF GTPases and phosphatidylinositol 4- 
phosphate 5-kinases exists. With this in mind, a biochemical approach was 
undertaken in an attempt to show differences in activation by these small G 
proteins in simplified cell-free systems using recombinant proteins. As a 
compliment permeabilised cells were also used to try and bring the biochemistry 
closer to cellular systems. Finally, I wanted to demonstrate a physical interaction 
between the two proteins using coprecipitation assays.
Another potential regulator of PI(4)P5Ks is PKC, according to a sequence 
analysis that predicts a hypothetical phosphorylation site within the lipid kinase. 
With this in mind, I tested the effect of the presence of PKC on the activity of 
PI(4)P5K. As part of this investigation the effect of different lipids on the activity 
of PI(4)P5Ks were tested leading to the unexpected discovery of the activation of 
the lipid kinase by diacylglycerol. A major aim was the characterisation of this 
new effect and comparison to the activation by the best described lipid-activator 
phosphatidic acid.
Finally, I wanted to determine whether ARF proteins also had an effect in 
the related group of lipid kinases PI3Ks (Class I). pllOy appeared to be strongly 
influenced by the GTPase and therefore I aimed to characterise this effect using a 
similar approach to that used with PI(4)P5K.
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3.1 MATERIALS
Reagents and Compounds
[y-32P]ATP, CDNB and potassium phosphate buffer (part of the GST 
Detection Module), CNBr-activated Sepharose 4 FastFlow beads, Glutathione 
Sepharose 4B beads and Phenyl Superose (HR10/10) column were purchased 
from Amersham Biosciences.
-  Agarose, bovine serum albumin, ammonium sulphate, benzamidine, 
bromophenol blue, culture media RPMI-1640 and DMEM, diC8:0-PA and 
diC8:0-DAG, EGTA, goat serum, HEPES, kanamycin, DL-a-dimyristoyl- 
phosphatidylcholine, myristic acid, nalidixic acid (sodium salt), PMA, PMSF, 
R59949 inhibitor, sheep anti-goat HRP-conjugate secondary antibody, SDS, 
sodium phosphate, streptolysin-O, TEMED, Tris-base, Tris-HCl, Trypsin- 
EGTA and Triton X-100 were from Sigma.
-  Heat-inactivated foetal calf serum was from Imperial Laboratories.
-  Ampicillin, antipain, aprotinin, ATP (disodium salt), GTPyS, leupeptin, 
Nutridoma-SP and pepstatin were from Roche.
-  Acetic acid, acetone, calcium chloride solution, chloroform, EDTA (disodium 
salt), glycerol, glycine, hydrochloric acid, imidazole, IPTG, lysozyme, 
magnesium chloride solution, methanol, PBS, potassium oxalate, reduced 
glutathione, sodium azide, sodium chloride and sodium hydroxide were 
from BDH Laboratory Supplies.
-  40% Acrylamide/Bis solution, APS, ethidium bromide, goat anti-mouse and 
goat anti-rabbit HRP-conjugate secondary antibodies and Supported 
Nitrocellulose membrane (0.2 pM) were from Bio-Rad.
-  Coomassie Brilliant Blue R250 was from Fluka.
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-  DTT and mouse anti-ARF 1D9 monoclonal antibody from Alexis 
Biochemicals.
-  Ni-NTA (Fast-Flow) and Polyfect Transfection Reagent from Qiagen.
-  LB broth, penicillin (5000 Units/ml), streptomycin (5000 pg/ml) and PKCa 
(old Panvera) were from Invitrogen.
-  VectaSpin Micro 10 pm Polypropylene Mesh filters, filter paper grade 1 and 
Silica Gel TLC 60 plates from Whatman (Fisher).
-  Tissue culture flasks and dishes from Helena Biosciences.
-  All synthetic diacylglycerols, phosphatidic acids, phosphatidylinositol, 
phosphatidylinositol 4-phosphate and phosphatidylinositol-4,5-bisphosphate 
were from Avanti Polar Lipids.
-  Recombinant DGK£ and anti-DGK^ antibody were obtained from Dr Matt 
Topham (Huntsman Cancer Institute, University of Utah School of Medicine, 
Salt Lake City, Utah, USA).
Cell Lines
-  Cos7 cells, monkey kidney cells transformed with SV40 virus T antigen, were 
from American Type Culture Collection, USA (www.atcc.org).
-  HEK293 cells, human embryo kidney cells transformed with sheared human 
Ad5 DNA, were from the European Collection of Animal Cell Culture, UK 
(www.ecacc.org.uk).
-  HL60 cells, human Caucasian promyelocytic leukaemia cells, were purchased 
from the European Collection of Animal Cell Culture, UK.
-  Clone 12CA5 hybridoma cells were a kind gift from Dr. Leo Price 
(Netherlands Cancer Institute (NIWI), Amsterdam, Netherlands)
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3.2 METHODS
Mammalian Cell Culture
Cos7 and HEK293 Cells
Cos7 cells and HEK293 cells were cultured in DMEM medium 
supplemented with 10% heat-inactivated foetal calf serum, penicillin (50 
units/ml) and streptomycin (50 pg/ml). Cells were grown typically in 100 mm 0  
culture dishes until confluent or 90% confluent respectively, in a humidified 
atmosphere containing 5% CO2 at 37°C. Cells were passaged as required by their 
state of confluence by removal of the medium, gentle wash with PBS followed by 
addition of 2 ml of Trypsin-EGTA. After 5-10 minutes, 20 ml of medium was 
added to the cells before they were dispersed with a pipette. Cells were then split 
into new dishes at a desirable dilution (generally 1/10) and 20 ml of fresh 
medium was added.
HL60 Cells
HL60 cells were cultured typically in 50 ml of RPMI-1640 medium 
supplemented with 10% heat-inactivated foetal calf serum, penicillin (50 
units/ml) and streptomycin (50 pg/ml). Cells were grown to a density of 
approximately lxlO6 cells/ml in a humidified atmosphere containing 5% CO2 at 
37°C. Cells were passaged every 48 hours (after collection by centrifugation) at a 
split ratio of 1:5 again in 50 ml of medium.
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Plasmid Construction
M urine PI(4)P5K B acteria l Expression Plasm id pGEX-4T-2-PI(4)P5K(%  
P  and y(G ST-fusion pro te in s) an d  M am m alian  Expression Plasm id  
pE B B -PI(4)P5K a-H A
pGEX-4T-2-PI(4)P5Ka, p and y and pEBB-PI(4)P5Ka-HA were the kind 
presents of Dr Chris Carpenter (Harvard Medical School, Boston, Massachusetts, 
USA).
Construction o f  th e  M urin e P I(4 )P 5 K a  M am m alian  Expression Plasm id  
pE B G -PI(4)P5K a (GST-fusion p ro te in )
DNA coding for PI(4)P5Ka was subcloned from the pGEX-4T-2~PI(4)P5Ka 
plasmid into the mammalian expression vector pEBG. BL21(DE3)pLysS bacteria 
transformed with the parent plasmid were grown overnight at 37°C in 10 ml of 
LB broth supplemented with ampicillin (100 pM). A miniprep of the culture 
(Qiagen's QLAprep Spin Miniprep Kit, according to the manufacturer's 
instructions) provided sample DNA. Both the pGEX-4T-2 and the pEBG 
plasmids were digested sequentially with Bst BI (65°C for 2 hours) and Not I 
(37°C for 2 hours) with DNA being recovered after the first step with GFX PCR 
DNA and Gel Band Purification Kit (Amersham Biosciences) as indicated by the 
manufacturer. The products of the consecutive digestions were analysed in a 1% 
agarose gel in order to confirm the presence of the right insert and the linearised 
pEBG. The band corresponding to the insert (~2 kb) was cut out of the gel and 
the DNA extracted from the agarose polymer using GeneClean III kit 
(Q-BioGene, according to the manufacturer's instructions).
The insert was ligated into the new vector in a reaction catalysed by T4 
DNA ligase (0.5 pi of 400 U/ml ligase) diluted in ligation buffer (250 mM Tris (pH
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7.6), 50 mM MgCh, 5 mM ATP, 5 mM DTT, 25% (w/v) PEG-8000) for 30 minutes 
at room temperature. Competent E. coli DH5a cells were then transformed with 
the new plasmid and plated on ampicillin-containing agarose. 5 colonies were 
picked from the plate and grown in 5 ml of LB broth and ampicillin overnight. 
Minipreps were made from each colony and the DNA was double-digested 
using the restriction enzymes Sal I and Not I for 1 hour at 37°C. The products of 
the digestion were run on a 1% agarose gel and two bands of the anticipated size 
confirmed the proper transformation of the bacteria with the expected construct.
Construction of the ARF Bacterial Expression Plasmid pMon5840-ARF I- 
(His)6 and pMon5840-ARF6-(His)6
DNA coding for ARF proteins was amplified by PCR from authentic 
samples using forward and reverse primers that coded for the termini of the 
sequence and any desired extensions. These extensions comprised 5' sequence 
for a Nco-1 restriction site and 3' sequence containing codons for six consecutive 
histidine residues followed by a Hind III restriction site. For example, the 
following primers were used for bovine ARF1:
N-terminus (sense strand)
5’ -  t a t a t a | c o a t g g | g g a a t a t c t t t g c a a a c c t c  -  3’
C-terminus (antisense strand)
5’ -  ATTATTjAAGCnjCA-GTG - ATG ■ ATG - ATG ■ ATG ATG TTTCTG • 
GTTCCGGAGCT GATTGGACAG -  3’
Restriction sites are in boxes, ARF1 sequence and reverse compliment 
ARF1 sequence are shown in blue, the stop codon is in red and the 6xHis coding 
sequence is in green. Related primers, but with sequence corresponding to 
fragments of ARF1 or full-length ARF6, were designed along similar lines with 
all restriction sites and other features as for the ARF1 primers. PCR products
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were digested with Nco I and Hind III, purified and ligated into a sample of 
plasmid pMon5840 (kind gift of Dr JI Gordon, Washington University Medical 
School, Missouri, USA) which had been previously cut with the same two 
restriction enzymes. After transformation into E. coli XL1 Blue cells and selection 
by ampicillin resistance, plasmid DNA was isolated from positive clones and the 
insert sequenced to exclude any mutations. Plasmids were then transformed into 
E. coli BL21-DE3 pLysS cells with or without co-transformation with expression 
plasmid pBB131 coding for the yeast N-myristoyltransferase 1 (NMT1, kind gift 
of Dr JI Gordon, Washington University Medical School, Missouri, USA) and 
selected by ampicillin or ampicillin plus kanamycin resistance respectively. 
Positive or double positive clones were expanded and stored as frozen glycerol 
stocks until required.
pXS-ARF I (wt)/ARF I ( T3IN)/ARFI (Q 7IL ) and pXS-AR F6(wt)/
ARF6(T27N)/ARF6(Q67L) (all H A -tagged) Plasmids
pXS plasmids coding for HA-tagged ARFl(wt), ARF1(T31N), 
ARF1(Q71L), ARF6(wt), ARF6(T27N) and ARF6(Q67L) were the kind gift of Dr 
Julie Donaldson (NIH, Bethesda, Maryland, USA).
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Expression and Purification of Recombinant Proteins
Expression and Purification o f  G ST  fusion PI(4)P5Ka, P  and y in  E. coli
Recombinant Type I phosphatidylinositol 4-phosphate 5-kinase a, (3 and y 
were prepared by methods similar to those described previously (Tolias et al, 
1998a).
For the expression and purification of PI(4)P5K proteins E. coli 
BL21(DE3)pLysS bacteria were transformed with pGEX-4T-2-PI(4)P5Ka, p or y 
plasmids. Use of these plasmids, where the insert is fused with the catalytic 
domain of the enzyme glutathione-S-transferase (GST), allows for easy recovery 
using beads coated with glutathione. Since the pGEX-4T-2 plasmid carries 
ampicillin resistance all cultures of the singly transformed bacteria can be 
selected at all points by use of this antibiotic at a suitable dilution (100 pg/ml).
An initial culture of transformed cells was grown in 5 ml of LB broth 
overnight at 37°C in presence of 100 pM ampicillin. Cells from the overnight 
culture were expanded in two conical flasks containing 200 ml of LB, in the 
presence of ampicillin, and allowed to grow overnight at 37°C. The next day the 
cells were expanded in four 1-litre flasks of LB without ampicillin for 3 hours. 
Expression of PI(4)P5K was then induced with 0.5 mM IPTG and cells were left 
to express for an extra 3 hours. They were then harvested by centrifugation at 
4420xg for 10 minutes at 4°C using a JA-10 fixed angle rotor in a J2-21 Centrifuge 
(Beckman). The cell pellet from a 4-litre culture was then resuspended in a total 
volume of 80 ml of lysis buffer 1 (50 mM Tris (pH 8.0), 40 mM EDTA, 25% (w/v) 
sucrose, 0.02% (w/v) NaN3, 1 mg/ml lysozyme) and incubated with gentle 
stirring for 30 minutes at room temperature. Cells were lysed by the addition of 
32 ml of lysis buffer 2 (50 mM Tris (pH 8.0), 100 mM MgCh, 0.2% (w/v) Triton X-
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100, 0.02% (w/v) NaN3). In addition, 1 mM DTT, 1 mM PMSF, 10 pg/ml antipain, 
2 pg/ml pepstatin, 1 jig/ml leupeptin and 1 pg/ml aprotinin were added to the 
suspension, which was then incubated for 30 minutes at 4°C with stirring. The 
broken cells were subsequently homogenised by using a Potter-Elvehjem 
homogeniser. The homogenate was clarified by ultracentrifugation at 10,000xg 
for 60 minutes at 4°C using a Type 35 Beckman rotor in a Sorvall Ultracentrifuge 
(OTD 65B model). In the meantime, 4 ml of 50% slurry of Glutathione Sepharose 
4B beads was washed three times in 25 ml of lysis buffer 1 and the final 2 ml of 
beads was resuspended in 3 ml of lysis buffer 1+2 (10:4 ratio). Supernatant 
containing PI(4)P5K protein was then split into three 50 ml-tubes and the GST- 
beads divided equally, and the mixture left rotating overnight at 4°C.
The beads were washed into dialysis buffer (50 mM Tris, 50 mM NaCl and 5 
mM MgCk, pH 7.5,1 mM DTT and 1 mM PMSF, pH 7.6 adjusted at 4°C) 3 times 
by centrifugation and resuspension before being collected together. Protein was 
eluted with three 5 ml washes of 10 mM reduced glutathione in dialysis buffer by 
rotating for 15 minutes at 4°C. The three elution products were pooled and 
dialysed to remove the glutathione (see Protein Dialysis and following sections 
for more details on protein analyses).
Expression and Purification o f  H is-tagged ARF I and ARF6 in E. coli
Recombinant ARF1 and ARF6, both myristoylated and nonmyristoylated, 
as well as [A17JARF1 were prepared as previously described (Randazzo et al., 
1995) with a few modifications. In the case of [A17JARF1 (His)6, its preparation 
did not require the co-translational addition of myristic acid as it is an ARF1 
mutant that lacks the first 17 amino acids of its N-terminus and therefore the 
myristoylation site.
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E. coli BL21(DE3)pLysS bacteria were transformed with either pMon5840- 
ARFl-(His)6 or pMon5840-ARF6-(His)6/ along with pBB131 (yeast NMT1). NMT 
catalyses the in vivo transfer of a myristate group to a glycine residue at position 
2 of the ARF protein. Bacteria lack this type of transferase activity, hence its 
coexpression with the different plasmids coding for ARF proteins under those 
circumstances where myristoylation is required, allows for the addition of the 
fatty-acyl chain to the N-terminus of the protein. A 6X His-tag was inserted into 
the sequence for ARF1, ARF6 and [A17]ARF1 at the C-terminus as described 
above. Since the pMon5840 plasmids carry ampicillin resistance and pBB131 
carries kanamycin resistance all cultures of the double or singly transformed 
bacteria can be selected at all appropriate points by combinations of these 
antibiotics, e.g. ampicillin (100 pg/ml) and kanamycin (50 jig/ml).
An initial culture of transformed cells was grown in 5 ml of LB overnight 
at 37°C in presence of ampicillin and kanamycin as required. Cells from the 
overnight culture were expanded in two conical flasks containing 200 ml of LB, 
once again containing antibiotics, and allowed to grow overnight at 37°C. The 
next day the cells were expanded in four 1-litre flasks of LB for 3 hours in the 
absence of antibiotics. 12.5 ml of a freshly prepared solution containing myristic 
acid (2.52 mg/ml) and BSA (20 mg/ml) was added to each flask. At the same, 
time, the expression of NMT, where required, was induced by addition of 1 mM 
IPTG and left to express for an additional hour. When required the temperature 
was then reduced to 26°C to optimise the yield of myristoylated proteins as 
previously shown by Franco et al. (1995). Nalidixic acid (25 mg/ml) was then 
added to induce ARF protein expression (1.25 ml of the freshly prepared 
nalidixic acid solution was added to each flask). After 3 hours of protein 
expression, further myristic acid and BSA was added and the culture was then 
allowed to grow overnight at 26°C. The cells were harvested by centrifugation at
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4420xg for 10 minutes at 4°C and the cell pellet from the 4-litre culture was 
resuspended in a total volume of 80 ml of lysis buffer 1 (50 mM Tris (pH 8.0), 
25% (w/v) sucrose, 0.02% (w/v) NaN3, 1 mg/ml lysozyme) and incubated with 
gentle stirring for 30 minutes at room temperature. Cells were then lysed by 
addition of 32 ml of lysis buffer 2 (50 mM Tris (pH 8.0), 100 mM MgCb, 0.2% 
(w/v) Triton X-100, 0.02% (w/v) NaN3). In addition, 1 mM DTT and PMSF were 
added to the suspension which was then incubated for 30 minutes at 4°C with 
stirring. The cells were subsequently homogenised and the homogenate was 
clarified by ultracentrifugation at 10,000xg for 60 minutes at 4°C. ARF proteins 
were then purified from the supernatant through two steps. Firstly, the 
supernatant obtained after ultracentrifugation was pumped through a 25 ml-bed 
volume column of Ni-NTA fast-flow beads with a Minipuls II pump (Gibson) at 
about 2 ml/min. The column was previously equilibrated with the following 
cycle: 100 ml of Nickel column buffer containing 20 mM NaH2PC>4, 20 mM Tris, 
300 mM NaCl, 0.2% (w/v) NaN3, pH 6.0, followed by 100 ml of the same buffer 
supplemented with 0.5 M imidazole and then followed by 50 ml of a mixture (5:2 
ratio) of lysis buffers 1 and 2 respectively. The Ni-NTA column was then 
connected to an FPLC system which was set at a flow rate of 2.5 ml/min. After a 
washing step, the protein was eluted with a continuous linear gradient of 0 to 0.5 
M imidazole in the Nickel column buffer. This particular column 
chromatography step was performed at room temperature or at 4°C with 
identical results. Fractions of 5 ml were collected. In a second chromatographic 
step, myristoylated ARFs were resolved from the underivitised forms by 
hydrophobic interaction chromatography on phenyl superose, if required, as 
follows. The pooled samples from the Ni-NTA column were mixed with solid 
ammonium sulphate to a final concentration of 1 M. In the cold, the pH was 
adjusted to 7.6 and the sample clarified by centrifugation and passage through a
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0.45 pM filter. The HR10/10 Phenyl Superose column was equilibrated in a cold 
Tris buffer (20 mM Tris (pH 7.6) and 0.02% (w/v) NaN3) containing 1 M 
(NH4)2SC>4. After passage of the sample through the column, the bed was washed 
with one volume of buffer containing 1.7 M (NH4)2S04. The column was then 
developed with a decreasing linear ammonium sulphate gradient in the same 
Tris buffer from 1 M (NH4)2SC>4 and 8 ml-fractions were collected. All flow rates 
were 0.5 ml/min or less. Proteins elution was monitored by absorbance at 280 
nm. Protein-containing fractions were dialysed against several changes of Tris 
buffer (100:1 volume ratios as above) in the cold and then concentrated as 
described for other samples and stored frozen in small aliquots.
Alternatively, the myristoylated protein could be collected by differential 
ammonium sulphate precipitation. Peak fractions from the Ni-NTA 
chromatography step containing the ARF protein mixture were pooled and 
dialysed against 1.7 M (NH4)2SC>4 (pH 7.6) overnight at 4°C. The pellet, 
containing the myristoylated proteins were dissolved in salt-free buffer and then 
dialysed to remove the highly concentrated salt (see Protein Dialysis and 
following sections for more details on protein analyses).
We could not detect biochemical difference between forms of 
myristoylated ARFs prepared by either of these two methods.
The extent of myristoylation of the protein preparations was assessed by 
reverse phase HPLC as myristoylated forms of the proteins show a characteristic 
increase in retention time.
Nucleotide-preloaded recombinant ARF proteins were obtained from Dr 
Neil Justin (MRC NIMR, Mill Hill, London).
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Expression and Purification o f  G ST fusion and H A -tagged Proteins in 
M am m alian  Cells
Several proteins were expressed and purified from mammalian cells after 
their transient transfection. For this matter, Cos7 cells were used most 
commonly, although HEK293 cells could be used as well with exactly 
comparable results. For the expression in Cos7 cells, the plasmids pEBB- 
PI(4)P5Ka-HA (product used in most PI(4)P5K activity assays), pEBG-PI(4)P5Ka 
(GST-fusion protein used in protein-interaction assays) and pXS-ARFl(wt), pXS- 
ARF1(T31N), pXS-ARF1 (Q71L) pXS-ARF6(wt), pXS-ARF6(T27N) and pXS- 
ARF6(Q67L) (all C-terminal HA-tagged) were employed.
Transfections were performed using Qiagen's Poly feet Transfection 
Reagent, exactly as indicated by the manufacturer's instructions. In some cases 
and exclusively with HEK293 cells, calcium phosphate precipitation could also 
be utilised as an alternative method to produce recombinant proteins. In both 
cases, after 48 hours of expression cells were washed in PBS and lysed using the 
so called low salt lysis buffer (50mM Tris (pH 8), 1% (v/v) NP-40 and 1 mM 
PMSF) on ice, after assessing different buffers and concluding that this buffer did 
not interfere with the activity of PI(4)P5K. Cells were then scraped from the 
plate, sonicated to ensure total lysis and the insoluble debris removed by 
centrifugation at 4°C for 30 minutes on a bench top Eppendorf centrifuge at 
14,000xg.
Addition of 100 pi of 50% slurry of either anti-HA antibody-coated 
sepharose beads or Glutathione Sepharose beads to each lysate (per 100 mm cell 
culture dish equivalent) allowed the efficient immunoprecipitation (HA-tagged) 
or affinity purification (GST fusion) of the recombinant proteins after 1 hour of 
rotation at 4°C. It was then straightforward to wash the beads 3 times into lysis
90
Materials and Methods
buffer and a final time into kinase assay buffer (in the case of PI(4)P5K), for 
immediate assessment of PI(4)P5K activity or storage of small aliquotes at -20°C. 
In the case of protein-interaction experiments, the whole lysate was frozen as 
such or in aliquots for its later use in coprecipitation assays.
Alternatively, both the GST fusion and the HA-tagged kinases could be 
eluted from the beads prior to activity assays, by performing a 1-hour elution at 
4°C using either 10 mM reduced glutathione or 2 mg/ml of HA peptide (NH2- 
YPYDVDYA-COOH) together with 2 mg/ml of BSA in kinase activity assay 
buffer. Dialysis was not required since neither the glutathione (at concentrations 
equal or lower than 10 mM) nor the HA peptide interfered significantly with the 
assay once further diluted into the reaction mixture.
General Protein Handling
Protein  Dialysis to  R em ove G lu tath ione, Im idazole o r  Am m onium  
Sulphate
Protein samples to be dialysed, for instance after elution of a protein from 
beads during its purification or its precipitation with ammonium sulphate, were 
transferred into a soaked dialysis tubing of 12 kDa molecular weight cut-off 
(Sigma) which was then carefully clamped and placed into a 5 litre-container 
filled with dialysis buffer (above) in the case of PI(4)P5K or 20 mM Tris (pH 7.6) 
in the case of ARF, at a volume about 100 times the volume of the protein 
sample. The container was then placed in a cold room set at 4°C. To facilitate 
equilibration of high salts, a spin bar was placed in the bottom of the container. 
The protein sample was dialysed for 24 hours with gentle stirring. Changes of 
buffer were performed 2 more times giving a one million-fold theoretical 
dilution.
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Protein  C oncen tra tion
In order to reduce the total volume in which a protein is dissolved, the 
sample was introduced into a properly preassembled 50 ml capacity Amicon 
concentrator (Millipore) containing a 10,000-MW cut-off Amicon ultrafiltration 
membrane (YM10 Millipore). The ultrafiltration membrane was placed in the 
bottom of the concentrator with its glossy side up. A nitrogen gas head at an 
operating pressure read between 20 psi (1.4 kg/cm2) and 30 psi (2.1 kg/cm2) was 
applied to the concentrator during stirring.
Consequently, further concentration of the protein could also be achieved 
using 10 kDa molecular weight cut-off Microsep microconcentrators (Pall, 
Gelman Laboratory) in order to get a smaller volume of protein sample (<0.5 ml). 
A maximum of 3.5 ml of protein sample was transferred into the sample 
reservoir of the microconcentrator which was then centrifuged at 3000xg using a 
JA-20 fixed angle rotor (Beckman) for 30 minutes at 4°C.
Protein  Q uantification
The concentrated protein samples of bacterial origin were 
quantified by using a dye-binding assay based on the method of Bradford (Bio- 
Rad or Pierce kits). The amount of protein in the sample was measured according 
to the manufacturer's instructions. The protein samples were read using an 
Ultrospec II spectrophotometer (LKB Biochrom) with reference to a BSA 
standard curve.
Protein  S torage
Recombinant proteins expressed in bacteria were dated and stored 
in 30% glycerol at -20°C for short term storage and -80°C for long-term storage.
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Protein  E lectrophoresis
SDS-PAGE was used to resolve different proteins, such as PI(4)P5K and 
ARF, according to their molecular weight. A 1-mm thick, 10% separating gel for 
PI(4)P5K and 12.5% for ARF was made, both with a <5% discontinuous stacking 
gel. The separating gel was made first, by mixing 10 ml of separating buffer (1.5 
M Tris (pH 8.8), 0.4% (w/v) SDS) for both 10 and 12.5% gels, with 20 or 17.5 ml of 
water respectively, 10 or 12.5 ml of 40% acrylamide/bis solution, 400 pi of 20% 
(w/v) APS and 30 pi TEMED. The separating gel was then poured between the 
slabs of the preassembled SE 600 vertical slab gel unit (Hoefer) in the dual gel 
casting stand to a level about 4 cm from the top of the gel. A few microlitres of 
water-saturated isobutanol was added on top of the separating gel to eliminate 
any air bubbles and prevent oxygen diffusion. While polymerisation of the 
separating gel was taking place, the stacking or upper gel was prepared by 
mixing 5 ml of stacking buffer (0.5 M Tris (pH 6.8), 0.4% (w/v) SDS) with 12.7 ml 
of water, 2 ml of 40% acrylamide/bis solution, 100 ml of 20% (w/v) APS and 10 
ml TEMED. After polymerisation of the separating gel, the small excess of 
alcohol was poured off and the surface of the polymerised separating gel washed 
3 times with distilled water. The stacking gel was then poured in on top of the 
separating gel. A 1 mm thick, 20-well comb was subsequently inserted, taking 
care not to trap any air bubbles below the teeth of the comb. The gel was allowed 
to sit for at least 30 minutes. After polymerisation, the comb was gently removed 
from the stacking gel and the newly formed wells were filled with tank buffer 
(0.025 M Tris, 0.192 M glycine, 0.1% SDS (pH 8.3)). The whole slab gel unit, 
which includes the gel, was introduced in the electrophoresis tank, half full with 
tank buffer, after assembling and filling an upper buffer chamber.
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Protein samples were mixed with 1/6 of their volume of 6X SDS sample 
buffer and then heated to about 80°C for 5 minutes and then loaded in the wells.
The SE 600 vertical slab gel unit was then connected to an Electrophoresis 
Power supply (Model 3000 Xi, Bio-Rad) and the gel run for 14 hours (overnight) 
at 7.5 mA constant current per gel.
W estern  B lotting
Western blotting was performed for identification and quantification of 
recombinant PI(4)P5K and ARF proteins using the following protocol. The SDS- 
PAGE gel containing the resolved protein bands following electrophoresis was 
cut off and washed 2 times in transfer buffer (25 mM Tris, 192 mM glycine, 10% 
(v/v) methanol for PI(4)P5K and 20% for ARF) for 15 minutes each time. A 
similarly equilibrated semi-dry transfer system was applied for the protein gel in 
a Multiphor II Electrophoresis System (Pharmacia Biotech). For each gel, one 
sheet of 0.2 pm pore nitrocellulose filter membrane (Bio-Rad) and 12 sheets filter 
paper (Whatman) were cut the same size as the gel and soaked in transfer buffer. 
Prior to protein transfer, a transfer sandwich was assembled on the anode plate 
in the following order: 6 sheets of filter paper, nitrocellulose membrane, SDS- 
PAGE gel and 6 sheets of filter paper. The Multiphor II Electrophoresis System 
was connected to a power supply (2303 Multidrive XL, LKB Bromma). The 
protein sample was transferred to the nitrocellulose membrane for 1 hours using 
0.8 mA/cm2 current density. After protein transfer, the nitrocellulose membrane 
was incubated in blocking solution containing 5% (w/v) skimmed milk powder 
in 100 ml TBS-Tween buffer (100 mM Tris, 0.9% (w/v) NaCl, 0.1% (w/v) Tween- 
20) for 1 hour at room temperature on a lab shaker (gently rocking). After 
blocking, the membrane was washed 3 times in 100 ml TBS-Tween for 5 minutes 
each time. PI(4)P5K and ARF proteins were then detected by incubating the
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membrane with a monoclonal primary antibody (see Table 2.1 for types of 
antibodies and working dilutions) diluted in TBS-Tween buffer for 1 hour at 
room temperature. After 3 buffer washes in TBS-Tween, the membrane was 
subsequently incubated with secondary antibody HRP (horseradish peroxidase) 
conjugate diluted in 100 ml TBS-Tween containing 5% (w/v) skimmed milk 
powder and 1% (v/v) goat serum (when applicable) for 1 hour at room 
temperature. The membrane was then washed 3 times in TBS-Tween for 5 
minutes each time and subsequently incubated with 10 ml of an HRP substrate 
solution made up of one volume of Stable Peroxide Solution and one volume of 
Luminol/Enhancer Solution (West Pico Chemiluminescent substrate, Pierce) for 
10 minutes at room temperature. Following the incubation time with 
chemiluminescent reagents, the membrane was laid flat between sheets of clear 
plastic and developed by short exposure in the FujiFilm Intelligent Dark Box. 
Images were captured, stored electronically and the amount of protein quantified 
using Aida software.
Antibodies
PRIMARY SECONDARY
A N TI- ORIGIN D ILU T IO N A N T I- ORIGIN D ILU TIO N
PI(4)P5Ka rabbit 1/1,000 Rabbit goat 1/3,000
GST goat 1/3,000 Goat sheep 1/10,000
H A mouse 1/200
Mouse goat 1/3,000
ARF (1D9) mouse 1/2,000
SERUM 
I % goat serum 
NO serum
I % goat serum
Table 2. 1 Antibodies and their dilutions used in different Western blots.
The table shows the primary monoclonal antibodies, their origin and the working dilution (in TBS- 
Tween buffer), as well as the corresponding secondary antibodies, along with their origin and working 
dilution. Indication of the use of 1% goat serum is also included in those cases w here it is applicable.
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Transformation and Transfection
P reparation  o f  C o m p e ten t B a cteria  for Transform ation
For bacterial cells to take up a plasmid, they need to be made competent. 
For this matter, a 2 ml-ovemight culture of E. coli XL1 Blue or DH5a in LB broth 
was expanded in 200 ml of the same medium, and left to grow for approximately 
2 hours, until the optical density value (A6oo) was of around 0.32. Then, cells were 
centrifuged at 6,000xg for 10 minutes at 4°C, resuspended in 10 ml of ice-cold 0.1 
M CaCb and left standing on ice for 10 minutes. The previous step was repeated 
once more and afterwards cells were centrifuged again and resuspended in 4 ml 
of CaCh. Cells were then competent and ready for transformation with the 
desired plasmid.
H ea t Shock Transform ation o f  C o m p e te n t B acteria
For transformation of bacteria with a desired plasmid, 100 pi of competent 
cells were mixed with the plasmid in question (approximate amount 0.1 pg) and 
left standing on ice for 10 minutes. The cells were then heat-shocked at 42°C for 
90 seconds and returned to ice for an extra 10 minutes. After that, 5 ml of LB 
broth was added to the cells and these were incubated at 37°C for 90 minutes. 
The majority of the supernatant was removed after centrifugation and the cells 
resuspended in the remaining 200 pi and plated onto a LB-Agar plate with 
ampicillin (100 pM) and left to grow overnight at 37°C. The following day 5 
colonies were selected from each plate and grown in 5 ml of LB with ampicillin 
overnight at 37°C. The following day minipreps were made to check that the 
bacteria had been transformed with the correct construct, using Marligen 
Bioscience's High Purity Miniprep System (as indicated by the manufacturer's 
instructions). This assessment could be done by digesting the plasmid with
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suitable restriction endonucleases and displaying the plasmid on an an agarose 
gel or more accurately by sequencing.
General DNA Handling
DNA E lectrophoresis
Linearised fragments of DNA could be run in an agarose gel to confirm 
their size and identity by comparison with a DNA ladder, composed of various 
fragments of DNA of known length or number of bases. The 1% agarose gels 
were made by mixing 100 ml of TAE buffer (121 g of Tris-base, 28.55 ml of glacial 
acetic acid, 18.6 g of Na2-EDTA-2H20 and 500 ml of distilled water, adjusted pH 
8.5) with 1 g of agarose and heated in a standard microwave until all the agarose 
was dissolved. 2 pi of ethidium bromide (10 mg/ml) was then added to the 
solution and this was poured into a casting tray to solidify, together with a well 
comb. Once solid, the gel could be inserted into a submarine electrophoresis 
apparatus and submerged in TAE buffer. The samples to analyse were mixed 
with 10X loading buffer and added onto the wells, and run at 100 V for 
approximately 20 minutes. Once the samples reached the end of the gel, this 
could be extracted and DNA visualised under UV light to localise and identify 
the separated fragments.
Experimental Assays
PI(4)P5K A ctivity  Assay
This is an in vitro assay that follows the production of PI(4,5)P2 from PI(4)P 
and [y-32P]ATP. For this assay, GST- or HA-tagged PI(4)P5K (any of the three 
isoforms) expressed in E. coli, Cos7 or HEK293 cells could be used, bound to or 
eluted from beads. Enzymes prepared in 10 pi reaction buffer (50 mM Tris pH
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7.5, 50 mM NaCl, 5 mM MgCb and 1 mM DTT), diluted to a predetermined 
concentration that would give a detectable signal, were mixed with 10 pi 
sonicated substrate vesicles (typically final 340 pg/ml DMPC, 40 pg/ml PI(4)P, 1 
mM sodium deoxycholate, 1 mM HEPES and 10 pM EDTA), on ice. Reaction 
buffer or 10 pi of ARF proteins and/or 10 pi of the non-hydrolysable GTP- 
analogue GTPyS (both diluted in the same buffer), as required, was added to give 
a total volume of 40 pi. Each reaction was started, after preincubation in a water 
bath if required, with the addition of 10 pi of ice-cold MgATP (50 pM final), 
-0.185 MBq [y-32P]ATP, MgCb (5 mM final) and DTT (1 mM final) and 
transferred to a water bath at the required temperature. Reactions were 
terminated after 20 minutes in most cases with 80 pi of 1M HC1 plus 180 pi of 
methanokchloroform (1:1) and thorough mixing. The emulsion was resolved into 
two phases by centrifugation and 10-40 pi of the organic phase spotted on a silica 
gel 60 TLC plate pretreated with potassium oxalate and preheated. Spots of 
[32P]PI(4,5)P2 were clearly resolved using chloroform:acetone:methanol:acetic 
acid:water (46:17:15:14:8) as the mobile phase and identified through comigration 
of standards. Radioactivity was quantified on a Fuji Bas phosphorimager.
PI3K A ctivity  Assay
This in vitro assay is equivalent to the PI(4)P5K activity assay but using 10 
pi of PI3K la, I|3,18 or Iy (both plOl/pllOy or 130 nM on its own). DMPC:PI(4)P 
vesicles are substituted by sonicated PI vesicles generated in the kinase activity 
assay buffer. PI(4,5)P2 vesicles could also be used to asses kinase activity. 
Recombinant pllOy was obtained from Prof Peter Shepherd (Department of 
Biochemistry, UCL, London), recombinant plOl/pllOy from Dr Len Stephens 
(Babraham Institute, Cambridge) and recombinant pllOa/p/8 from Prof Mike 
Waterfield (Ludwig Institute for Cancer Research, UCL, London).
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Pl(4)P 5K  Assay in SLO -P erm eabilised HL60 Cells
In order to be able to gain access to the interior of the cell, where the 
interaction and activation between PI(4)P5K and ARF proteins takes place, it was 
necessary to permeabilise HL60 cells using the toxin streptolysin-O (SLO). SLO is 
a cytolytic protein secreted by the genus of bacteria Streptococcus, which 
specifically binds to cholesterol present in the plasma membrane and penetrates 
it, by generating transmembrane channels or pores of between 25 and 30 nm in 
diameter (Bhakdi et al, 1985). At the concentrations used in this study SLO 
generally preserves the architectural integrity of the cells, but allows the loss of 
soluble components of the cytosol through these pores, and not those cellular 
components that have strong interactions with membranes or the cytoskeleton. 
Thus way, the reintroduction into cells of specific low molecular weight agents, 
such as ARF or GTPyS, becomes possible and allows for the study of their 
influence on the activity of PI(4)P5Ks.
After 48 hours of growth, 40 ml from a 50 ml HL60 cell culture was 
centrifuged and resuspended in 978 pi of kinase activity assay buffer together 
with 20 pi of SLO (final 0.4 IU/ml) and 2 pi of EGTA (final 0.2 mM). EGTA was 
included in the buffer to chelate any free calcium released during 
permeabilisation. The cells were permeabilised for 10 minutes at 37°C. Proteins 
such as ARF were shown to leak out of the cells within 5-10 minutes (Fensome et 
al, 1996). At the end of this step, the permeabilised cells were sedimented by 
centrifugation at 3000xg for 5 minutes to remove the cytosolic components that 
had leaked out during permeabilisation. The permeable HL60 cells were then 
resuspended in kinase buffer once more. For time course experiments the cells 
were then split into 4x400 pi tubes, together with 200 pi of buffer and 10 pi of 1M 
DTT, as well as 200 pi of ARF (1 pM final), GTPyS (10 pM final) and/or buffer on
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ice. The mixes were left standing on ice for 5 minutes to allow for the different 
components to diffuse inside the cells. The phosphorylation reaction was started 
by transfer of the tubes into a 37°C water bath along with synchronised addition 
of 200 pi of [y-32P]MgATP (same final concentration as in the standard kinase 
assay). Triplicate samples were taken out of each tube at established time-points 
and transferred into tubes containing 80 pi of 1M HC1 in order to halt the 
reactions. The rest of the procedure coincides exactly with the standard PI(4)P5K 
activity assay. The amount of PIP, PIP2, PIP3 and PA yielded during the 
incubation was established by differential migration on the TLC plate. The 
identity of spots on the TLC plates was confirmed by HPLC analysis or co­
migration of standard samples.
A variation of this assay is used in Chapter 5 (below) at fixed-time points 
(10 minute) with recombinant PI 3-kinase (pllOy) in half of the samples, as well 
as nonmyristoylated isoforms of ARF1 and 6 and a N-terminal truncated isoform 
of ARF1. All other constituents were used at the same final concentration but 
divided from the beginning into separate 50 pl-final reaction volumes (per 
triplicate). The reactions were conducted as if performing a PI(4)P5K activity 
assay. All tubes carried 10 pi of cell resuspension and 10 pi of MgATP, together 
with 10 pi of ARF proteins, 10 pi of GTPyS and/or 10 pi of diluted pllOy (130 nM 
stock) substituted with buffer under those conditions where one or several of 
these components were absent from the mixture.
Protein  Interaction  E xperim en ts
In an attempt to demonstrate the existence of a physical association of 
PI(4)P5K and ARF proteins, the following method was developed. 100 pi of HA 
antibody-coated packed beads was initially blocked with 1 ml of lysis buffer 
containing 5 mg/ml of BSA for 1 hour at 4°C. The supernatant was removed and
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the beads resuspended in fresh BSA-containing lysis buffer, total volume of 1 ml. 
In order to immunoprecipitate the HAe-tagged ARF proteins, 50 pi of the pre­
blocked 50% bead slurry was added to 300 pi of cells lysates containing 
recombinant ARF (typically one millilitre of lysate corresponded to the whole 
lysed content of a transfected 100 mm-dish), alongside a control tube composed 
of 50 pi of slurry solution and 300 pi of 1 mg/ml HA peptide (to block the 
antibody) and 0.1 mg/ml BSA in lysis buffer, and left to rotate at 4°C for 1 hour. 
Subsequently, the beads were washed 3 times in lysis buffer (plus BSA) and 25 pi 
of GST-fusion PI(4)P5Ka-containing lysate. Another 175 pi of lysis buffer (plus 
BSA) was added to the beads. Recombinant HA-ARF loaded beads and 
PI(4)P5Ka lysates were left to rotate at 4°C for 1 hour, after which the beads were 
washed 3 more times in lysis buffer and a final time in kinase activity assay 
buffer. After resuspension of the beads in a final volume of 100 pi of kinase 
activity assay buffer, 10 pi were used to asses the associated lipid kinase activity 
(standard PI(4)P5K activity assay) and the remaining 90 pi were used to quantify 
the amount of ARF (using anti-HA antibody), PI(4)P5Ka (using anti-PI(4)P5Ka 
antibody) and final amount of beads after extensive handling (by measuring the 
final amount of HA antibody present per sample using the anti-mouse HRP- 
conjugate secondary antibody). These values were used to normalise the ARF- 
associated PI(4)P5Ka protein mass and activity.
In Vitro Effect o f P K C a o n  PI(4 )P 5 K a  A ctivity
To evaluate the effect of the protein kinase PKCa on the activity of soluble 
PI(4)P5Ka expressed in bacteria, the following protocol was developed. First, it 
was necessary to combine and preincubate both enzymes with the required 
PKCa-activating effectors (see Chapter 4). In a total volume of 30 pi, 15 pi of 
soluble PI(4)P5Ka and 1 pi of PKCa (1/10 dilution of 0.11 mg/ml stock) had to be
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preincubated together for 60 minutes at 37°C in the presence of 6 pi of 375 pM 
ATP and 6 pi of PS/DAG/Ca2+ solution (500 pg/ml PS, 100 pg/ml DAG, 1 mM 
HEPES (pH 7.4), 0.03% (w/v) Triton X-100, 0.02% NaNs and 500 pM CaCk) and 2 
pi of standard PI(4)P5K activity assay buffer to make up the volume.
After allowing time for potential phosphorylation to occur, the lipid 
kinase could be extracted from the mixture by affinity purification using 
glutathione sepharose beads. 50 pi of packed beads was added along with kinase 
activity assay buffer and rotated for 1 hour at 4°C. Consequently, all PKC 
effectors could be removed from contact with PI(4)P5Ka to avoid their direct 
interference in its activity. To achieve this the beads were first introduced into 10 
pm-pore microfilters (Whatman) to minimise losses of small quantities of beads 
through manipulation. The activity of the associated lipid kinase could then be 
assessed either on the beads or after its elution through the microfilters using 10 
mM reduced glutathione.
Finally, normalisation of the results became imperative as handling of the 
beads provided differences in the recovery of the different samples in any one 
experiment. Since the lipid kinase was generated as a GST-fusion protein, its 
associated glutathione S-transferase activity could be used as a direct indicator of 
protein concentration. Such activity was proportional to the quantifiable rate of 
formation of a yellow product after addition to the protein solution of 1 mM final 
concentration of reduced glutathione, 1 mM l-chloro-2,4-dinitrobenzene (CDNB) 
and 10 mM potassium phosphate buffer (pH 6.5) at room temperature (according 
to the Amersham GST Detection Module protocol). The rate of appearance of the 
yellow product was measured in a plate reader at 340 nm, and the kinase activity 
values normalised against these rates.
Alternatively, the same assay could be performed by substitution of the 
soluble PI(4)P5Ka from bacterial origin for enzyme expressed in mammalian
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cells. In this case, HA-tagged PI(4)P5Ka was used associated with beads. The 
preincubation and quantification of the kinase activity was performed as before, 
without eluting the lipid kinase from the beads due to the limited yield of this 
process.
In Vivo Effect o f  PA/DAG/PM A on PI(4) P S K a  A ctivity
Cos7 cells were grown to the appropriate confluence for transfection 
(according to Qiagen's Polyfect Transfection Reagent instructions) in fifteen 35- 
mm dishes, and twelve of them were transfected with the pEBG-PI(4)P5Ka or 
pEBB-PI(4)P5Ka-HA plasmids. After 48 hours of expression, the cells were 
gently washed with PBS, and 500 pi of fresh DMEM medium were added (to the 
3 untransfected control and 3 transfected control dishes), along with 1 mM diC8- 
PA (3 transfected dishes), 1 mM diC8-DAG (3 transfected dishes) or 100 nM 
phorbol myristate acetate (PMA) (3 transfected dishes). The cells were left to 
incubate at 37°C for 30 minutes, after which the medium was removed, the cells 
washed with PBS and lysed using 500 pi of the previously described standard 
low salt lysis buffer, on ice. The lysates were collected in eppendorf tubes, 
sonicated to ensure complete cell lysis and cellular debris removed by 
centrifugation. All steps were performed at 4°C. The recombinant kinase was 
then extracted out of the supernatant as described previously, with 30 pi of 50% 
slurry of either glutathione sepharose beads or HA-antibody coated beads, as 
appropriate, washed and resuspended in 100 pi final volume of kinase activity 
assay buffer. 10 pi samples were used to assay kinase activity and the remaining 
90 pi to quantify the amount of kinase recovered through western blotting in 
order to normalise the activity against the amount of kinase expressed/recovered.
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N eutrophil M igra tion  A ssay
Isolation of Neutrophils. Human whole blood was collected by ante-cubital 
venipuncture into acid citrate dextran, ACD (4.2%, (w/v) disodium hydrogen 
citrate-l,5-hydrate and 5%, (w/v) D-glucose). 20 ml of blood was mixed with an 
equal volume of 6-hydroxy ethyl starch (eloHAES) and 5 ml 10% (v/v) ACD 
(ACD diluted 1:10 (v/v) in 0.9 % (v/v) NaCl) and incubated for 45 min to allow 
sedimentation. The upper layer containing the leukocyte rich buffy coat was 
removed and centrifuged at 600xg for 10 min at 18°C. The resulting supernatant 
was discarded except for 2 ml in which the cell pellet was resuspended. Percoll 
diluted 10:1 (v/v) with 9% (v/v) NaCl, was designated 100% percoll. This was 
then further diluted with PBS to produce 80%, 70% and 55% (v/v) percoll 
solutions. Gradients were prepared with 4 ml 80% percoll as the base layer, 4 ml 
70% percoll as the middle layer and 3 ml 55% percoll as the top layer. The 
resuspended cell pellet was gently layered on top of the percoll gradient and 
centrifuged at llOOxg for 25 minutes at 18°C. This procedure separated the 
neutrophils held at the 80/70% interface and they were then washed three times 
in HBSS. The cells were counted using a haemocytometer and Kimura counter­
stain, and resuspended at 2x106 cells/ml in neutrophil buffer (HBSS 
supplemented with 20mM HEPES (pH 7.2) and 0.1% BSA). The neutrophils were 
left to recuperate for 1 h prior to chemotaxis.
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M easurem ent of Chem otaxis. Chemotaxis of neutrophils was measured in a 48 
well modified Boyden chamber (Neuro Probe Inc.) by modification of standard 
methods (Wilkinson, 1998; Matsushima et al., 1989). Neutrophils were 
resuspended at a concentration of 2x106 cells/ml in neutrophil buffer. 
Chemoattractant peptide fMLP (lOnM) in neutrophil buffer was loaded into the 
lower wells, so that the wells were filled with a slight convex meniscus 
(approximately 29pl), taking care to ensure that no air bubbles were present in 
the wells. For each compound dissolved with the chemoattractant, 6 wells were 
filled. A 3-pm pore cellulose nitrate filter, pre-soaked in neutrophil buffer was 
placed over the lower wells. The rubber gasket was placed onto the filter and the 
upper block was clamped over the lower block. The chamber was then covered
Figure 2.1 An overview of measurement of chemotaxis
Chemoattractant (29jj.I) is loaded into the bottom  wells and a cellulose nitrate filter is placed on top. A 
rubber gasket is placed over the top  of the filter and the upper chamber is clamped on top. The 
chamber is preincubated for 15 min at 37°C and 50|il neutrophils at 3 x I06 are loaded into the top 
well. The chamber is then incubated for 90 min at 37°C before the filter is removed. The filter is then 
fixed and stained and mounted on microscope slides prior to  cell counting
3xl06 neutrophils/ml
Upper chamber: 
Neutrophils
Filter fixed, stained and mounted 
on microscope slide
Lower chamber: 
Chemoattractant
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with a glass slide to prevent evaporation and p re-incubated at 37°C for 15 min. 
Following preincubation, 50 pi neutrophil cell suspension was loaded into each 
of the upper wells; again care was taken to ensure there were no air bubbles 
present in the wells. Together with the cells, Brefeldin A (5 pg/ml), wortmannin 
(100 nM), butan-l-ol or butan-2-ol (1% v/v) were also loaded to assess their effect 
on migration. Controls with DMSO (<0.2 % v/v) were also tested in both the 
upper and lower chambers to discount any effect caused by the solvent. The 
chamber was incubated at 37°C for 60 min to allow migration of the cells through 
the filter. The filter was then removed and the cells in the filter fixed in 70% (v/v) 
ethanol. The neutrophil nuclei were stained with haematoxylin and the filter 
dehydrated with a series of alcohol steps as follows:
Solution
A lc o h o l D e h y d ra t io n
Tim e Effect
70% (v/v) ethanol 5 min Fixative
Distilled H20 1 min Wash
Haematoxylin 45 sec Stain
Distilled H20 1 min Wash
Tap water 2-3 min Wash
70% (v/v) ethanol 2 min Dehydration
95% (v/v) ethanol 2 min -
8:2 ethanolrbutanol 5 min .
Table 2.2 Protocol for dehydration of the cellulose nitrate filter.
List of washes with different com pounds and the corresponding incubation times for dehydration of the 
cellulose nitrate filter for visualisation and quantification of em bedded cells.
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The cellulose nitrate filters are opaque, and must be cleared in xylene 
before mounting onto glass slides. Once the filter had been dehydrated it was 
soaked in 100% (v/v) xylene overnight. The filter was cut into 4 sections and 
mounted onto glass slides using DePex mounting medium (EMS). A glass 
coverslip was applied, making a waterproof seal to prevent the filter from 
rehydrating. The same field was chosen at the centre of each well and cells were 
counted blind to limit observer bias (40x objective, 6x eyepiece). All cells that had 
migrated more than 20 pm into the filter were counted. This is termed the 
leading front method. An overview of measurement of chemotaxis is presented 
in Figure 2.2. Studies by Wilkinson (1998) have shown that the leading front 
method yields consistently closer replicates for each concentration of 
chemoattractant used. Figure 2.2 indicates two possible migration patterns of 
cells through the filter. At a set point in the filter 20pm there may be an equal 
number of cells in the presence of two different concentrations of 
chemoattractant (A and B). However, the number of cells in the filter after this 
point will vary. This means that two different concentrations of chemoattractant
Figure 2.2 Example of 
different migration patterns 
of neutrophils towards a 
chemoattractant
A and B represent the 
migration patterns of 
neutrophils through a 120 pm 
filter in the presence of tw o 
different concentrations of 
chem oattractant. The arrow  
indicates the same num ber of 
cells at the given distance of 20 
pm.
Distance into the filter (pm)
100 i
80 -
33a>
© 60 - a .
©
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I  4 0  -  c
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may give the same apparent cell migration at a chosen distance, while in reality 
the total number of cells migrating through the filter is different. The leading 
front method allows all the cells in the filter beyond a set point to be counted, in 
order to indicate the actual migration of the cells into the filter. The start point is 
chosen where there are enough cells per field to represent the population 
(approximately 1-200 cells), but where each cell is distinct from neighbouring 
cells. In all chemotaxis experiments, the start point was standardised at 20 pm 
from the top of the filter.
Preparation of Compounds
P reparation  o f  Lipid M ix tu res for Kinase A ctiv ity  Assays
The standard lipid mixture for PI(4)P5K activity assay was prepared by 
mixing in an eppendorf tube 1.7 mg of DMPC and 100 pi of 2 mg/ml PI(4)P. 
Subsequently, the chloroform was evaporated under nitrogen gas and 500 pi of 
10 mM sodium deoxycholate and 500 pi of 10 mM HEPES (pH 7.5) and 0.1 mM 
EDTA solution were used to resuspend the lipids by thorough sonication and 
vortexing (yielding a final concentration following dilution in the standard assay 
mixture of 40 pM PI(4)P and 500 pM DMPC). The 1 ml of lipid stock solution was 
kept at -20°C.
Variations to this lipid mixture were also used to assess the influence of 
different lipids in the activity of PI(4)P5K. In such cases, the preparation 
procedure was the same, nevertheless the amount of PI(4)P was generally 
increased to 80 pM final to equal that of the other lipids under study. The effect 
of the presence or absence of DMPC and deoxycholate or Triton X-100 was also 
determined by using different combinations of lipids with DMPC and 
detergents.
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the external medium and thus simplify the purification process by reducing the 
amount of soluble proteins in the supernatant. Cells were grown until they 
senesced and started dying. The supernatant was then collected after 
sedimentation of the cells and the soluble antibody concentrated by ammonium 
sulphate precipitation (75% saturation) at 4°C during a minimum period of 4 
hours. The precipitate was collected by centrifugation and then dialysed over 24 
hours with three changes of 5 litres of 0.1M NaHCCh and 0.5M NaCl at 4°C. The 
final protein concentration was adjusted to 5 mg/ml before coupling to 
sepharose. CNBr-activated Sepharose 4 FastFlow beads were used, after their 
activation by 10 consecutive washes with 50 ml of ice cold ImM HC1 (according 
to the manufacturer's instructions). The beads and the antibody were mixed 
together and left to rotate overnight at 4°C, leading to efficient coupling. The 
remaining reactive groups were then blocked with 0.05M glycine (pH 8), and the 
beads aliquoted and stored at -20°C until needed.
Preparation  o f  6 X  SDS S am ple Buffer
6X SDS sample buffer (0.376 M Tris, pH 6.8,12% SDS, 60% (w/v) glycerol, 
0.6 M DTT, 0.06% (w/v) bromophenol blue) was prepared by diluting 9.4 ml of 1 
M Tris (pH 6.8) into 15.6 ml of water in a beaker. Then, 15 g of liquid glycerol, 3 g 
of SDS, 15 mg of bromophenol blue and 2.3 g of DTT was added to the Tris 
buffer and allowed to dissolve. Another extra 15 g of glycerol was finally added 
after complete dissolution of the components, and aliquots of 6X SDS sample 
buffer were finally stored at -20°C.
Expression of Data
All results presented are from individual experiments repeated at least 
three times with similar results, unless otherwise stated. Within each of these
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individual experiments all discrete measurements were made as triplicates and 
occasionally quadruplicates, with the exception of the protein-interaction 
experiments where single replicates were used. Data and statistical analysis were 
performed by SigmaPlot 8.0 and Excel software. Statistical significance of the 
values was evaluated by Student's Mest. Oftentimes it was necessary to describe 
the significance of statistical relationships between various different 
measurements within one experiment. Under these circumstances, precise p 
values are described in the accompanying text.
The analyses of the amino acid sequences of the proteins of interest 
described in this thesis were conducted as described in the legends of the 
corresponding figures and tables. Further analysis was performed to determine 
the extent of sequence identity between representative members of a particular 
protein, using ClustalW (www.ebi.ac.uk/clustalw) and Boxshade 
(www.ch.embnet.org/software/BOX_form.html). Domain information was obtained 
using the Conserved Domain Database or CDD (www.ncbi.nlm.nih.gov/Structure/ 
cdd/wrpsb.cgi).
Molecular models of proteins obtained by crystallography were rendered 
using PyMOL 0.97 Software (DeLano, W.L. The PyMOL Molecular Graphics 
System (2002) (www.pymol.org). Coordinates were retrieved from PDB.
I l l
Chapter Four
Regulation of Type I 
PI(4)P5K by ARF
Proteins
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4.1 INTRODUCTION
There are six known mammalian ARF family members which have been 
classified in three different groups according to their size and sequence 
similarity. Class I is composed of ARF1, ARF2 and ARF3, ARF4 and ARF5 form 
Class II and ARF6 is the sole member of Class III (Moss and Vaughan, 1995). This 
group of small GTP-binding proteins are post-translationally modified with the 
addition of a myristate group on a glycine (G2) on their N-terminus by N- 
myristoyltransferase (NMT) (Khan et a l, 1988). This acyl chain is indispensable 
for the effective binding of ARF to membranes where it needs to be localised to 
fulfil its function.
ARF1, ARF5 and ARF6 have been shown to be activators of Type I 
PI(4)P5K, but there have been no exhaustive comparative studies aiming to 
clarify whether there is any preferred combinations of G-protein or kinase 
isoforms. Using a bacterial co-expression system based on the yeast myristoyl- 
CoA:protein NMT coexpression system of Duronio et al. (1990), recombinant 
ARF1 and ARF6 were synthesised in E. coli in their fully myristoylated or 
nonmyristoylated forms. These purified proteins were used to investigate the 
comparative activation of Type I PI(4)P5Ks using both cell-free and 
permeabilised-cell assays. Finally, wild type ARF proteins along with 
constitutively active and dominant-negative mutants were expressed in 
mammalian cells and used for precipitation experiments to try and prove a direct 
interaction between ARF and Type I PI(4)P5K and explore the properties of the 
interaction.
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4.2 RESULTS
Purification Of ARF Proteins And PI(4)P5Ks
ARF proteins purified from bactera were subjected to two consecutive 
purification steps. ARF proteins obtained from cell lysis were first loaded on Ni- 
NTA column and eluted with a linear gradient of imidazole (Figure 4.1). A single 
symmetric peak for each ARF isoform was obtained and the corresponding 
fractions under this pead were pooled and loaded on a penyl Supersoe column in
B
ARF6ARF I
Figure 4 . 1 Elution of ARF proteins from Ni-NTA column.
The supernatant obtained after cell lysis was applied to  a 25 ml bed volume column of Ni-NTA, which had 
previously been equilibrated in 100 ml of Nickel column buffer (20 mM NaH2P 0 4, 20 mM Tris, 300 mM 
NaCl, 0.2% NaN3 (w/v), pH 6.0) followed by 100 ml of the same buffer supplemented with 0.5 M 
imidazole and then followed by 50 ml of a mixture (5:2 ratio) of lysis buffers I and 2 respectively (see 
Materials and Methods section for more details). Proteins were eluted with a linear gradient of 0 to 0.5 M 
imidazole in the Nickel column buffer. Fractions of 5 ml were collected. Protein elution was monitored by 
absorbance at 280 nm.
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a second chromatographic step in which myristoylated ARFs were resolved from 
the underivitised forms by hydrophobic intection chromatography. Example of 
chromatogram of phenyl Superose fractionation step in ARF1 purification is 
shown in Figure 4.2. The peaks of myristoylated ARF1 and nonmyristoylated 
ARF1 are indicated.
The extent of myristoylation of the protein preparations was determined 
by reverse phase HPLC. The myristoylated forms of the proteins showed a 
characteristic increase in retention time. The profile of myristoylated and
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F igu re 4 .2  Bovine ARF I w as coexpressed  with NMT and purified as described in 
Materials and M ethods section.
A. Elution o f myristoylated recombinant ARF I from phenyl-Superose. Fractions pooled from  th e  Ni- 
NTA column w ere  concen tra ted  and m ade to  I M w ith solid ammonium sulphate and applied to  
th e  phenyl-Superose column equilibrated w ith buffer containing I M ammonium sulphate. Proteins 
w ere  eluted w ith a descending am m onium  sulphate gradient and 8 ml fractions w ere  collected. 
Protein elution was m onitored  by absorbance at 280 nm. T he peaks of nonmyristoylated (peak I) 
and myristoylated (peak 2) a re  indicated.
B. Analysis by HPLC o f purified recombinant bovine ARF I. The tw o peaks correspond  to  
nonmyristoylated ARF I (RT a  28 min) and 10 0 %  myristoylated ARF I (RT a  4 1 min). T he peaks can 
be seen to  have been resolved in th e  tw o  separate, but overlaid, chrom atogram s.
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Figure 4 .3  Analysis by HPLC of purified m ouse ARF6.
Mouse ARF6 was coexpressed with NMT and purified as described in Materials and Methods 
section. A. The second peak corresponds to  nonmyristoylated ARF6 (RT *  15 min). B. The second 
peak corresponds to  myristoylated ARF6 (Rx «  26 min).
nonmyristoylated ARF1 and ARF6 is shown in Figures 4.2 and 4.3.
SDS-PAGE analysis indicated a unique 21 kDa band corresponding to the 
expected molecular weight of ARF1 (Figure 4.4).
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Figure 4.4 SDS-PAGE analysis of purified 
recombinant myristoylated ARF I and ARF6.
SDS-PAGE analysis of fractions of His-tagged 
myristoylated ARF I and ARF6 following the 
hydrophobic interaction chromatographic step. 
The proteins w ere visualised using Coomassie 
blue dye.
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ARF Proteins Activate All Isoforms Of Recombinant Type I 
PI(4)P5K Expressed In Bacteria
In the following experiment, the ability of recombinant ARF proteins 
expressed in bacteria to activate the three known isoforms of 
phosphatidylinositol 4-phosphate 5-kinase, a, P and y was tested in vitro. The 
recombinant kinase used was also of bacterial origin (see figure 4.5). It is 
important to clarify that the ARF proteins used in these experiments were either 
100% myristoylated or not myristoylated at all. Previous comparative work 
found in the literature has generally been based on the use of partially 
myristoylated recombinant ARF proteins, w ith no exact details about the degree 
of myristoylation or equalisation of this factor between ARF isoforms. This is a 
key point when it comes to comparing the potency of activation of the lipid 
kinase by different ARFs, especially if it is true that the myristoylation has an 
effect on the interaction.
a p a
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Figure 4.5 SDS-PAGE analysis of 
purified recombinant Type I PI(4)P5Ks.
SDS-PAGE analysis of fractions of 
recombinant GST-tagged PI(4)P5K a, P and 
y expressed in bacteria (left panel), and 
recombinant HA-tagged PI(4)P5Ka (right 
panel). The proteins were visualised using 
Coomassie blue dye.
The kinase has a basal activity and this can be increased by ARFs in the 
presence of GTPyS. Figure 4.6 shows that 100% myristoylated ARF1 used at 1 pM 
(hereafter, all the experiments were performed using a 1 pM concentration unless 
otherwise stated) had an effect in the amount of PI(4,5)P2 generated by all three 
isoforms of the kinase. This is the first demonstration of the universality of this
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600
100%  m yristoylated ARF I N onm yristoylated  ARF I
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Figure 4 .6  In vitro activation of recombinant Type I PI(4)P5K a ,  P and y expressed in bacteria 
by 100% myristoylated ARF I and nonmyristoylated ARF I.
Recombinant Type I PI(4)P5K was expressed in £  coli as GST-tagged fusion protein, recovered on 
glutathione-sepharose beads, eluted from the beads with 25 mM reduced glutathione, dialysed and stored in 
frozen aliquots. A sample of each kinase was taken and diluted in kinase buffer to  obtain detectable and 
similar phosphorylation levels, and mixed with the different ARFs at I |oM final concentration with or without 
10 pM GTPyS. Reactions were stopped after 20 minutes at 25°C by addition of 80 pi of 10% (v/v) HCI. PIP2 
levels were measured as described in the Materials and Methods section.
Data shown are mean ± S.E.M. of 4 (mARFI) and 3 (ARFI) separate experiments within which 
measurements were made in triplicate. For comparison, data are shown relative to  the appropriate internal 
control since the absolute activity varied with kinase isoform. The statistical significance of the data was 
evaluated using Student’s t te s t
effect towards all known PI(4)P5K isoforms. The effect was more prominent in 
the case of the a  isoform, 328 ± 13%, followed by PI(4)P5K p, 226 ± 24% and y, 170 
± 16% (P<0.004/n=4). In all cases, the sole addition of GTPyS or the recombinant 
protein in the absence of GTPyS was not sufficient to increase the production of 
PI(4,5)P2. When the same experiment was performed using nonmyristoylated 
ARF1, there was no variation on the activity of the kinase in comparison to the 
control in any of the three isoforms assayed. This means that the myristate group 
is strictly necessary for the activation of PI(4)P5K by ARF1.
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Figure 4 .7  In vitro activation of recombinant Type I PI(4)P5K a ,  P and y expressed in bacteria 
by 100% myristoylated ARF6 and nonmyristoylated ARF6.
Recombinant Type I PI(4)P5K was expressed in £. coli as GST-tagged fusion protein, recovered on 
glutathione-sepharose beads, eluted from the beads with 25 mM reduced glutathione, dialysed and stored in 
frozen aliquots. A sample of each kinase was taken and diluted in kinase buffer to obtain detectable and 
similar phosphorylation levels, and mixed with the different ARFs at I pM final concentration with or without 
10 pM GTPyS. Reactions w ere stopped after 20 minutes at 25°C by addition of 80 pJ of 10% (v/v) HCI. PIP2 
levels were measured as described in the Materials and Methods section.
Data shown are mean ± S.E.M. of 4 separate experiments within which measurements were made in 
triplicate. For comparison, data are shown relative to  the appropriate internal control since the absolute 
activity varied with kinase isoform. The statistical significance of the data was evaluated using Student’s t test.
The requirement for myristoylation was also observed when ARF6 was 
used instead of ARF1 (Figure 4.7). In this case, 100% myristoylated ARF6 
activated the a  isoform more strongly, 496 ± 36%, followed by y and then p, 298 ± 
25% and 268 ± 19% (p<0.001/n=3) respectively. Curiously, there was also a small 
effect of mARF6 in the absence of GTPyS in the case of the murine P isoform (125 
± 14%) (p=0.019/n=3). In the presence of non myristoylated ARF6, neither the a 
nor the y isoforms were activated. However, the levels of PIP2 generated by the p 
isoform were still increased in the absence of the myristate group (203 ± 34%), 
and even in the absence of GTPyS (159 ± 13%) (P<0.012/n=3).
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Finally, Figure 4.8 shows how the effect of a mutant form of ARF1 which 
lacks the 17 amino acids which constitute the N-terminal a-helix and, 
consequently, the myristate group, rendered unchanged the activity of the three 
lipid kinase isoforms. This mutant has been shown to maintain its ability to bind 
guanine nucleotide but not to activate phospholipase D (Zhang et al, 1995; Jones 
et al, 1999; Ha, 2003). Therefore, the failure to activate phosphatidylinositol 4- 
phosphate 5-kinase is not due to the inability to bind GTPyS and subsequently 
undergo structural transitions in switch regions associated with this change.
AI7ARFI
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Figure 4.8 In vitro activation of recombinant Type I PI(4)P5K a, P and y expressed in bacteria by 
the nonmyristoylated A 17ARFI mutant.
Recombinant Type I PI(4)P5K was expressed in E. co/i as GST-tagged fusion protein, recovered on glutathione- 
sepharose beads, eluted from the beads with 25 mM reduced glutathione, dialysed and stored in frozen 
aliquots. A sample of each kinase was taken and diluted in kinase buffer to obtain detectable and similar 
phosphorylation levels, and mixed with the different ARFs at I pM final concentration with or without 10 pM 
GTPyS. Reactions were stopped after 20 minutes at 25°C by addition of 80 pi of 10% (v/v) HCI. PIP2 levels 
were measured as described in the Materials and Methods section.
Data shown are mean ± S.E.M. of 3 separate experiments within which measurements were made in triplicate. 
For comparison, data are shown relative to the appropriate internal control since the absolute activity varied 
with kinase isoform. The statistical significance of the data was evaluated using Student’s t test.
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Effect Of The Temperature On The Activation Of 
Recombinant PI(4)P5Ka Expressed In Bacteria By ARF I
The previous experiments were performed by preincubating the reaction 
mixture containing the lipid kinase, ARF, GTPyS and PI(4)P:DMPC vesicles in 
the absence of ATP at 37°C for 40 minutes. This is to maximise the exchange of 
nucleotides on ARFs and to allow protein-complex formation. Subsequently, the 
mix was set at room temperature and [y-32P]ATP together with carrier ATP was 
added to start the phosphorylation reaction. But considering that this 
preincubation could be altering the properties of the interaction, different 
preincubation times were used to assess this possibility. Also, the effect of the 
presence or absence of PI(4)P5Ka in the preincubation was considered.
Figure 4.9 (graphs on the left) shows the effect of different times of 
preincubation, 0, 20 or 40 minutes, without PI(4)P5K present in the mixture but 
added at the end immediately prior to the assay of kinase activity. The presence 
of mARFl (from now onwards, the use of ARF proteins will be restricted to the 
100% myristoylated forms unless otherwise stated) and GTPyS increased the 
production of PI(4,5)P2, with no significant differences amongst the different 
preincubation times assessed. If any, there might have been a slight increase in 
the activation by mARFl and GTPyS as the duration of preincubation was 
increased. But this improvement is relative to the control condition where there 
was only phosphatidylinositol 4-phosphate 5-kinase a  and PI(4)P vesicles and no 
preincubation. The activity of the control was also augmented by simply 
preincubating the reaction mixture, which means that in terms relative to each 
internal control, there was not only no improvement but a decrease in the effect 
of mARFl.
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F igu re 4 .9  In vitro  activation of recombinant PI(4)P5K l a  expressed in bacteria by 
mARF I after different tim es of preincubation with and without the kinase.
Recombinant Type I PI(4)P5Ka was expressed in £. coli as GST-tagged fusion protein, recovered 
on glutathione-sepharose beads, eluted from the beads with 10 mM reduced glutathione, dialysed 
and stored in frozen aliquots. A sample of the kinase was taken and diluted in kinase buffer to 
obtain detectable phosphorylation levels. PI(4)P/DMPC vesicles w ere mixed with o r w ithout 
recombinant mARF I at I pM final concentration and with or without 10 pM GTPyS. The mixtures 
w ere incubated at 37°C with o r w ithout the lipid kinase for 0, 20 or 40 minutes, after which they 
w ere set at room tem perature and 50 pM MgATP/[y-32P]ATP final concentration w ere added to 
start the phosphorylation reaction. After 20 minutes at 25°C, the reaction was quenched by 
addition of 80 pi of 10% (v/v) HCI. PIP2 levels w ere measured as described in the Materials and 
Methods section.
Data shown are mean ± S.E.M. of 3 separate experiments within which measurem ents w ere 
made in triplicate. For comparison, data have been plotted using the absolute values in relation to 
the control with only lipid vesicles (Total Values), and relative to  the appropriate internal control 
since activity of the kinase varied with the different preincubation times (Relative Values). The 
statistical significance of the data was evaluated using Student's t test.
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When the experiment was repeated but now with the inclusion of the lipid 
kinase in the reaction mixture (Figure 4.9, graphs on the right), a remarkable 
decrease in the production of PI(4,5)P2 was observed under all conditions relative 
to the control where there was no preincubation. However, if these results were 
plotted once again relative to the appropriate control for each time of 
preincubation, the greatest activation of the lipid kinase by mARFl and GTPyS 
was obtained after 40 minutes of preincubation.
The inclusion of the lipid kinase in the reaction mixture and the clear 
decrease in PI(4,5)P2 formation raises the question of what happens to the kinase 
that provokes such a dramatic reduction of activity? The one answer is that a 
fraction of the lipid kinase has suffered a process of denaturation due to the 
temperature, therefore the amount of active kinase capable of phosphorylating 
PI(4)P has been reduced and the ratio of ARF molecules per phosphorylating 
unit has increased, improving its apparent activation. Alternatively, 
preincubation might improve the capacity of the enzyme for auto­
phosphorylation once ATP is added, thus reducing its activity.
To properly evaluate this possibility, a time course of the production of 
PI(4,5)P2 at different temperatures was performed using recombinant 
phosphatidylinositol 4-phosphate 5-kinase la  expressed in £. coli. As seen in 
Figure 4.10, the production of PI(4,5)P2 was nearly linear and increased with time 
when the phosphorylation reaction was carried out at room temperature (25°C). 
Surprisingly, increasing the temperature provoked a decrease in the amount of 
PI(4,5)P2 generated, instead of accelerating the phosphorylation of substrate as 
would be expected from a situation closer to physiological conditions. When the 
reaction was performed at 30°C, after 20 minutes the amount of product was 
reduced to around half of the amount of product generated at room temperature 
(P=0.04/n=3). After 40 minutes the reduction was similar, just over one half
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Figure 4 .1 0  Time course of th e  production of PI(4,5)P2 by PI(4)P5K la  expressed in £. 
coli depending on th e tem perature.
A sample of kinase was taken and diluted in kinase buffer to  obtain detectab le phosphorylation levels 
and mixed with PI(4)P/DMPC vesicles. It w as then  se t at th e  determ ined tem pera tu re , and th e  
reaction was started  by addition of MgATP/[y-32P]ATP. Reactions w e re  sampled at each tim e point 
by removal of 3x50 pi identical triplicate sam ples of each reaction m ixture and transferred  into new 
tubes containing 80 pi o f 10% (v/v) HCI. PIP2 levels w ere  m easured as described in th e  Materials and 
M ethods section.
Data show n are mean ±  S.E.M. of 3 separate  experim ents within which m easurem ents w ere  m ade in 
triplicate. D ata shown have been  plo tted  relative to  th e  maximum overall value. T he statistical 
significance of th e  data w as evaluated using S tudent’s t test.
(P=0.003/n=3). When the reaction was performed at 37°C, after 20 minutes the 
amount of PIP2 was down to almost 1/6 of the equivalent at 25°C, and after 40 
minutes down to 1/9 (P<0.01/n=3). In fact, the amount of PI(4,5)P2 generated at 
37°C did not increase with time after the first 10 minutes, staying at a constant 
level throughout the rest of the time course. Clearly the enzyme had been 
effectively inhibited after only 10 minutes.
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ARF6 Is A B ette r Activator Of Recombinant Type I 
PI(4)P5Ka Expressed In Bacteria Than ARF I
In order to compare the potency of the activation of recombinant 
phosphatidylinositol 4-phosphate 5-kinase la  expressed in bacteria by 
recombinant 100% myristoylated ARF1 and ARF6, the effect of ARF proteins
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Figure 4 .1 I In vitro activation of recom binant PI(4)P5K la  expressed in bacteria by 
mARFI and mARF6 after 0 and 40 m inutes preincubation.
A sample of th e  kinase w as taken and diluted in kinase buffer to  obtain detectable phosphorylation 
levels. PI(4)P/DMPC vesicles w ere  mixed w ith or w ithout recom binant mARFI and mARF6 at I pM 
final concentration and w ith o r w ithout 10 pM GTPyS. The mixtures w ere incubated at 37°C with the 
lipid kinase for 0 o r 40 minutes, after which they  w ere  set at room tem perature and 50 pM MgATP/[y- 
32P]ATP final concentration was added to  s ta rt th e  phosphorylation reaction. After 20 minutes at 25°C, 
the  reaction was quenched by addition of 80 pi of 10% (v/v) HCI. PIP2 levels w ere  m easured as 
described in the  Materials and M ethods section.
Data shown are m ean ± S.E.M. of 3 separate  experim ents within which m easurem ents w ere  m ade in 
triplicate. For com parison, data have been plotted relative to  the appropriate internal control since 
activity of th e  kinase varied w ith th e  different preincubation tim es. The statistical significance of the  data 
was evaluated using S tudent’s t test.
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after 0 and 40 minutes of preincubation were compared. As Figure 4.11 shows, 
both mARFI and mARF6 were good activators of the lipid kinase in the presence 
of GTPyS, especially after preincubation at 37°C for 40 minutes. mARFI activated 
the kinase 3.60 ± 0.54 fold and mARF6 did it 4.96 ± 0.28 fold (p<0.008/n=3). But 
once again, the total am ount of PIP2 produced had been considerably reduced in 
comparison to the absence of preincubation, which is not noticeable in the graph 
since the values have been plotted relative to each internal control. This 
reduction was around 85% (data not shown). In the absence of preincubation, the 
activation by mARFI was more modest, 1.73 ± 0.10 fold; whereas mARF6 
provoked a 3.52 ± 0.44 fold activation of the lipid kinase (P<0.002/n=3). In both 
cases, it was clear that under the same conditions and using the same am ount of 
100% myristoylated small G protein, ARF6 was a better activator of PI(4)P5K la  
expressed in bacteria than ARF1. There was also a small activation of PI(4)P5K la  
by both mARFI and mARF6 in the absence of GTPyS under both preincubation 
conditions, being more apparent after 40 minutes; none were statistically 
significant.
ARF6 Is A Better Activator Of Recombinant Type I 
PI(4)P5Ka Expressed In Mammalian Cells Than ARF I
All the previous experiments were performed using recombinant 
phosphatidylinositol 4-phosphate 5-kinase expressed in bacteria. This raises the 
question of how trustw orthy the results are considering that any post- 
translational modifications of the enzyme are not achieved by using prokaryotic 
expression systems. To clarify this matter, the same experiments were carried out 
using recombinant phosphatidylinositol 4-phosphate 5-kinase a  expressed in 
mammalian cell lines, typically Cos7 cells. The recombinant kinase had a HA tag
126
Regulation o f Type 1 PI(4)P5K by ARF Proteins
100 i
E 80 -9E
X
CD
E 60 -
o
0 20 30 5010 40
Time (minutes)
Figure 4 .12 Time course of the production of PI(4,5)P2 by PI(4)P5K la  expressed in 
Cos7 cells depending on the tem perature.
Recombinant PI(4)P5K la  w as expressed  in C os7 cells as HA-tagged fusion protein, recovered  on 
anti-HA antibody-coated ^ a r o s e  beads, w ashed and s to red  in frozen aliquots. A sam ple of kinase- 
loaded beads was taken and diluted in kinase buffer to  obtain detectab le phosphorylation levels and 
mixed with PI(4)P/DMPC vesicles. It w as then  se t at th e  determ ined  tem peratu re , and th e  reaction 
was started  by addition of MgATP/[y-32P]ATP. Reactions w e re  sampled at each tim e point by 
removal of 3x50 pi identical triplicate sam ples o f each reaction m ixture and transferred  into new  
tubes containing 80 pi of 10% (v/v) HCI. PIP2 levels w e re  m easured as described in th e  Materials and 
M ethods section.
Data show n are mean ± S.E.M. of 3 sep ara te  experim ents within which m easurem ents w ere  m ade in 
triplicate. D ata shown have been p lo tted  relative to  th e  maximum overall value. T he statistical 
significance of th e  data w as evaluated using S tudent’s t test.
fused to its C-terminus which allowed for easy recovery after expression and 
lysis of the cells, using anti-HA antibody-coated (12CA5) sepharose beads.
Firstly, the influence of the temperature on the lipid kinase expressed in 
mammalian cells attached to the beads was tested. Once again increasing the 
temperature reduced the final am ount of PI(4,5)P2 as seen in Figure 4.12. In this 
case, when the reaction was run at room temperature (25°C), the 
phosphorylation rate stayed approximately linear only up to 30 minutes, 
whereas in the case of the enzyme expressed in E. coli it was linear all the way up
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Figure 4 .13 In vitro activation of recom binant PI(4)P5K la  expressed in Cos7 cells 
by mARF I and mARF6 after 0 and 40 minutes preincubation.
A sample of the  kinase was taken and diluted in kinase buffer to  obtain detectable 
phosphorylation levels. PI(4)P/DMPC vesicles w ere  mixed with or w ithout recombinant mARF I 
and mARF6 at I pM final concentration and w ith or w ithout 10 pM GTPyS. T he mixtures w ere 
incubated at 37°C with the  lipid kinase for 0 o r  40 minutes, after which they w ere  set at room 
tem perature and 50 pM MgATP/[y-32P]ATP final concentration was added to  start the 
phosphorylation reaction. After 20 minutes at 25°C, the  reaction was quenched by addition of 80 
pi of 10% (v/v) HCI. PIP2 levels w ere  m easured as described in the Materials and Methods 
section.
Data shown are mean ± S.E.M. of 5 separate experim ents within which measurem ents w ere 
made in triplicate. For comparison, data have been plotted relative to  the appropriate internal 
control since activity of th e  kinase varied with the  different preincubation times. The statistical 
significance of th e  data was evaluated using Student’s t test.
to at least 70 minutes (see Figure 4.10). When the reaction was run at 30°C, the 
amount of product generated was also lower than that generated at 25°C, and it 
was maintained linear only up until 20 minutes. After that time point, the 
production of PI(4,5)P2 did not increase for another 10 minutes and subsequently 
it declined possibly indicating PI(4,5)P2 hydrolysis, but this was not explored 
further. The same pattern was observed when the reaction was run at 37°C,
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although the linearity was only maintained for the first 10-12 minutes and also 
suffered a decline but at an earlier time point of 20 minutes. The amount of 
product at 37°C was 1/4 of that produced at room temperature after 20 minutes, 
and around 1/10 after 40 minutes (P=0.004/n=3).
Next, the activation of the recombinant lipid kinase from the mammalian 
expression system by mARFI and mARF6 was tested, with or without 
preincubation at 37°C. PI(4)P5K la  was present in the preincubation mixture. 
Figure 4.13 shows how an increase in the amount of PI(4,5)P2 was achieved by 
addition of both ARF isoforms, even though the greatest activation, 4.21 ± 0.3 
fold (P=0.0004/n=5), was with mARF6 and GTPyS after 40 minutes of 
preincubation at 37°C. In this case, as it happened with the enzyme expressed in 
bacteria, the preincubation enhanced the activation by mARF6 although the total 
levels of PI(4,5)P2 were considerably reduced if compared to the levels obtained 
without preincubation (it cannot be seen in the graph since the data have been 
plotted relative to the control of each preincubation condition). This reduction 
was of around 95% of the activity (data not shown). In the absence of 
preincubation, the activation by mARF6 and GTPyS was also considerable, 2.08 ± 
0.24 fold (P=0.011/n=5), even though it was less prominent. Again, there was an 
effect by mARF6 in the absence of GTPyS, 1.80 ± 0.42 fold (P=0.034/n=5) after 
preincubating the reaction mix. In the case of mARFI, the effect over the 
production of PI(4,5)P2 was much less significant than that obtained with the 
lipid kinase expressed in bacteria. The recombinant small G protein also exerted 
a positive influence on the activity of PI(4)P5K la, 1.51 ± 0.08 fold (P=0.003/n=5), 
but preincubating the mixture did not improve this effect considerably, 1.8 ± 0.42 
fold, as it did with the bacterial kinase or with mammalian mARF6. All in all, 
ARF6 was a better activator of phosphatidylinositol 4-phosphate 5-kinase la  in 
all different conditions tested (after 40 minutes preincubation P=0.009/n=5).
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ARF Myristoylation Is Necessary For The Activation Of 
Recombinant Type I PI(4)P5Ka Expressed In Mammalian 
Cells
Figure 4.14A presents the effect of nonmyristoylated ARF1, ARF6 and the 
deletion mutant A17ARF1 on the production of PI(4,5)P2 by recombinant 
phosphatidylinositol 4-phosphate 5-kinase la  expressed in Cos7 cells. No 
preincubation was carried out prior to starting the phosphorylation reaction of 
PI(4)P. None of the three isoforms was capable of activating the lipid kinase to 
considerable levels at any of the two concentrations assayed, 1 and 10 pM. In 
fact, the opposite effect was achieved in the case of ARF1. Unexpectedly, the 
production of PI(4,5)P2 was reduced as the am ount of ARF1 was increased. At 10 
pM, the amount of PIP2 had been reduced dow n to 48 ± 0.13% (P=0.01/n=3) of the 
control, and slightly more w ith GTPyS. A17ARF1 did now show an inhibitory 
effect at low concentrations, bu t it did as the am ount of the m utant small G 
protein was increased to 10 pM. At that concentration, A17ARF1 in the presence 
of GTPyS reduced the lipid kinase activity down to half of the control 
(P=0.009/n=3). None of these inhibitory effects were seen in the presence of ARF6. 
It must be pointed out that all three isoforms, specially at 1 pM, seem to provoke 
a reduction in activity of PI(4)P5K la  w hen GTPyS is present in comparison to 
when its absent. This is quite striking, considering that the activation by small G 
proteins of the ARF family is dependent on the binding of the nucleotide, or at 
least when they are myristoylated. Thus the influence of partially myristoylated 
ARF proteins in activation assays should be carefully reconsidered due to the 
inverse behaviour of the nonmyristoylated forms at high concentrations, which 
would be altering the overall picture of activation. Obviously, data obtained by
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other investigators using partially myristoylated ARFs will need to be re­
evaluated. 
Comparatively, Figure 4.14B shows the effect of the myristoylated forms 
of ARF1 and 6 on PI(4,5)P2 generation in the absence of preincubation. Both
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F igure 4 . 14  In vitro activation of recombinant PI(4)P5K la expressed in Cos7 cells by 
different ARFs at different concentrations.
Recombinant Type I PI(4)P5K a  was expressed in Cos7 cells as HA-tagged fusion protein, recovered 
on anti-HA antibody-coated agarose beads, washed and stored in frozen aliquots. A sample of 
kinase-loaded beads was taken and diluted in kinase buffer to  obtain detectable phosphorylation 
levels. It was then mixed with PI(4)P/DMPC vesicles, with or without I o r 10 pM ARF proteins and 
with (■) o r w ithout ( • )  10 pM GTPyS at room  tem peraure. The reaction was started by addition of 
MgATP/[y-32P]ATP. After 20 minutes at 25°C, 80 pi of 10% (v/v) HCI w ere added to  quench the 
reaction. PIP2 levels w ere  m easured as described in the Materials and Methods section.
Data shown are mean ± S.E.M. of 4 (A) o r 3 (B) separate experiments within which m easurem ents 
w ere made in triplicate. Data shown have been plotted relative to  the control. The statistical 
significance of the data was evaluated using Student’s t test.
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mARFI and mARF6 activated PI(4)P5K la  in a concentration dependent manner 
and exclusively in the presence of GTPyS. At both 1 and 10 pM concentrations, 
mARF6 was a better activator of the lipid kinase (P<0.02/n=4). In the absence of 
GTPyS there was a very m odest activation at 1 pM, of around 26% (P<0.001/n=4) 
by both isoforms which decreased as the am ount of ARF raised. In the case of 
mARFI, when the concentration reached 10 pM the am ount of PIP2 produced 
was reduced to 63 ± 0.30% (P=0.014/n=4) in the absence of GTPyS. This effect is 
similar to that observed w ith nonmyristoylated ARF1 or A17ARF1 at high 
concentrations, and it did not occur in the case of myristoylated ARF6.
Nonmyristoylated, Fully GDP- and GppNHp-Loaded ARF6 
Is A Better Activator of PI(4)P5Kla Than ARF I
In an attempt to reject the hypothesis that the better activation by ARF6 
was a consequence of better nucleotide loading capability in comparison with 
ARF1, fully GDP- or G ppN Hp- (another non-hydrolysable GTP analogue) 
loaded recombinant proteins were obtained and their ability to activate PI(4)P5K 
la  expressed in mammalian cells was assessed. Nonetheless, the ARFs were not 
myristoylated, implying that the conclusions extracted m ust be considered 
carefully as that is not the physiological nature of the wild-type small G protein. 
Figure 4.15 represents the am ount of PI(4,5)P2 generated by the lipid kinase in 
the presence of the different ARF proteins, demonstrating that the preferential 
activation by ARF6 is still m aintained (p<0.03/p=3) even after fully loading of the 
GTPases with both GDP and G ppN H p and in the absence of myristoylation. No 
effect was seen at 25°C or at 1 pM-ARF concentration (not shown).
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Figure 4 .15 In vitro activation of recom binant PI(4)P5K la expressed in Cos7 cells 
by recombinant preloaded nonm yristoylated GDP/GTP-ARFI and ARF6.
A sample of the kinase w as taken and diluted in kinase buffer to  obtain detectable 
phosphorylation levels. PI(4)P/DMPC vesicles w ere  mixed with o r  w ithout recom binant 
nonmyristoylated preloaded GppNHp/GDP-ARFI and ARF6 at 10 pM final concentration. The 
mixtures w ere  incubated at 37°C  for 30 minutes, after which they w ere  se t at room  
tem perature and 50 pM MgATP/[y-32P]ATP final concentration was added to  start the 
phosphorylation reaction. After 20 m inutes at 25°C, the  reaction was quenched by addition of 
80 pi of 10% (v/v) HCI. PIP2 levels w e re  m easured  as described in the  Materials and Methods 
section.
Data shown are mean ± S.E.M. of 3 separate  experim ents within which m easurem ents w ere  
made in triplicate. The statistical significance of th e  data was evaluated using S tudent’s £ test.
ARF Activates Type I PI(4)P5Ka Eluted From Beads
To rule out the possibility that the apparent activation of Type I 
phosphatidylinositol 4-phosphate 5-kinase a  expressed in a mammalian system 
by ARF or that its apparent magnitude is an artefactual consequence of 
differential interaction or release of the lipid kinase from the beads by the small 
G protein, kinase expressed in mammalian cells was eluted from beads and 
assayed for activation by mARF6. Since the kinase is bound to the beads by the
133
Regulation o f Type I PI(4)P5K by ARF Proteins
coo
jn
0)
>
<d
500 n
400 -
300 -
200 -
CM
CL
CL 1 0 0
i . I O n B e a d s  
■ ■ 1  Off B e a d s
ML
I
UL
Control mARF6 Control mARF6
GTPyS GTPyS
No Preincubation 30’ Preincubation
F ig u re  4 .1 6  In vitro activation of recombinant Type I PI(4)P5K a  expressed in Cos7 cells 
on and off beads by mARF6 after 0 and 30 minutes preincubation.
Recombinant Type I PI(4)P5K a  was expressed in Cos7 cells as HA-tagged fusion protein, recovered on 
anti-HA antibody-coated agarose beads, washed and stored in frozen aliquots. A sample of the kinase 
was taken and diluted in kinase buffer to  obtain detectable phosphorylation levels. Another sample was 
used to elute th e  lipid kinase by addition of 100 pi of 2 mg/ml HA peptide and 2 mg/ml BSA, after 
removal of the supernatant of the beads. After rotating the beads at 4°C for I hour, these w ere 
removed by centrifugation and the supernatant used for the experiment. PI(4)P/DMPC vesicles w ere 
mixed with or w ithout recombinant ARF6 at I pM final concentration and 10 pM GTPyS. The mixtures 
were incubated at 37°C with the lipid kinase for 0 o r 30 minutes, after which they w ere set at room 
temperature and 50 pM MgATP/[y-32P]ATP final concentration was added to start the phosphorylation 
reaction. After 20 minutes at 25°C, the reaction was quenched by addition of 80 pi of 10% (v/v) HCI. 
PIP2 levels w ere measured as described in the Materials and Methods section.
Data shown are mean ± S.E.M. of triplicate samples within a single experiment. For comparison, data 
have been plotted relative to  the appropriate internal control since activity of the kinase was reduced 
after the preincubation. The statistical significance of the data was evaluated using Student’s t test.
HA tag, addition of synthetic HA peptide to the beads releases it into solution, as 
the peptide competes with the fusion protein to bind to the antibody. The 
efficiency of this reaction is not very high, giving only small yields of kinase from 
large am ount of beads. This is the reason why all the previous experiments were
134
Regulation of Type I PI(4)P5K by ARF Proteins
performed with the kinase on beads instead of in solution. However, in this case, 
the release of protein was sufficient to determine whether the nature of the 
activation by ARF was altered in any way by the immobilisation of the lipid 
kinase. Figure 4.16 shows that the effect of mARF6 on the amount of PI(4,5)P2 
produced was still present after eluting the kinase from the beads, and it was 
indeed amplified both with and without preincubation. Probably the free state of 
PI(4)P5K la  in solution allows for better interaction with the substrate and with 
ARF, this being a more ready physiological situation.
Phosphatidic Acid Or The Exchange Factor Cytohesin-1 Do 
Not Improve The Activation Of Type I PI(4)P5Ka By ARF
Honda et al. were the first to report the activation in vitro of Type I 
PI(4)P5K by ARF1. However, in their system the presence of phosphatidic acid 
(PA) was indispensable to achieve the activation of the kinase using PI(4)P/PA 
vesicles. Later, Jones D.H. et al (2000) found that the reported activation was 
completely abolished if instead of using PI(4)P vesicles they used a mixture of 
phosphadylcholine (PC), PI(4)P and PA (10:1:1 ratio respectively). The kinase 
assay conditions used throughout this thesis include the use of PI(4)P/PC vesicles 
in a 1:6 ratio (approximately). Figure 4.17 shows how the addition of PA into the 
lipid vesicles does not improve the activation of PI(4)P5K la  by ARF proteins. In 
the case where there is no preincubation, ARF6 activation is slightly reduced by 
the addition of PA. After preincubation of the samples, the activation is 
considerably reduced, down to more than half of the control value. PA does not 
completely abolish the activation by ARF6 in this system as it was reported by 
Jones D.H. et al, but this is probably due to the different proportions of PA and 
PC used in the vesicles.
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Figure 4 .17 In vitro activation of recombinant Type I PI(4)P5K a  expressed in Cos7 cells 
with PI(4)P/DMPC or PI(4)P/PA/DMPC vesicles by mARF6 after 0 and 40 minutes 
preincubation.
Recombinant Type I PI(4)P5K a  was expressed in Cos7 cells as HA-tagged fusion protein, recovered on 
anti-HA antibody-coated agarose beads, washed and stored in frozen aliquots. A sample of the  kinase was 
taken and diluted in kinase buffer to  obtain detectable phosphorylation levels. PI(4)P/DMPC ( 1: 10) or 
PI(4)P/PA/DMPC ( 1: 1: 10) vesicles w ere  mixed with or without recombinant ARF6 at I pM final 
concentration and 10 pM GTPyS. T he mixtures w ere  incubated at 37°C with the lipid kinase for 0 or 40 
minutes, after which they w ere  set at room  tem perature and 50 pM MgATP/[y-32P]ATP final 
concentration was added to  start the  phosphorylation reaction. After 20 minutes at 25°C, the reaction 
was quenched by addition of 80 pi of 10% (v/v) HCI. PIP2 levels w ere measured as described in the 
Materials and Methods section.
Data shown are mean ± S.E.M. of quadruplicate samples within a single experiment. For comparison, data 
have been plotted relative to  the appropriate internal control since activity of the kinase was reduced 
after the preincubation. The statistical significance of the  data was evaluated using Student’s t test.
Small G proteins are enzymes which depend on the binding of the 
nucleotide GTP for their activation. GDP-bound ARF is thought to be the 
biologically inactive state and the substitution of GDP by GTP triggers its 
activation. The use of the non-hydrolysable compound GTPyS is a widespread
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practice to draw ARF into a permanently activated status. Even then, the loading 
of ARF with GTPyS is a limiting factor in the activation of ARF. It can be 
estimated that spontaneously, only 3% of ARF becomes GTP loaded and 
therefore fully activated in in vitro conditions in the absence of a guanine 
nucleotide exchange factor (GEF) (Ha, 2003). In an attempt to increase the ratio of 
active ARF and consequently favour its effect onto PI(4)P5K, a small ARF-GEF 
was added to the preincubation mixture. GEFs catalyse the exchange of GDP for 
GTP to promote the activation of small G proteins. The binding of small ARF- 
GEFs to polyphosphoinositides such as PIP2 and PIP3, but not PIP, via their PH 
domain is crucial for their function by increasing the amount of exchange factor 
localised to the membrane where it can enhance the rate of ARF nucleotide 
exchange. For this matter, an initial 10-minute preincubation at 37°C containing 
the ARF-GEF Cytohesin-1, PC:PI(4,5)P2 vesicles (50:1), ARF proteins and GDP or 
GTP was performed, followed by the addition of PI(4)P5Ka, MgATP and its 
substrate, PI(4)P. Nonetheless, no improvement on PI(4)P5K activation was 
achieved as compared to conditions where the exchange factor was absent (data 
not shown). This is probably due to the conditions of the preincubation. 
Amongst other things, the inclusion of PIP2 in the assay could be 
counterproductive as it acts as a product inhibitor of PI(4)P5K (Moritz et al., 
1992),
ARF6 Is A Better Promoter Of PI(4,5)P2 Synthesis In 
Permeabilised HL60 Cells Than ARF I
There have been several reports in the literature showing that ARF 
proteins promote the synthesis of PI(4,5)P2 in cells. This increase in PIP2 seems to 
be by the sole direct activation of Type I phosphatidylinositol 4-phosphate 5- 
kinase by ARF (Godi et al., 1999; Jones D.H. et al, 2000; Lawrence et al, 2003) or
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Figure 4 .1 8 Visualisation of [y-32P]-labelled lipid-content of HL60 cells on TLC plate.
Radioactive lipid content of triplicate tim e points of a typical HL60-cell permeabilisation/reconstitution 
assay after readdition of recom binant ARF I and GTPyS (in this particular case). The lipids w ere 
separated using the solvent system described in the Materials and Methods section. The migration 
position of each phosphoinositide is indicated on the left.
in concert with PLD (Fensome et al., 1996; Martin, et a l, 1996; Honda, et al, 1999; 
O'Luanaigh, et al, 2002; Skippen et a l, 2002). PLD hydrolyses PC to produce PA 
which is a potential cellular activator of Type I PI(4)P5K (Moritz et a l, 1992; 
Jenkins et al, 1994; Jones D.R. et a l, 2000). In some of these reports, the use of 
ARF1 and ARF6 has been stated to be equivalent in its potency to promote PIP2 
synthesis (Way et a l, 2000; Skippen et a l, 2002; O'Luannaigh et a l, 2002) but this 
statement was not based on a rigorous comparison of equally fractionally 
myristoylated recombinant ARF proteins. Indeed partially myristoylated 
proteins were used and the degrees of derivatisation were not estimated.
In the following experiment, the effect of readdition of 100% 
myristoylated ARF1 and ARF6 to permeabilised HL60 cells was compared. Using 
thin layer chromatographic plates (TLC), variations in the levels of the resolved 
radiolabelled phospholipids/polyphosphoinositides could be quantified, as 
depicted on Figure 4.18. It has previously been proven that the majority of ARF 
proteins leak out of the cells within 5-10 minutes of permeabilisation (Fensome et
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al, 1996), whereas Rho proteins do not substantially escape from the cells (Way et 
al., 2000). It has also been reported that the concentration of ARF1 in HL60 cells is 
around 10 pM and that of ARF6 0.5-1 pM (Skippen et al, 2002), so the use of 1 pM 
100% myristoylated recombinant ARF proteins would be in accordance with 
physiological values. As seen in Figure 4.19, the capability of permeabilised cells 
to generate PIP2 was enhanced by the readdition of mARFI and GTPyS. The 
increase in production started after an initial lag of 2 minutes, and reached a 
maximal 1.73 fold-increase in comparison to the GTPyS-only curve after 20 
minutes (p=0.03/n=7). In the case of mARF6 and GTPyS, the activation was much 
more potent. The apparent increase had a faster on-set and the generation of PIP2 
increased as time evolved, ranging from 2-fold increased production after 2 
minutes up to a 3-fold increase after 20 minutes (p=2.2xl0_5/n=7). In the case of 
the sole addition of GTPyS, there was a not very significant increase of around 
1.3-fold between minutes 2 and 15 of the reaction and failed to increase after that 
time point. In all cases, after 15 minutes the amount of PIP2 declined, probably 
due to its degradation by other enzymes, most probably phosphatases, which 
had not been deliberately inhibited.
From the same experiment, readings on the amount of PIP and PA 
showed no major changes, except those caused by the addition of GTPyS on its 
own. Thus, the production of these two metabolites did not seem to be 
influenced by ARF proteins. The rapid production of radioactive PA could only 
be a consequence of the hydrolysis of PIP2 by phospholipase C (PLC) into IP3 and 
DAG in this case, and the consequent phosphorylation of DAG by diacylglycerol 
kinase (DGK). Indeed, historically the accumulation of radiolabelled PA in cells 
and membranes derived from phosphate transfer from [32P-y]ATP to DAGs was 
one of the first definitive experimental indicators of PLC activity. An alternative 
route for the production of radioactive PA would be by the hydrolysis of PC into
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Figure 4 .19 Effect of the 
readdition of recombinant 
100% myristoylated ARF I or 
ARF6 and GTPyS on lipid 
production on permeabilised 
HL60 cells.
After 10 minutes of 
permeabilisation with streptolysin 
O (0.4 lU/ml) at 37°C, cytosol- 
depleted HL60 cells w ere 
centrifuged and resuspended in 
buffer containing 50 pM 
MgATP/[y-32 P] AT P final
concentration (added last to start 
the reaction), I pM ARF I or 
ARF6 and 10 pM GTPyS. 
Reactions were run at 37 °C and 
sampled at each time point by 
removal of 3x50 pi identical 
triplicate samples of each 
reaction mixture and transferred 
into new tubes containing 80 pi 
of 10% (v/v) HCI. Lipid levels 
w ere measured as described in 
the Materials and Methods 
section, using the characteristic 
migration properties of lipids on a 
TLC system to  quantify the effect 
of the constituents on the 
different lipids.
Data shown are mean ± S.E.M. of 
7 separate experiments within 
which measurements were made 
in triplicate. Data have been 
plotted relative to the maximum 
value of the control curve. The 
statistical significance of the data 
was evaluated using Student’s t 
test.
Time (minutes)
choline and PA by PLD, and a subsequent dephosphorylation and 
rephosphorylation cycle by phosphatidate phosphohydrolase (PAP) and DGK
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respectively. Again, if the observed radioactive PA had been generated through 
this route, variations in its levels would have been expected from the addition of 
ARF and GTPyS for PLD is also a well known target for small G proteins of the 
ARF family.
HPLC analysis of the data (see Figure 4.20) shows how the majority of 
PIP2 corresponds to PI(4,5)P2 and the majority of PIP corresponds to PI(4)P, as 
expected.
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Figure 4.20 HPLC analysis identifies PI(4)P and PI(4,5)P2 as the major phosphoinositides 
formed in the presence of ARF I and GTPyS.
Permeabilised HL60 cells w ere  reconstituted with ARF I and GTPyS, in the presence of [y32P]ATP. 
Polyphosphoinitides w ere extracted and deacylated and the resulting glycerol-phospho inositols 
analysed by HPLC. Peaks corresponding to  the deacylation products of authentic tritium-labelled 
internal standards are represented in red. The 32P-labelled deacylation products of the inositol lipids 
extracted from the cells are in blue. The peaks are labelled with respect to  the different parent 
polyphosphoinositides.
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ARF Proteins Pull Down Type I PI(4)P5Ka From 
Transfected HEK293 Cell
In order to asses whether a stable physical interaction between ARF 
proteins and phosphatidylinositol 4-phosphate 5-kinase a  takes place, 
recombinant HA-tagged ARF proteins and GST-tagged PI(4)P5Ka were 
overexpressed separately in HEK293 cells. One of the two could then be 
recovered from the lysates with either HA antibody-coated sepharose beads or 
glutathione sepharose beads respectively. The beads could then be washed and 
incubated with the other lysate, recovered, washed and analysed for pulled- 
down protein using western blotting and specific antibodies.
GST-PI(4)P5Ka from lysates was coupled to glutathione-beads, washed 
and added to lysates containing overexpressed recombinant HA-tagged ARF 1 
and 6 wild-type proteins, and two mutants of each. After one hour of incubation, 
the beads were extracted, washed and subjected to western blotting with a 
monoclonal anti-HA antibody in an attempt to discover if ARF proteins were 
pulled down after interacting with the lipid kinase. However, technical 
difficulties did not allow for any interaction to be detected, principally the low 
mass of PI(4)P5K present in cells in which it is overexpressed.
The other option was to recover the different HA-tagged ARFs out of the 
lysates using HA antibody-coated sepharose beads, and put them in contact with 
the lysates of overexpressed GST-tagged PI(4)P5Ka. The amount of GST- 
PI(4)P5Ka recovered bound to ARF was quantified by western blotting using a 
monospecific anti-peptide PI(4)P5Ka antibody and also by PI 4-phosphate 5- 
kinase activity assay. In an ideal system, HA antibody-coated beads should not 
pull down any GST-PI(4)P5Ka since no specific interaction is meant to occur 
between the two. This is not what happens in reality, and due to the existence of
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unspecific interactions between the kinase (amongst other cell proteins) and the 
beads, some kinase and/or activity was pulled down solely by the beads. Other 
bead types are known to have fewer non-specific interactions, especially 
glutathione-beads, but as stated above they did not perform satisfactorily. In an 
attempt to minimise such interactions, the beads were blocked with bovine 
serum albumine for 1 hour at 4°C. This procedure clearly reduced the amount of 
kinase that bound non-specifically to the beads, but it did not completely abolish 
it. The best solution would have been to swap tags by creating new plasmids 
with GST-ARF and HA-PI(4)P5Ka to avoid these interactions.
The following model of the interaction was developed to allow for the 
unspecific binding of the kinase to the beads and therefore be able to detect the 
specific interaction.
PI(4)P5K la  Control
IgG Light Chain IgG Light Chain
Puled Down Kinase =zr --------------------------------------------------------
ARF
The factor Control/IgG Light Chain normalises for the amount of kinase 
that is pulled down by unspecific binding, since the mass of beads in each 
individual sample is equivalent to the amount of anti-HA antibody light chain. 
The light chain is conveniently quantified by detection with anti-mouse 
secondary antibody in a later step. Theoretically, the amount of beads and, 
therefore, the amount of anti-HA light chain should be the same in all cases 
presuming the same amount has been used to capture the target protein. 
However, in some of the experiments the amount of beads used for the control 
and some of the different isoforms were not exactly the same, owing to extensive 
manipulation of samples during washes, etc (see Figure 4.21). Even in the cases
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where seemingly similar am ounts of bead slurry had been used, the reading of 
the light chain showed considerable differences at times. So this is a useful means 
of normalising the results to account for the final amount of beads recovered and 
the unspecific binding of the kinase to these beads.
This value is then subtracted to the total amount of kinase detected in the 
blot, per amount of beads once more, PI(4)P5K la/IgG Light Chain. This 
subtraction would then give an idea of the amount of kinase pulled down by 
specific interaction, since the unspecifically bound kinase has been deducted.
This final figure is divided by the amount of ARF detected in the blot 
using HA antibody in each one of the conditions. This is necessary when it comes 
to comparing the ability of the different ARF isoforms and mutants to bind the 
kinase, because the amount of ARF may vary depending on the level of 
expression in cells in each case. The final number would then be a reliable 
indicator of the amount of kinase pulled down by specific interaction with ARF.
GST-Plf4^P5K la
IgG Light Chain 
ARF
ARF I ARF6
C w t T 3 I N  Q 7 I L  w t T 27N  Q67L
GST-PI(4)P5Ka
sample
Figure 4 .2 1 Association of PI(4)P5K l a  with ARF proteins.
HA-tagged ARF proteins bound to  HA antibody-coated beads w ere incubated with 25 |nl of Cos7 cells- 
lysates from cells transfected with GST-PI(4)P5K la. Incubations lasted for I hour at 4°C. The beads 
w ere washed and the proteins displayed by SDS-PAGE and transferred to  a nitrocellulose membrane. 
The blots w ere incubated sequentially with anti-PI(4)P5K la  antibody and anti-HA (anti-recombinant 
ARF) antibody. The first lane on the left is a control from untransfected cells and the last lane on the 
right is a sample of recom binant GST-PI(4)P5K la  produced in bacteria.
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As seen in Figure 4.22A, when the beads were loaded with ARF proteins 
there was an increase in the amount of pulled down PI(4)P5K la  in comparison 
to the control. The control shows specific kinase binding but it must be 
remembered that this is a representation of the detected amount of kinase minus 
the control. The wild-type proteins and two mutants were used in order to 
compare whether the activation state of ARF had any influence in the interaction 
with PI(4)P5K la. The GTPase deficient mutants ARF6(Q67L) and ARF1(Q71L) 
are permanently GTP-bound and so they can be used as constitutively-active 
ARFs. The GTP-exchange suppressing mutants ARF6(T27N) and ARF1(T31N) 
are thought to represent permanently GDP bound forms of ARF and are used 
extensively as dominant-negative mutants. In the case of ARF1, the GTPase 
deficient ARF1(Q71L) mutant increased the binding 3.4 ± 0.22 fold (P=0.002/n=5) 
in comparison to the wild type. The GDP-binding ARF1(T31N) mutant did not 
increase the binding significantly. In the case of ARF6(Q67L), the mutant 
increased the binding of the lipid kinase by 3.12 ± 0.20 fold (P=0.009/n=5) if 
compared to the ARF1 wild type, 3.8 fold if compared with its own wild type 
protein (P=0.002/n=5). ARF6(T27N) showed similar binding levels to ARF6 wild 
type.
The other useful information that can be extracted from these pull down 
experiments is the amount of kinase activity associated to the ARF beads. As 
with the total amount of detectable protein in the blots, part of which is 
specifically bound and part unspecifically, there is unspecific kinase activity that 
binds to the beads as well as specific. The previous equation can be used by 
substituting the protein mass with the amount of PI(4,5)P2 generated in a kinase 
assay where precipitating beads are added as the source of enzyme. Thus, 
unspecifically bound kinase activity will be subtracted from the final activity 
value. Figure 4.22B shows such values of activity. ARF1(Q71L) was the highest,
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Figure 4.22 Pull down of 
recombinant PI(4)P5K la  
from Cos7 cell lysates using 
recombinant ARF proteins on 
sepharose beads.
Cos7 cells w ere transfected with 
GST-PI(4)P5K la  o r with
different HA-ARF constructs
using Polyfect transfection 
reagent, left to  express for 48 
hours, lysed, centrifuged and 
frozen in small aliquots. HA-ARFs 
w ere  immunoprecipitated using 
anti-HA antibody-coated
sepharose beads (previously
blocked for I hour at 4°C with 5 
mg/ml BSA), washed and put in 
contact with GST-PI(4)P5K la  
lysates for I hour at 4°C. The 
beads w ere then washed in lysis 
buffer and one last time in kinase 
buffer, and resuspended in a final 
volume of 100 pi. 10 pi w ere 
used to  assay kinase activity and 
the remaining 90 pi w ere boiled 
in SDS-PAGE sample buffer and 
run on a 10%  polyacrilamide gel.
A. Specifically bound am ount of 
PI(4)P5K la  per amount of ARF 
protein used in the pull down. 
The am ount of ARF on the gel 
was quantified using monoclonal 
mouse anti-HA antibody, of 
beads/anti-HA antibody using 
anti-mouse secondary antibody 
and of PI(4)P5K la  using 
monoclonal rabbit antiPI(4)P5K 
la  antibody.
B. Specifically bound kinase 
activity per amount of ARF 
protein used in the pull down. 
The kinase assay was perform ed 
by addition to  the beads of 80 
pM PI(4)P (DMPC) vesicles, 50 
pM MgATP and 5pCi/reaction of 
[y-32P]ATP, and was run for 20 
minutes at room  tem perature.
C. Specific activity of the pulled 
down kinase. B/A values.
Data shown are mean ± S.E.M. of 
5 separate experiments within 
which single measurem ents w ere 
made. The statistical significance 
of the data was evaluated using 
Student’s t test.
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5.49 ± 0.27 fold of wild type (P=0.0001/n=5). Strikingly, the activity of the kinase 
pulled down by the mutant ARF6(Q67L) was not as high as that of the equivalent 
ARF1 mutant. It was still 2.97 ± 0.83 fold higher than wild type ARF1 (not 
statistically significant).
By dividing the values of kinase activity by the amount of pulled down 
lipid kinase, an indication of the specific activity of the specifically pulled-down 
kinase can be obtained. Figure 4.22C shows that the variations in specific activity 
were relatively small and with no statistical significance.
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4.3 DISCUSSION
This chapter has focused on the comparative activation of Type I 
phosphatidylinositol 4-phosphate 5-kinase enzymes by Class I and III ARF 
proteins, ARF1 and ARF6 respectively. To my knowledge, this is the first time 
that such a rigorous study of the differences in the activation of Type I PI(4)P5K 
by these two ARF isoforms has been carried out, by in vitro enzymatic assays, 
permeabilised-cell assays and coimmunoprecipitation experiments.
Honda et al were the first to establish a direct activation of murine 
PI(4)P5K la  by ARF in vitro. Previously, there had been reports showing that 
addition of ARF proteins increased the production of PI(4,5)P2 in cell membranes 
(Fensome et al, 1996; Martin et al, 1996) and in the Golgi complex, by 
recruitment of an unidentified Type I PI(4)P5K (Godi et al., 1999). Later on, 
another one of the three isoforms of the lipid kinase, PI(4)P5K Iy, was found to 
also be activated by ARF6 in neurons (Krauss et al, 2003; Aikawa and Martin, 
2003). In order to see whether the activation by ARF proteins was common to the 
three known isoforms of Type I PI(4)P5K, the enzymes were mixed individually 
with recombinant ARF proteins. It was patently clear that all three isoforms of 
lipid kinase, a, (3 and y, were activated by both ARF1 and ARF6, but that this was 
always dependent on the presence of the myristate group and of the non- 
hydrolysable guanosine triphosphate nucleotide. There was only one instance 
where the myristate group was not strictly necessary for the activation of the 
lipid kinase by ARF6, in the case of the recombinant murine (3 isoform expressed 
in E. coli (GTPyS and the myristoylation of ARF6 improved its activation though). 
This isoform seemed to be more sensitive to activation by ARF6 regardless of its
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myristoylation state and even in the absence of GTPyS. It could be that the p 
isoform interacts more easily with a region of ARF6 that does not require 
rearrangement upon GTP loading (outside switch or inter-switch regions) but 
not with ARF1. This characteristic would differentiate the murine p (human a) 
isoform from the other two, perhaps revealing the possibility of specialised 
regulation by ARF6. Murine PI(4)P5K Ip, which corresponds to human PI(4)P5K 
la, is the isoform that is thought to be located on the plasma membrane, where 
ARF6 is also thought to be concentrated.
There is only one reference in the literature where the presence of the 
myristate group is considered to be necessary for the activation of Type I 
phosphatidylinositol 4-phosphate 5-kinase. Honda et al presume this 
requirement when comparing the activation of Type I PI(4)P5K by their 10%-50% 
myristoylated recombinant ARF1 protein with the considerably stronger 
activation achieved with the isolated native protein. In the rest of the published 
studies of PI(4)P5K activation by ARF proteins, the use of partially myristoylated 
proteins is a widespread practice. Biochemical studies have established that, 
following activation, ARF-GTP exposes its myristoylated N-terminus and 
interacts with membranes via both the myristoyl group and hydrophobic and 
basic residues from the N-terminal a-helix. Myristoylation of ARF6 has been 
shown to be necessary for its interaction with membranes, as around only 5% of 
the nonmyristoylated protein can actually interact with lipid bilayers (D'Souza- 
Schorey and Stahl, 1995). No significant binding is detectable when ARF is not 
myristoylated or when anionic phospholipids (PG or PS, but not PIP2) are absent 
from the vesicles (Antonny et al, 1997). On the other hand, it has also been 
reported that the presence of the myristate group is only necessary for the 
membrane binding of the GDP-bound form of ARF1, whereas in the case of GTP-
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ARF1, the acyl group is dispensable. Its presence would therefore be necessary 
for ARF1 to interact with its exchange factors on the membrane, which would 
catalyse the interchange of GDP for GTP and thus activate the small GTP binding 
protein (Haun et al, 1993; Franco et al, 1993, 1995, 1996). In the cell-free 
experiments performed throughout this investigation, there are no exchange 
factors to catalyse this reaction (its inclusion proved to be pointless under the 
conditions in use) or non-anionic lipids (PG or PS) included in the vesicles, 
therefore, no significant interaction between these vesicles and nonmyristoylated 
ARF proteins should have been expected. In accordance with this, the 
experiments clearly revealed that in the absence of the myristate group, ARF 
proteins were not capable of activating Type I PI(4)P5K under conditions 
equivalent to those where an activation occurs in the presence of the myristate 
group, for instance, at 1 pM ARF and 25°C-incubation conditions. It is reasonable 
to assume that this is a consequence of the failure of nonmyristoylated ARF to 
increase the tethering of its effector to the vesicles.
When the amount of recombinant nonmyristoylated ARF proteins was 
augmented to increase the probability of co-localising both proteins onto vesicles 
by mass action, no activation of PI(4)P5K was seen if the reaction was performed 
at 25°C. Not only was there not an improvement but, in the case of 
nonmyristoylated ARF1 and A17ARF1 there was a decrease in the production of 
PI(4,5)P2 below the control levels which did not take place with ARF6, or at least 
not as markedly. Only when fully GDP- or GppNHp-loaded ARF proteins were 
used, exclusively at 37°C and at high concentrations (10 pM), was the activation 
of PI(4)P5K seen with myristoylated ARF proteins recapitulated. Conceivably, 
this is a consequence of a temperature- and mass-action-driven effect. There is a 
large molar excess of ARF over PI(4)P5K. Moreover, temperature has been 
shown to improve the binding of ARF molecules to vesicles (Haun et al, 1993),
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thus possibly increasing the strength and duration of the interaction of ARF- 
PI(4)P5K with the lipids a n d  consequently allowing for a more prolonged 
generation of PI(4,5)P2 even in  the  absence of the myristate group.
In comparative terms and  under all the assayed conditions, ARF6 is 
always a better activator of T ype I phosphatidylinositol 4-phosphate 5-kinase 
than ARF1. From experiments performed by collaborating colleagues we know 
that spontaneous GTP-loading by ARF6 is 2 to 3 times more efficient than ARF1 
in the absence of ARF-GEFs (Ha, 2003). To rule out the possibility that the 
recurrent preference is a consequence of better nucleotide loading, fully GDP- or 
GTP-loaded nonmyristoylated ARFs were used. By using these proteins, the 
ambiguities due to differences in  GTP-loading can be eliminated, although in the 
necessary absence of N-myristoylation the affinity of ARF (or any complexes it 
forms) for lipid vesicles is probably  reduced. Hence, this system will primarily 
reflect the degree of ARF-PI(4)P5K binding (and catalytic activation if existent) 
rather than recruitment onto vesicles. This experiment showed that even then, 
ARF6 managed to stimulate PI(4)P5K more efficiently than ARF1 presumably 
due to a preferential binding to  PI(4)P5K of ARF6 over ARF1. This preference is 
further supported by equivalent experiments using a different lipid kinase, 
pllOy, where there is no ap p aren t preference and which will be discussed later 
on in this thesis.
Only twice in the literature have these two isoforms of ARF been 
compared in their potency to  activate PI(4)P5K la. Honda et al. compared the 
activation in vitro of bacterially-expressed recombinant PI(4P)5K la  by ARF1, 5 
and 6 expressed in Cos7 cells, which would therefore be expected to be 100% 
myristoylated. ARF1 and 6 provoked a similar five fold activation of the lipid 
kinase whereas ARF5 increased activity seven fold. From the experiments in this
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chapter it became clear that there are certain differences in behaviour depending 
on the origin of the recombinant Type I PI(4)P5K. The enzyme expressed in 
bacterial systems is much more responsive to the influence of both ARF1 and 6, 
showing little difference in activation by both isoforms. Nevertheless, when the 
lipid kinase is expressed in a mammalian system (and therefore subjected to all 
the post-translational changes carried out in mammalian cells) the activation by 
both isoforms of ARF is importantly diminished, especially by ARF1. Therefore, 
especial care should be taken when drawing conclusions based on bacterial 
recombinant PI(4)P5K, and further characterisation of the effects should be 
established by comparison with mammalian recombinant enzymes.
The other example in the literature of differential activation of Type I 
PI(4)P5K by ARF proteins was carried out by Skippen et al. (2002), who also 
compared the two ARF isoforms in HL60 cells and concluded that they were 
equally effective in restoring PI(4,5)P2 synthesis. However, their ARF proteins 
were partially myristoylated and they did not state to what percentage or 
whether the fractional derivatisation was equivalent or different. Consequently, 
given the triple impact of myristoylation on nucleotide exchange rates, 
membrane affinity and effector activation (discussed here) then the comparison 
cannot be considered technically valid. Moreover, they confirmed that most of 
the PI(4,5)P2 produced in HL60 cells by readdition of ARF1 was generated at the 
plasma membrane since it was brefeldin A resistant, that is, under the control of 
the low molecular weight family of ARF-guanine nucleotide exchange factors 
(GEFs) that reside in this compartment (Jackson and Casanova, 2000). ARF6 is 
thought to be the only isoform of ARF present at the plasma membrane, whereas 
ARF1 is mostly Golgi-localised if not cytosolic (Peters et al, 1995). Therefore, it is 
possible that the activation of Type I PI(4)P5K by ARF1 may not be its normal 
function, although due to the large amount added to the permeabilised cells, it
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compensates for the absent ARF6 at the plasma membrane. When similar 
experiments were performed using permeabilised HL60 cells and 100% 
myristoylated recombinant ARF1 and ARF6, there was also an increase in 
PI(4,5)P2 production by both isoforms, but again this was stronger in the case of 
ARF6.
Finally, a direct interaction between ARF and PI(4)P5K l a  was 
demonstrated by co-precipitation experiments. Separate expression of the 
recombinant proteins and their subsequent combination allowed for the recovery 
of phosphatidylinositol 4-phosphate 5-kinase l a  by interaction with the HA- 
tagged ARF proteins. The level of interaction was similar with the two ARF 
isoforms under study, ARF1 and ARF6. Both the wild type and the dominant- 
negative mutants pulled down similar amounts of kinase, while the 
constitutively active mutants were much more efficient in doing so. This shows 
that PI(4)P5K l a  is capable of binding ARF in any of its activation states, but the 
interaction is more efficient when it is GTP-bound. It is possible that the 
interaction of PI(4)P5K l a  with ARF happens in part with residues outside the 
switch and inter-switch region, but the rearrangements of ARF switch 1 and 2 
induced upon nucleotide exchange strengthen the interface contact. Solution of 
the GDP- and GTP-bound structures of ARF1 and ARF6 from single crystal X-ray 
diffraction data proved that there was little structural difference between the 
active form of the two proteins, but that the switch regions of the inactive GDP- 
bound conformation is the discriminatory factor between the two isoforms 
(Pasqualato et al, 2001). This could suggest that GTP-bound ARFs may establish 
specific interactions outside the switch regions and/or be recognised differently 
in their cellular context rather than as isolated proteins. In this pull-down 
experiment there are no natural membranes and therefore the cellular context
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has been distorted, and so the interaction we can see is the pure structural one 
rather than the one that may happen within cells. Hence the interaction here is 
devoid of the influence of the cellular localization and of the multiple effectors 
that control the functioning of these proteins. In the case of the interaction of 
ARF with PLD, it has been established that it occurs with the N-terminal helix 
and the following loop, the a2 helix and part of the [32 strand (Jones et al, 1999; 
Sung et al, 1999). These residues become exposed after GTP-binding, and they 
are similar contact sites to those involved in the interaction with exchange factors 
(Goldberg, 1998). These data must be directly compared with the interaction of 
PI(4)P5K with other small G proteins. Both Racl and RhoA, (but not Cdc42), 
have been shown to interact with the lipid kinase in a GTP-independent manner, 
through binding with the C-terminal region of the GTPases (Tolias et al, 1995; 
Ren et al, 1996; van Hennik et al, 2003; Weemink et al, 2004). Consequently their 
function is no other than recruitment of the lipid kinase onto membranes, and 
not catalytic activation of the enzyme. It seems conceivable that this is the case 
with ARF as well: binding of the two proteins is nucleotide-independent (see the 
effect of fully nucleotide-loaded ARF proteins), but apparent activation is GTP- 
dependent due to the necessity to tether PI(4)P5K to the membrane where its 
substrate lies.
The novel aspect of this experiment is the simultaneous assay of kinase 
activity pulled down with the ARF isoforms. The constitutively active isoforms 
pulled down a higher PI(4)P phosphorylating activity. However, it was 
intriguing to see that the amount of PI(4,5)P2 produced by the ARF1(Q71L)- 
associated kinase was more than that associated with the ARF6 mutant. In 
accordance with my in vitro and permeabilised-cell assays, it would have been 
expected to be the other way around. Nevertheless, there is a major difference in 
the way the interaction is presented in the different systems. In the in vitro
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activation assays, ARF was always free in solution and PI(4)P5K was either in 
solution or bound to beads, which makes little difference on the activation by 
ARF; if anything, there was a slight improvement when PI(4)P5K was free in 
solution, probably because the freely diffusible state favours the interaction 
between the two proteins by better co-localisation on the lipidic surface. In this 
case, it is ARF that is bound to beads and cannot diffuse freely in the reaction 
solution. The stoichiometry of the interactions of these two proteins is unknown. 
Blocking the free movement of ARF restricts the way the interaction takes place. 
Type I PI(4)P5Ks are known to associate in homo and heterodimers and most 
probably, in oligomeric protein complexes. In the case of PI(4)P5K Ip, gel 
filtration analysis revealed that the kinase is present in high molecular weight 
protein complexes (Galiano et a l, 2002). On the other hand, it has been suggested 
that ARF1 may also form dimers during its biological function due to the 
occurrence of a dimer in one crystal form (Greasley et al, 1995). These data taken 
together add multiple possibilities to the way these two proteins could interact, 
therefore making it a potentially complex situation when it comes to comparing 
activation and interaction using different experimental methods, for these might 
limit the possibilities found in living cells. This is probably the reason why there 
is a clear contradiction between the only two examples of PI(4)P5K and ARF 
interaction in the literature. Krauss et al (2003) used an affinity purification 
approach to try to demonstrate an interaction between ARF and PI(4)P5K Iy. 
They managed to pull down the y isoform from brain extracts by interaction with 
ARF6(Q67L) exclusively, but they saw no interaction with the GTP-binding 
suppressed mutant ARF6(T27N). They also tried to use the ARF1(Q71L) mutant 
and they concluded that there was no interaction with PI(4)P5K Iy, even though 
in the blot presented in the article there was a band corresponding to the pulled 
down kinase. The contradiction was exposed a month later when Aikawa and
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Martin published data on the coimmunoprecipitation of ARF6 with PI(4)P5K Iy 
after coexpressing the two proteins in PC12 cells. They found that the mutants 
ARF6(Q76L) and ARF6(N122I) (another GTP-binding deficient mutant) exhibited 
similar associations with PI(4)P5K Iy, which where enhanced by Ca2+ influx. They 
concluded that the interaction between ARF6 and PI(4)P5K is regulated by a 
Ca2+-dependent mechanism, involving the activation of PKC and the 
phosphatase PP1, with the consequent dephosphorylation of PI(4)P5K as 
previously established by Park et al. (2001). All in all, the interaction between 
ARF6 and PI(4)P5K appeared to be governed principally by the phosphorylation 
state of PI(4)P5K rather than the guanine nucleotide-bound state of ARF6. These 
results are in direct conflict with those of Krauss et al., despite the fact that both 
use the same PI(4)P5K and ARF isoforms. The different methods used to look for 
interaction may be the cause for the discrepancy in the results.
In addition, since the interaction between the two proteins has been 
obtained in a system where the amount of recombinant proteins is in excess due 
to overexpression, the result could be distorting the real situation that takes place 
in physiological conditions, forcing a higher degree of interaction. Furthermore, 
the use of these mutants blocks the normal cycle of GTP binding, hydrolysis, and 
release. Therefore, although the GTPase-deficient mutants are in the active 
conformation, they do not fully imitate all the actions of the GTPase (Santy, 
2002). Finally, in this case recombinant ARF proteins had been expressed in 
mammalian cells whereas in previous instances they were of bacterial origin. All 
these factors could explain why in this case ARF6 is not more efficient in 
activating PI(4)P5K, as opposed to the previous experiment. In conclusion, this 
pull-down experiment should be considered as a demonstration that a direct 
interaction between the two proteins takes place, but not as a reference of 
comparative binding or activation by different isoforms of ARF.
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In the same line but in terms of specific activation, there are no statistically 
significant differences between the different ARF mutants. Therefore, it could be 
concluded that ARF proteins are responsible for binding and recruiting PI(4)P5K 
onto membranes, but not of catalytically activating it, as it is also the case with 
GTPases of the Rho family.
Considering them together, the results presented in this chapter clearly 
highlight myristoylation as a critical feature in the activation of Type I PI(4)P5K 
by ARF proteins, without which ARF is not capable of activating the lipid kinase 
and at high concentrations, it can cause the opposite effect on the generation of 
PI(4,5)P2. Hence optimal data in biochemical assays using recombinant ARF 
proteins are highly dependent on the generation of fully-myristoylated ARF 
proteins and failure to achieve this may devalue the relevance of any data 
obtained. Also, reports based on the use of recombinant Type I PI(4)P5K 
expressed in bacteria should be carefully evaluated because its behaviour is not 
exactly that of the same enzyme expressed in mammalian cells, conceivably due 
to the absence of post-translational modifications. Finally, the comparison of the 
effects of ARF1 and ARF6 on Type I PI(4)P5K strongly points to a role for ARF6 
and not ARF1 as the factor that directly regulates PI(4)P5K la  in permeabilised 
cells and cell-free model systems and therefore most probably also in vivo. This 
statement is supported by several articles where ARF6 and PI(4)P5K or regions 
with high PI(4,5)P2 concentration have been shown to co-localise in living cells 
(Brown et al, 2001, Krauss et al, 2003, Aikawa and Martin, 2003), while ARF1 and 
PI(4)P5K do not (Honda et al, 1999).
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5.1 INTRODUCTION
Many stimuli such as hormones or growth factors provoke a transient 
increase in levels of cellular diacylglycerol through hydrolysis of PI(4,5)P2 by 
phospholipase C. Many of these stimuli also promote the activation of 
phospholipase D with the consequent generation of phosphatidic acid through 
hydrolysis of phosphatidylcholine, which can be in turn converted into 
diacylglycerol by phosphatidate phosphohydrolases. DAG is a renowned second 
messenger, being the activation of PKC enzymes, specifically members of the 
conventional and novel subgroups, one of its best characterised effects. However, 
it may also have other cellular targets such as a- and |3-chimaerins, guanine 
nucleotide-exchange factors for Ras and Rap, nonselective cation channels, 
Munc-13, DGKa, p and y, and PKD isozymes (van Blitterswijk and Houssa, 2000; 
Brose and Rosenmund, 2002; Yang and Kazanietz, 2003).
Because sequence analysis predicted a potential PKC phosphorylation site 
within phosphatidylinositol 4-phosphate 5-kinase enzymes, I made an attempt to 
characterise the effects of PKCs on the activity of the lipid kinase.
During the course of these experiments, I made the novel discovery of a 
possible direct activation of phosphatidylinositol 4-phosphate 5-kinase by DAG 
that stimulates the production of PI(4,5)P2.
Finding a DAG-dependent regulation of PI(4)P5Ks in addition to that 
mediated by PKCs would even more firmly place these lipid kinases directly 
downstream of the activation of PLC enzymes. Because PLCs cause PI(4,5)P2 
hydrolysis upon reception of a stimulus, then this would create a very effective 
mechanism of replenishing the vital polyphosphoinositide.
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5.2 RESULTS
Existence Of A Potential Phosphorylation Site For PKCa 
and PKA Within The Sequence Of PI(4)P5K la
One of the highly specific control methods utilised inside cells to 
transduce signals, activate and inactivate proteins and produce signalling 
cascades is protein phosphorylation, either on tyrosine or serine/threonine 
residues. There are more than 500 protein kinases in mammalian genomes and 
all of them usually alter in some way the localisation, activity and function of 
other proteins. The activation of these kinases is often the consequence of some 
extracellular signal.
In an attempt to determine whether Type I PI(4)P5Ks could be regulated 
by phosphorylation by protein kinases, an analysis of the amino acid sequence of 
murine PI(4)P5K la  was carried out using a range of bioinformatic resources. For 
example, Scansite (Obenauer et al, 2003), predicted some statistically probable 
phosphorylation sites. Table 5.1 shows the predicted sites for a group of 
serine/threonine kinases, including PKC and PKA. There are other 
phosphorylation sites predicted such as those for Cdk5 kinase and Cdc2 kinase 
of the proline-dependent serine/threonine kinases, but they are not tabulated as 
they are not relevant to this study. As observed, there are good potential 
consensus phosphorylation sites for PKCa and PKA both at serine 214. The 
percentile value given for the sequence regarding potential phosphorylation by 
PKCa is lower than that for PKA, but the internal score obtained for PKA 
phosphorylation is slightly lower than that for PKC. So both protein kinases are 
predicted to be reasonable phosphorylating agents for the lipid kinase according
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PKC a/p/y S2I4 0.3687 0.089% 4.122 STYKRRASRKEREKP
M e d iu m  S tr in g e n c y
Enzyme Residue Score Percentile S.A. Sequence
PKA S2I4 0.3650 0.266% 4.122 STYKRRASRKEREKP
PKCa/IVy S2I4 0.3687 0.089% 4.122 STYKRRASRKEREKP
PKCe S468 0.4252 0.502% 0.848 DLVPSTPSLFEAASL
PKCS S26 0.4349 0.521% 0.425 KTYKKTASSAIKGAI
PKCe T224 0.4408 0.716% 2.470 EREKPNPTFKDLDFL
pkg; S393 0.4934 0.355% 0.639 RFLKFMNSRVFKKIQ
Table 5.1 Prediction of phosphorylation sites for basophilic serine/threonine kinases on 
the sequence of murine PI(4)P5K la  using Scans'rte.
The Score value starts at 0.000 if the  sequence optimally matches the given motif, and it increases for 
sequences as they diverge from the optimal match. The Percentile value is representative of how much 
better is the selected sequence as a target for the specific kinase in comparison to  the rest of existent 
similar consensus sequences in the  database (i.e. a 0.089%  value means that this sequence is better 
than 99 .91 I %  of sequences in the  SwissProt database as a theoretical phosphorylation site). A high 
stringency search will only collect hits with percentile values below a threshold of 0.2%. The S.A. value 
is representative of the  surface accessibility of the amino acid residue; the higher the value over I, the 
more exposed the residue. This value is obtained from the amino acid sequence and not with reference 
to  any known structures.
The figure on top of the tables represen ts the PFAM-predicted domains and predicted phosphorylation 
sites of murine PI(4)P5K la  using the  high stringency search and below is the surface accessibility chart.
to this particular bioinformatic analysis.
The structure of Type I PI(4)P5Ks has not been elucidated to date. The 
only known structure of a significantly similar kinase is that of Type II
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PI(4)P5K|3, which is a phosphatidylinositol 5-phosphate 4-kinase (Rao et al, 
1998). Type I and type II PI(4)P5Ks share only around 35% (global) sequence 
identity, but the majority of the similarity is localised within the core kinase 
homology domain (Ishihara et al, 1996, 1998; Loijens et al, 1996a). Outside this 
region there is little sequence identity. Considering that the predicted 
phosphorylation site for both protein kinases lies within the kinase domain, and 
using the structure of the Type II kinases as a reference, a first-approach model of 
the structure of Type I enzymes was generated using SwissModel. In this model, 
the position of serine 214 could be predicted to be located in the external surface 
of the protein close to the catalytic site of the lipid kinase as seen in Figure 5.1.
PKCa Inhibits Type I PI(4)P5Ka Expressed in E. coil
Given a good match to a consensus phosphorylation site and likely 
surface exposure assessed by both model building and sequence analysis, the 
following experiment was developed to assay the possibility of an effect of 
recombinant PKCa on recombinant PI(4)P5K la  expressed in bacteria. In order 
for PKCa to function correctly it requires the addition of certain effectors, namely 
phosphatidylserine, diacylglycerol and Ca2+. These effectors can be added with 
the protein kinase into the reaction mixture that includes the target substrate 
protein. However, in this particular assay a problem arises because at least one of 
these effectors, PS, is a known activator of Type I PI(4)P5K (Cochet and 
Chambaz, 1986). This means that the relative effect of PKC on the activity of the 
lipid kinase, quantified by measuring changes in the generation of PI(4,5)P2, 
might be masked by the effect of PS if both protein phosphorylation and lipid 
phosphorylation reactions were performed simultaneously or sequentially in the 
same reaction mixtures. For this reason, it was imperative to develop a method 
that would allow for the separation of the two steps of the reaction. Initially,
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Figure 5 .1 Crystal structures of a m onom er of PI(5)P4Kp and a model of PI(4)P5Ka.
Same sagittal projection of a PI(5)P4KP m onom er (human PI(5)P4KP; PDB I BO I) and a model of a 
PI(4)P5Ka m onom er generated using SwissModel. The location of the potential PKC/PKA 
phosphorylation Serine is indicated in blue spacefill in both monomers. The location of the interacting 
membrane would be beneath the  structure.
PKC, its effectors and PI(4)P5K were mixed together to allow PKC to 
phosphorylate the lipid kinase. Subsequently, PI(4)P5K la  had to be extracted 
from the mixture, the effectors washed off and the lipid kinase mixed with its 
substrates, PI(4)P and MgATP, to allow for quantification of its phosphorylation
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capacity. By adding glutathione coated agarose beads to the first mixture, the 
recombinant GST-fusion PI(4)P5K la  could be recovered, washed thoroughly to 
remove the PS and its activity then tested. In case the activity of the kinase could 
be altered by being bound to the agarose beads, it was necessary to compare it 
both on beads and eluted from the beads. For this matter, reduced glutathione 
could be used to release the kinase. While developing this assay I found that final 
concentrations of glutathione greater than 10 mM inhibited PI(4)P5K.
Nevertheless, continuous handling of the relatively small amount of beads 
during the washes, elution and resuspensions generated errors due to loss of 
beads and therefore of PI(4)P5K. This problem needed to be solved in order to 
maintain the proportions and to be able to compare the different conditions 
assayed by developing a system to normalise the results. Several different 
strategies were tested. Determination of the protein concentration by a 
colorimetric assay was the most straightforward method, but its results could not 
be completely trusted because the amount of kinase released using low 
concentration of reduced glutathione was very small and both glutathione and 
the lipids interfered with the determination system. The small amount of protein 
was also a problem when trying to quantify it by precipitating the lipid kinase to 
separate it from the interfering substances, using acetone or trichloroacetic acid 
precipitation methods. These approaches also yielded negative results. Other 
methods such as 3H-NSP-labelling (N-succinimidyl-[2,3-3H]-propionate) of the 
protein were tested but without success.
Finally, I used the glutathione S-transferase activity associated with the 
GST-fusion protein as a direct indicator of protein concentration. This was done 
by measuring the rate of formation of a yellow product at 340 nm after addition 
of reduced glutathione (1 mM final), l-chloro-2,4-Dinitrobenzene (CDNB, 1 mM) 
and potassium phosphate buffer pH 6.5 (10 mM final) at room temperature. The
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Figure 5.2 In vitro effect 
of PKCa and its effectors on 
recombinant PI(4)P5K la  
expressed in E  coli.
A sample of GST-PI(4)P5K la  
expressed in bacteria was taken 
and incubated for I hour at 37°C 
with 75 pM MgATP and with or 
without PKCa and/or 
PS/DAG/Ca2+. The beads w ere 
then recovered, washed
thoroughly in microfilters and 
200 pi of 10 mM reduced 
glutathione added to  elute part 
of th e  kinase for 15 minutes at 
room tem perature. The 
supernatant was filtered through 
and 4x30 pi used in a typical 
kinase assay. A nother 65 pi w ere 
used to  normalise the  am ount of 
protein by performing a GST 
assay with 6.5 pi of CDNB, 7 1.5 
pi of buffer and 572 pi of distilled 
w ater. T he remaining beads 
w ere  resuspended in kinase 
buffer and assayed for kinase 
activity as well for 20 minutes at 
room tem perature as described 
in th e  Materials and Methods 
section.
Data shown are mean ± S.E.M. 
of 5 separate experim ents within 
which m easurem ents w ere 
made in quadruplicate. The 
statistical significance of the data 
was evaluated using Student’s t 
test.
rate of colour change was directly proportional to the amount of GST fusion 
protein present in the solution and this allowed for a direct estimation of the 
amount of PI(4)P5K.
Figure 5.2 shows the effect of commercial recombinant PKCa on 
recombinant GST-tagged PI(4)P5K la  expressed in E. coli. As expected from the 
results on the previous chapter, assaying the kinase activity on beads or free in 
solution did not make a significant difference in the results. Recombinant PKCa
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was capable of inhibiting the activity of eluted PI(4)P5K la  down to 16.2 ± 2.6% 
(p=1.2xl06/n=5) of the control in the absence of the effectors. If these effectors 
were present during the preincubation, both in the absence or presence of PKCa, 
there was an overall apparent increase in PI(4,5)P2 production presumably due to 
an incomplete removal of the lipids after the washes, which tended to vary in 
each separate experiment. In the presence of DAG, PS and Ca2+, the inhibition of 
PI(4)P5K la  by PKCa decreased from a 143.5 ±30.1% of activity with respect to 
the control down to 48.1 ± 22.8% (p=0.0017/n=5 with respect to the general 
control), therefore the reduction of around 77% (p=0.049/n=5 with respect to the 
internal control).
When the same experiment was performed excluding ATP from the 
preincubation, a surprising result was obtained. As seen in Figure 5.3, the 
inhibition of PI(4)P5K la  is still present in the absence of ATP. In this case the 
effectors did not seem to affect the kinase significantly, and PI(4,5)P2 levels were 
down to 29.7 ± 4.7% (p=0.001/n=4) of the control in their absence and down to 
27.8 ± 2.4% (p=0.001/n=4) if they were present in the preincubation. If ATP was 
included in the preincubation, a potent inhibition of PI(4)P5K la  was also 
observed, down to 35.3 ± 6.1% (p=0.003/n=4). In this case, the only possible 
explanation is the existence of inhibitory autophosphorylation. Type I PI(4)P5Ks 
are known to be able to autophosphorylate in serine/threonine residues 
attenuating their activity, effect that is markedly enhanced by the addition of PI 
(Itoh et al., 2000). It is possible that the 1 hour preincubation in the presence of 
ATP is sufficient for the lipid kinase to increase its levels of autophosphorylation 
and consequently diminish its activity.
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Figure 5.3 In vitro effect of PKCa and its effectors on recombinant PI(4)P5K la  expressed 
in E. coli.
Recombinant Type I PI(4)P5K was expressed in E. coli as GST-tagged fusion protein and recovered on 
glutathione-sepharose beads. A sample of th e  kinase was taken and incubated for I hour at 37°C with or 
without 75 pM MgATP and/ or PKCa and/or PS/DAG/Ca2+. The beads w ere then recovered, washed 
thoroughly in microfilters and 200 pi of 10 mM reduced glutathione added to elute part of the kinase for 
15 minutes at room tem perature. T he supernatant was filtered through and 4x30 pi used in a typical 
kinase assay for 20 minutes at room  tem peratu re  as described in the Materials and Methods section. 
Another 65 pi w ere used to  normalise the  am ount of protein by performing a GST assay with 6.5 pi of 
CDNB, 7 1.5 pi of buffer and 572 pi of distilled water.
Data shown are mean ± S.E.M. of quadruplicate samples within a single experiment. The statistical 
significance of the data was evaluated using Student’s t test.
PKCa Has No Effect On PI(4)P5K l a  Expressed In 
Mammalian Cells
When the same experiments were performed using HA-tagged PI(4)P5K 
la  expressed in Cos7 cells no statistically significant differences were observed, 
as illustrated on Figure 5.4. This figure represents an experiment where the beads 
were not washed after the preincubation (to minimise handling-artefacts), which
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F ig u re  5 .4  In vitro  effect o f PK C a and its effectors on recom binant PI(4)P5K la  
expressed  in Cos7 cells.
Recom binant T ype I PI(4)P5K w as e x p re ssed  in Cos7 cells as HA-tagged fusion p ro tein  and 
recovered  on anti-HA an tibody-coated  agarose  beads. A sam ple of th e  kinase was taken  and 
incubated for I ho u r at 37°C  w ith  o r  w ith o u t P K C a an d /o r PS/DAG/Ca2+. The beads w ere  then  
split into 3x30 pi sam ples and th e  kinase activity w as assayed for 20 m inutes at room  
te m p era tu re  as described  in th e  M aterials and M ethods section.
D ata show n are m ean ±  S.E.M. o f 4  ex p e rim en ts  w ithin w hich m easurem ents w ere  m ade in 
triplicate. T he statistical significance of th e  d a ta  w as evaluated using S tuden t’s t test.
explains why in the presence of the effectors there was such an increase in the 
activity of PI(4)P5K. There was a statistically significant difference between the 
control and those conditions were the effectors were included, but the increase 
was due to their presence. There was no statistically significant difference 
between those conditions where PKCa was present or absent together with the 
effectors. The same experiment was performed introducing washes after the 
preincubation and including ATP, but again, variations in the data between 
experiments did not allow for an unambiguous result. However, these variations
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were due to the impossibility of normalising the final data by quantification of 
the amount of protein. The only possible way to do this was by western blotting 
against the kinase, however this did not render a detectable signal, most certainly 
due to the very small amount of PI(4)P5K la  present. The one thing that was 
clear from all the experiments was that the inhibition by PKCa was not present 
as it was when PI(4)P5K la  was expressed in bacterial cells.
PA, PS And DAG Activate PI(4)P5K la Expressed In 
Mammalian Cells
The activation of Type I phosphatidylinositol 4-phosphate 5-kinases by 
different lipids in vitro has been known for many years. Cochet and Chambaz 
reported some 18 years ago a dose dependent activation of the lipid kinase by 
phosphatidylserine. 6 years later, Moritz et al. showed that phosphatidic acid was 
also a strong activator of the phosphoinositide kinase. These two lipids have 
been considered to be its main activators in vitro for a long time, but a direct 
proof of such activation in vivo has always been surrounded by certain degree of 
scepticism due to the intricate connections of the pathways that control the 
activity of Type I PI(4)P5K and the production of PA.
In the following experiment, the activation by these and other lipids was 
tested in vitro in an attempt to confirm the literature, as well as determining the 
exact origin of the stimulation of phosphoinositide kinase activity observed in 
the PKCa experiments. Figure 5.5 exemplifies the effect caused by the inclusion 
of different lipids in PI(4)P-containing vesicles, in the presence and absence of 
dimyristoyl-phosphatidylcholine as a carrier lipid and of two detergents with 
different chemical properties: the nonionic detergent Triton X-100 and the 
anionic detergent, sodium deoxycholate. These two detergents are both
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nondenaturing agents. PI(4)P was always included in the mixtures at 80 |iM 
concentration, and the different lipids under study were included in the vesicles 
at an equimolar concentration, i.e. 1:1 (PI(4)P/PA for example). PC was included 
at 500 pM, rendering an approximate molar ratio of, for instance, 6:1:1 
(PC/PI(4)P/PA). It must be noted that control PI(4)P vesicles generated using the 
different detergents or PC varied the phosphorylation capacity of the lipid 
kinase, therefore the results were plotted relative to each internal control to 
account for such variations, and a representation of such values was plotted on 
the side for comparison (see inset in Figure 5.5). For instance, the sole inclusion 
of PC in the PI(4)P vesicles caused a 38 ± 10.7% (p=0.0004/n=5) decrease in the 
level of phosphorylation by PI(4)P5K la.
Both PA and PS were confirmed as activators of the lipid kinase, but only 
under some of the conditions examined. In those cases where the vesicles were 
prepared using detergents, no significant activation was achieved by either one 
of the two lipids. In fact, whenever deoxycholate was used to prepare the 
vesicles in combination with PC, an inhibition of PI(4)P5K la  was observed 
below internal control levels, down to 41.1 ± 9.77% in the case of PA, 37.56 ± 
10.41% with PS and 74.42 ± 5.54% with DAG (p<0.0003,n=5). The effect under all 
other conditions where detergents were present was not statistically significant.
PA activated PI(4)P5K la  expressed in mammalian cells both on PI(4)P/PA 
vesicles, 290.97 ± 39.74% of control (p=0.001/n=5), and on PC/PI(4)P/PA vesicles, 
181.93 ± 31.53 of internal control (p=0.02/n=5). This activation was also present in 
the case of PI(4)P/PS vesicles, up to 437.15 ± 38.7 (p=2.35xl0*5/n=5). However, 
when PC was included in the vesicles the PS effect disappeared completely.
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F igu re 5 .5  In vitro activation of recombinant PI(4)P5K 
la  expressed in Cos7 cells by different lipid mixtures.
Recombinant PI(4)P5K la  was expressed in Cos7 cells as HA- 
tagged fusion protein, recovered on anti-HA antibody-coated 
agarose beads, washed and stored  in frozen aliquots. A sample of 
the kinase was taken and diluted in kinase buffer to  obtain 
detectable phosphorylation levels. Different lipid vesicles w ere 
tested, composed of 80 pM PI(4)P and PA, DAG and/or PS, in 
combination with 500 pM DMPC as carrier lipid, and detergents 
such as Triton X -I00 (0 .1%) o r deoxycholate (ImM). After 20 
minutes at 25°C, the phosphorylation reaction was stopped by the 
addition of 80 pi of 10% HCI. PIP2 levels w ere  measured as 
described in the Materials and M ethods section.
Data shown are mean ± S.E.M. of 5 separate experiments within 
which measurem ents w ere  m ade in triplicate. For comparison, data 
are shown relative to  the appropriate internal control since the 
absolute activity varied with substrate type (see insert). The 
statistical significance of the data was evaluated using Student's t 
test,
PI(4)P
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Startlingly, DAG also promoted an increase in the amount of PI(4,5)P2 
generated by PI(4)P5K la  expressed in Cos7 cells. Using PI(4)P/DAG vesicles, the 
levels of product rose to 279.15 ± 35.08% (p=0.0009/n=5); PC/PI(4)P/DAG vesicles 
up to 305.05 ± 79.6 of control (p=0.032/n=5). The reduction in activity that the 
kinase suffered after addition of PC into the PI(4)P/PA or PI(4)P/PS vesicles did 
not occur in this case; indeed, there was a slight increase in activity although it 
had no statistical significance. This seems like a situation more in line with 
physiology of cell membranes.
Finally, the combined use of DAG and PS in PI(4)P vesicles was also 
tested, in an attempt to directly assay the effect of these two PKCa-effectors in 
the activity of Type I PI(4)P5K. As expected, the levels of PI(4,5)P2 generated 
were raised to 647.78 ± 51.52% in the absence of PC (p=5.99xl0 5/n=5) and 372.81 ± 
124.18% with PC (p=0.04/n=5). It seems likely that both the effect of DAG and PS 
added up to increase the performance of PI(4)P5K la.
Polyunsaturated DAG Is A Better Activator of PI(4)P5K la 
Expressed In Mammalian Cells Than Saturated Species
PA and DAG are related lipid species which are interconvertable by 
simple enzymatic reactions. PA, the major hydrolysis product of phospholipase 
D, can be turned into DAG by a dephosphorylation step which in living cells is 
catalysed by the enzyme phosphatidate phosphohydrolase (PAP). On the other 
hand DAG, the major hydrolysis product of phospholipase C, can be readily 
phosphorylated to generate PA by the enzyme diacylglycerol kinase (DGK). 
They are both signalling molecules with separate functions in cells. However, if 
these two lipids could be generated through any of the two different 
phospholipases and indiscriminately converted into the product of the other, an
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F ig u re  5 .6  In vitro  activation  o f recom binant PI(4)P5K la  expressed  in Cos7 cells by 
different DAG m ixtures.
Recom binant Type I PI(4)P5K a w as e x p re ssed  in C os7  cells as HA-tagged fusion protein, 
recovered  on  anti-HA an tibody-coated  agarose  beads, w ashed and sto red  in frozen aliquots. A 
sam ple of th e  kinase w as tak en  and d ilu ted  in kinase buffer to  obtain detec tab le  phosphorylation 
levels. D ifferent lipid vesicles w e r e  te s te d , com posed  of 80 pM PI(4)P and different DAGs, in 
com bination w ith 500 pM D M PC  as c a rr ie r  lipid, and deoxychola te  (Im M ). A fter 20 m inutes at 
25°C, th e  phosphorylation  reac tio n  w as s to p p e d  by th e  addition of 80 pi o f 10%  HCI. PIP2 levels 
w ere  m easured  as described  in th e  M aterials and M ethods section.
D ata show n are m ean ±  S.E.M. o f 3 se p a ra te  experim en ts w ithin which m easurem ents w ere  
m ade in triplicate. For com parison , d a ta  a re  show n relative to  th e  appropriate  internal contro l 
since the  absolute activity varied  w ith  su b s tra te  ty p e  (see insert). T he statistical significance of the  
data w as evaluated using S tu d e n t’s t  te s t.
uncontrolled signalling loop could arise. Therefore, subtle differences in the 
nature of the two acyl chains that form part of the lipid might conceivably 
determine different substrates and origins, and thus, limit the chances of 
interconversion products possessing the same signalling functions as the 
precursor (Hodgkin et a l, 1998). This way, the activation of these attenuating 
enzymes may serve as a way of curtailing the signal initiated by either DAG or 
PA, amongst other functions.
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With this in mind, diacylglycerols with different fatty acid chains were 
tested in order to see whether there were different activation patterns of PI(4)P5K 
la  expressed in mammalian cells. Figure 5.6 illustrates how under certain 
conditions, i.e. in the absence of any detergents or lipids other than PI(4)P, the 
longer the acyl chains and the more polyunsaturated the lipid, the stronger was 
the activation of the lipid kinase. Dipalmitoyl-glycerol, which contains two fatty 
acid chains of 16 carbons with no double bonds (diC16:0 DAG), exerted the 
smallest effect of the three under comparison, raising PI(4,5)P2 levels to 163.79 ± 
22.91% of control (p=0.049/n=3). Distearoyl-glycerol (diC18:0 DAG) increased the 
activity to 327.9 ± 14.14% (p=8.6xl0'5/n=3), whereas stearoyl-arachidonoyl- 
glycerol did it to 391.76 ± 29.11% (p=5.5xl0*4/n=3), the highest of the three. These 
increasing values were only observed when the vesicles were composed solely of 
PI(4)P and DAG. If PC was included, the activation was similar on the three 
cases, between 225.2% and 271.5% (p<0.039/n=3). As expected, no activation was 
seen when detergents, deoxycholate in this case, and PC were included in the 
vesicles.
Rejection of the Possibility that the DAG-effect Is Caused 
by the Coprecipitation of Native DGK^ with Recombinant 
PI(4)P5K la
There are two reports in the literature on the association of PI(4)P5K with 
DGK£. Tolias et al (1998b) reported the formation of a complex of PI(4)P5K and 
DGK that was in turn capable of binding the small G protein Rac both in vitro 
and in vivo. They tried to identify the DGK but failed, although from the tests 
performed it was most likely to be DGK£. On the other hand, Luo and colleagues 
(2004) have characterised the same interaction between PI(4)P5K la  and DGK£,
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Figure 5.7 In vitro  activation of recombinant PI(4)P5K la  expressed in Cos7 cells and 
PI(4)P5K 1(3 expressed in bacteria by PA and DAG with and without the DGK inhibitor R59949.
Recombinant PI(4)P5K la  was expressed in Cos7 cells as HA-tagged fusion protein, recovered on anti-HA 
antibody-coated agarose beads; GST-tagged PI(4)P5K ip was expressed in bacteria, recovered on 
glutathione beads and eluted using reduced glutathione . A sample of each kinase was taken and diluted in 
kinase buffer to  obtain detectable phosphorylation levels. Different PI(4)P vesicles w ere tested, composed of 
80 pM PI(4)P and 80 pM PA (cellular extract) or diC16:0 DAG, with or without 30 pM R59949. After 20 
minutes at 25°C, the phosphorylation reaction was stopped by the addition of 80 pi of 10% HCI. PIP2 levels 
w ere measured as described in th e  Materials and Methods section.
Data from I experiment representative of another two. S.E.M. represents the deviation amongst triplicate 
samples. The statistical significance of the  data was evaluated using Student’s t test.
arguing that colocalisation drives the activity of PI(4)P5K by locally producing 
PA from DAG, especially at sites of actin remodelling such as lamellipodia.
To rule out the possibility of the activation of PI(4)P5K by DAG being a 
consequence of the coprecipitation of DGK£ bound to PI(4)P5K la  expressed in 
mammalian cells, and therefore a real PA-activation rather than a DAG one, two 
different approaches were taken.
M am m alian P I(4)P5K a 
M am m alian P I(4)P5K a + R5994< 
Bacterial PI(4)P5Kp 
Bacterial PI(4)P5Kp + R 59949
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First, beads carrying overexpressed, recombinant HA-tagged PI(4)P5K la  
from mammalian cells were western blotted using a DGK^-specific antibody 
alongside lysates from Sf9 cells overexpressing authentic DGKC, as a positive 
control. No DGKt, could be detected in the PI(4)P5K la  lysates (data not shown).
Second, a lipid-dependent activation of P(4)P5K was carried out in the 
presence of a DGK inhibitor to stop the production of PA from DAG. The 
specificity of this inhibitor would suppress the activity of several other DGK 
isoforms bound to PI(4)P5K la. R59949 is an exclusive inhibitor of Class I DGKs 
(a, p and y) and hence it is only valid to reject the input of isoforms of this class 
but not the other four, including the £ isoform which belongs to group IV (van 
Blitterswijk and Houssa, 2000). For this matter, together with the inhibitor, I 
tested the effect of PA and DAG on a PI(4)P5K Ip expressed in bacteria. No 
relevant mammalian DGKs can associate with PI(4)P5K in this system, 
definitively ruling out this possibility. Figure 5.7 shows how the inhibitor did in 
fact reduce the stimulation caused by DAG, and also PA. However, the levels of 
PI(4,5)P2 in the controls were also reduced, which means that the decline was a 
consequence of the inhibition of the 5-kinase activity of PI(4)P5K directly. 
Although it cannot be seen in the figure, the stimulation caused by both PA and 
DAG in relation to their corresponding internal controls in the presence of 
inhibitor was even stronger than in its absence. PI(4,5)P2 levels in the presence of 
PA rose to 10 ± 0.5 fold and those of DAG to 2.5 ± 0.07 fold (p<0.0002/n=3) when 
the DGK inhibitor was absent. When R59949 was included, even though the 
general activity decreased, the stimulation by PA in relation to its control was of 
42 ± 4.8 fold and that of DAG of 12 ± 0.7 fold (p<0.001/n=3). Similar increases in 
activation were obtained with bacterial PI(4)P5K ip, indicating that the DAG 
effect is not restricted to the PI(4)P5K a  isoform (see below).
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There Are No Major Significant Differences In The 
Activation Of PI(4)P5K By PAs And DAGs With Equivalent 
Fatty-Acyl Chains
Finally, a side-by-side comparison of the activation of mammalian 
PI(4)P5K la  and bacterial PI(4)P5K la , Ip and Iy by DAG and PA with equivalent 
fatty acyl chain composition was performed. The possibility of some PAs being 
activators of PI(4)P5Ks but not the corresponding DAGs and vice versa is an 
attractive one that could provide a mechanism to silence the signals arising from 
different pathways by metabolic interconversion. Figure 5.8 illustrates the 
different degrees of stimulation attained using saturated (diC16:0 and diC18:0), 
monounsaturated (C16:0/C18:l and diC18:l) and polyunsaturated (C16:0/C20:4) 
PAs and DAGs. There were no significant differences between the PAs and 
DAGs with matching acyl chain compositions.
There are important differences in the behaviour of mammalian 
PI(4)P5Ka and bacterial PI(4)P5Ka, as well as the other two bacterial isoforms. 
Comparatively, the a  isoform, expressed both in mammalian and bacterial cells, 
was always slightly less sensitive to DAGs than to the corresponding PAs. The p 
and y isoforms however, in the case of unsaturated acyl chains, were more 
sensitive to DAGs than to PAs. In all cases, mono and polyunsaturated lipids 
were much more effective activators of PI(4)P5Ks than saturated ones.
The a  isoform expressed in mammalian cells appeared to be more 
responsive to unsaturated DAGs and PAs than the bacterial one, but not to 
saturated forms of the lipids. The stimulation of the p and y isoforms from 
bacterial origin was generally greater than that of a, especially in response to 
saturated DAGs where the activation was greater than the corresponding PAs, as 
opposed to the a  isoform.
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Figure 5 .8  In v itro  a ctiv a tio n  o f  reco m b in a n t T ype I PI(4)P5K  isoform s ex p ressed  
both in C os7  cells and b a cter ia  by d ifferen t lipid m ixtu res.
Recombinant Type I PI(4)P5K a  w as expressed  in C os7 cells as HA-tagged fusion protein, 
recovered on anti-HA an tibody-coated  agarose beads, w ashed and stored  in frozen aliquots. 
A sample of th e  kinase w as taken  and diluted in kinase buffer to  obtain detectable 
phosphorylation levels. D ifferent lipid vesicles w e re  tested , com posed of 80 pM PI(4)P and 
PS, PA o r DAG. After 20 m inutes a t 25°C , th e  phosphorylation reaction was stopped by the  
addition o f 80 pi of 10%  HCI. PIP2 levels w e re  m easured as described in th e  Materials and 
M ethods section.
Data show n are m ean ± S.E.M. of 3 separa te  experim ents within which m easurem ents w ere  
made in triplicate. For com parison , da ta  are show n relative to  the  appropriate internal 
control. T h e  statistical significance o f th e  data  w as evaluated using S tudent's t test.
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DAG and PMA provoke stable changes in the specific 
activity of PI(4)P5K la in vivo
To further confirm the regulation of Type I PI(4)P5K by diacylglycerols, an 
in vivo treatment of transfected cells with membrane permeable DAG and PA, 
both with 8 carbon fatty acid chains (diC8:0), was performed. Phorbol 12- 
myristate 13-acetate, PMA, which is a potent allosteric activator of conventional 
and novel PKCs was also included in the experiment to account for the direct 
effect of PKC activation on PI(4)P5K la. The aim of these experiments was to 
asses whether any of these three molecules were capable of provoking stable 
changes in PI(4)P5K la  that would alter its activity after extraction of the enzyme 
from the cells. As seen in Figure 5.9, treatment of the cells with the three 
compounds for half an hour at 37°C and subsequent ex vivo examination of the 
PI(4)P-phosphorylating capability of PI(4)P5K la  showed an enhancement in all 
three cases. PA provoked a 155 ± 12.36% increase in comparison with the lipid 
kinase extracted from untreated cells (p=0.01/n=3), DAG a 267 ± 33.85% increase 
(p=0.007/n=3) and PMA a 323 ± 31.47% increase (p=0.002/n=3).
The activation by DAG and PMA was stronger and statistically significant 
(p<0.036/n=3) in comparison with PA. The effect by DAG and PMA is supposed 
to be equivalent in that they both would serve as activators of PKC, although 
PMA is more potent for it is non-degradable by the cell machinery
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Figure 5.9 Activation of PI(4)P5K la by treatm ent of transfected cells with short chain 
PA/DAG/PMA in vivo and subsequent activity analysis in vitro.
Cos7 cells w ere transfected with GST-tagged PI(4)P5K la  and let to  express for 48 hours, then washed 
with PBS and incubated for 30 minutes with medium, o r with medium containing diC8:0 PA (I mM), 
diC8:0 DAG (I mM) o r PMA (100 nM). They w ere  then lysed with low salt buffer, centrifuged and GST- 
PI(4)P5K la  was recovered using glutathione-sepharose beads. After 3 washes in lysis buffer and one wash 
in kinase buffer, the  beads w ere  resuspended into 100 pi total volume, out of which 10 pi w ere used to 
test for kinase activity and th e  remaining 90 pi w ere  mixed with SDS-PAGE sample buffer and resolved in a 
polyacrylamide gel. T he levels of expressed kinase w ere  quantified using anti-PI(4)P5K la antibody and 
these values w ere  used to  normalise th e  am ount of PI(4)P phosphorylation under the different 
preincubation conditions. T he control cells w ere  transfected cells incubated only with medium, without 
activators, for 30 minutes.
Data shown are mean ± S.E.M. of 3 separate experiments within which measurements w ere made in 
triplicate. The statistical significance of the data was evaluated using Student’s t test, * indicates P<0.05.
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5.3 DISCUSSION
Sequence analysis can detect a potential phosphorylation site for PKC 
within the amino acid sequence of Type I PI(4)P5Ks at S214 but this was not 
supported experimentally. However the drastic reduction lipid kinase activity by 
PKCa points to a possible interaction between the two proteins. This inhibition 
was achieved regardless of PKCa. activity. The ATP-independent activation of 
PLD1 and DGK serve as other examples of the regulation of lipid metabolism by 
PKCa mediated through protein-protein interactions rather than 
phosphorylation (Singer et al., 1996 and Hu and Exton., 2003) although 
phosphorylation can play its part. In both cases, PKCa has been proven to bind 
and phosphorylate PLD1 and DGK , inducing opposite effects. DGK£ appears to 
be bound to PKCa under basal conditions, which prevents PKCa from being 
activated by DAG as it is rapidly metabolised to PA by DGK£. When an 
extracellular stimulus generates an increase in the level of DAG, DGK£ can no 
longer fully attenuate the activation of PKCa and as a consequence, the complex 
dissociates leaving PKCa free to phosphorylate its targets. One of these targets is 
DGK£ itself, which becomes inhibited upon phosphorylation by PKCa and thus, 
the levels of DAG can be sustained to support the activity of PKCa (Luo et ah, 
2004). In the case of PLD1, its activation by PKCa in vitro has been shown to be 
independent of phosphorylation (Conricode et ah, 1992; Hammond et ah, 1995; 
Singer et ah, 1996; Min et ah, 1998; Hu and Exton, 2003). Hu and Exton (2003) and 
Chen and Exton (2004) have demonstrated that both PLD1 and PLD2 
respectively are regulated by PKCa through a dual mechanism in vitro and in 
vivo. Both isoforms are activated by a fast initial protein-protein interaction with 
PKCa that is independent of ATP. However, a slower phosphorylation of PLD 
also takes place, which correlates with the inactivation of the phospholipase.
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The absence of a significant effect of PKCa on PI(4)P5K la  expressed in 
mammalian cells might indicate a role for post translational modification of the 
lipid kinase in this effect. Park et al (2001) reported that PI(4)P5K la, (3 and y 
expressed in NIH 3T3 cells are extracted as a phosphoprotein (S214), and the 
kinase responsible for it is PKA. On the other hand, Itoh et al. (2000) also report 
the existence of phospho-PI(4)P5K (again S214) although in their case they this 
was attributed to autophosphorylation. It is a distinct possibility that prior 
phosphorylation at S214 impedes PKCa and PI(4)P5K la  interaction and is 
another means of integrating signals from different sources.
Nishikawa et al. (1998) proved the association of both Type II PI4K and 
Type I PI(4)P5K with the most divergent isoform of the PKC family, PKCp or 
PKD. Part of their study was based on the coprecipitation of PI 4-kinase or PI(4)P 
5-kinase activity together with different isoforms of PKC overexpressed in Cos7 
cells. No PI(4)P5K-activity could be detected associated with PKCa. Once again, 
this assay does not rule out the possibility of a prior phosphorylation of PI(4)P5K 
by PI(4)P5K, PKA, PKC or another kinase which could be impeding the 
association.
The fact that the observed inhibition takes place regardless of the presence 
of ATP and that, when extracted from mammalian cells, this interaction does not 
take place could point at a possible regulation similar to that of DGK£. 
Conceivably, PKCa could inhibit PI(4)P5Ka by direct protein contact which is 
relieved upon auto or trans phosphorylation of the lipid kinase.
The approach that was taken to determine any existent interplay between 
PKCa and PI(4)P5K was perhaps not exhaustive. Similarly straight-forward 
complimentary approaches include the detection of actual phosphorylation of 
the lipid kinase by PKCa using radioactive phosphate incorporation and
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coexpression/coprecipitation studies to demonstrate a physical association of the 
two kinases.
Confirmation of the effects of the two lipid-activators PA and PS on 
PI(4)P5K was obtained and interestingly this was sensitive to the presence of 
combinations of lipids and detergents. If these results are compared with the 
literature describing the effect of PA on Type I PI(4)P5K then fundamental 
differences in the activation of the kinase are found. Moritz et al. in 1992 (using 
PI(4)P5K from bovine brain membranes), Jenkins et al in 1994 (using PI(4)P5K 
from bovine erythrocyte membranes) and Ishiahara et al. in 1996 (using 
recombinant HA-tagged PI(4)P5K expressed in Cos7 cells), all used 0.1% Triton 
X-100 to generate substrate vesicles. All report different levels of activatio: 20, 8- 
15 and 10-fold respectively. Jenkins et al. also tested the activation by PA in the 
absence of Triton X-100, reporting a smaller activation of 3-fold. Jones D.R. et al. 
(2000) also excluded the detergent from the vesicles, arguing that it inhibits the 
basal activity of the lipid kinase (an observation that is not made in my system, 
see inset Figure 5.5), and reported a more modest 2-fold activation. These last 
two reports are more in accord with my results. Jones D.H. et al. also studied the 
activation of PI(4)P5K in PI(4)P/PA (1:1) or PC/PI(4)P/PA (10:1:1) vesicles, 
concluding that the presence of PC in their vesicles inhibit the otherwise 2-fold 
stimulation of Type I PI(4)P5K by PA. Again, this is not completely true in my 
system even though an important reduction is observed. In this last case, the 
differences may be due to the different mole fraction lipid ratios in the vesicles.
Far more interesting is the novel discovery of the activation of PI(4)P5K by 
DAG. Moritz and colleagues are the only ones to ever test the effect of this lipid 
on PI(4)P5K but they reported no effect. This could be due to the presence of 
Triton X-100 in their vesicles masking the activation since this abolished
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activation in my hands. However since activation by PA under those same 
conditions could not be achieved this implies that the detergent is not 
responsible for this discrepancy but rather another factor. If we consider the vast 
differences in activation dependent on the nature of the fatty acyl chains of the 
phospholipids (see Figure 5.8), we could presume that if Moritz had used short 
chain DAGs (it is not specified in the article), it is likely that the stimulatory effect 
could have passed unnoticed.
In any case, from my in vitro experiments it is clear that under conditions 
where PI(4)P5K is activated by PA or PS then DAG is also an activator. I reject 
the possibility of coprecipitation of a DGK^ activity, previously shown to 
associate with PI(4)P5K (Tolias et al., 1998b; Luo et al., 2004), that could be 
responsible for the stimulation caused by DAG. Moreover, the use of the Class I 
DGK-inhibitor R59949 did not directly modify the pattern of activation caused by 
DAG but provoked a direct inhibition of PI(4)P5K. At concentrations above 10 
pM the drug has non-specific effects on overall lipid and protein metabolism 
(Palicz et al., 2001). The definitive test was to use PI(4)P5K expressed in bacteria 
which do not contain soluble DAG-kinase enzyme. In this case the effect of DAG 
was still present confirming that it is an intrinsic property of the enzyme rather 
than an artefact. All three isoforms of the lipid kinase expressed in bacteria were 
responsive to the presence of both PA and DAG.
Comparison of the fatty acyl dependence of PA and DAG activation of 
PI(4,)P5K allowed investigation of the likely sources of DAG in any cellular 
activation through this route in cells. 30 to 80% of cellular phosphoinositide is 
typically the sn-l -stearoyl-2-archidonoyl species. On the other hand, 
phosphatidylcholine predominantly contains saturated and monounsaturated 
fatty acids (Hodgkin et al., 1998). DAG accumulation in stimulated cells is often 
biphasic showing a rapid rise in polyunsaturated DAGs followed by a slower
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sustained phase of monounsaturated DAG accumulation alongside smaller 
amounts of poly-DAGs (polyunsaturated DAGs). During the initial phase, DAG 
is produced from the hydrolysis of PI(4,5)P2 by PLC whereas that of the 
sustained phase is originated by PC-hydrolysis via PLD activation with 
subsequent dephosphorylation of PA by phosphatidate phosphohydrolase. The 
same applies to the generation of PAs in stimulated cells. Few stimuli activate 
PIP2-PLC or PLD without simultaneously activating the other phospholipase. 
The extent and duration of the accumulation of the lipid products of PLC and 
PLD activity depends on the stimulus and receptor; bombesin desensitises 
rapidly within minutes and thus PI(4,5)P2 or PC hydrolysis finishes rapidly while 
cholecystokinin (CCK) or muscarinic cholinergic stimuli desensitise much more 
slowly, allowing poly-DAGs to accumulate for much longer due to a persistent 
PLC-activation (Hodgkin et al., 1998).
It is thought that it is only the polyunsaturated DAGs from PLC or the 
monounsaturated PAs, generated by PLD that have biological functions. Hence, 
interconversion of poly-DAG into poly-PA or saturated/monounsaturated PA 
onto the corresponding DAG would serve as a method of functional inactivation 
of the signal (Pettitt et al., 1997; Hodgkin et al., 1998; Wakelam, 1998). However I 
find no remarkable differences in the effects of corresponding pairs of acyl- 
species of DAG and PA on PI(4)P5K. Thus in contrast to signalling to PKCs and 
Munc-13 phosphorylation of DAG lipid by DGKs would not serve to halt the 
stimulation of PI(4,5)P2 synthesis.
Amongst PAs and DAGs from PC-hydrolysis, there are differences 
amongst acyl-species principally in the effects of saturated and 
monounsaturated species. Saturated PAs are relatively good activators of the 
lipid kinase, whereas saturated DAGs are poor. Monounsaturated PAs are very 
strong activators of PI(4)P5K, whereas monounsaturated DAGs are less good in
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the case of the la  isoform and far better in the case of 1(3 and Iy PI(4)P5K. PS is 
also a better activator of these two isoforms than it is of PI(4)P5K la. Both murine 
PI(4)P5K 1(3 and Iy are the two isoforms thought to be located at the plasma 
membrane whereas the a  isoform is thought to be located at the Golgi. This 
experiment demonstrates the existence of differential responsiveness to lipids by 
the distinct isoforms in vitro. Regarding saturated lipids, this could be the only 
way of achieving activation following PLD activation while its conversion into 
DAG could attenuate the signal. Nonetheless, when measuring the different fatty 
acids present in PA derived from PC, saturated and monounsaturated species 
seem to generally similar. But considering the extremely divergent effects of the 
two, it is conceivable that further separation of the functions of these two fatty- 
acyl chain species could take place within cells, allowing for further differential 
regulation. When PC is included in the vesicles these differences tend to 
disappear and so care should be taken before drawing definitive conclusions. 
The behaviour in vivo could be far from that depicted by these results.
Finally, I tested whether the activation of PKC within cells had a direct 
effect on PI(4)P5K that could modulate its activity once extracted from the cells, 
implying a permanent modification of the enzyme. The addition to cells of 
permeable DAG serves as a means of mimicking an external signal through PLC. 
The experiment proved that the addition of either DAG or PMA (a type of 
phorbol ester that mimics DAG-action by binding the Cl domain of cPKCs and 
nPKCs) provoked some stable change in the lipid kinase increasing its intrinsic 
activity. Park et al. have previously reported phosphorylation of Type I PI(4)P5K 
by PKA, with the consequent attenuation of its activity, and that PKC provoked a 
decrease in the phosphorylation, increasing its activity. Dephosphorylation was
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mediated by PP1 phosphatase in response to PKC activation. My results are in 
accord with this model.
Cell permeable PA was also capable of altering the activity of the lipid 
kinase albeit much less efficiently. This result would confirm that obtained by 
Jones D. R. et al, who also reported such an effect after treatment of transfected 
cells with diC8:0 PA, hence allegedly demonstrating an in vivo activation of 
PI(4)P5K la  by PA. Alternatively PA may promote the activation of other 
enzymes that would permanently alter the activation state of the lipid kinase by 
methods such as phosphorylation or dephosphorylation. In addition to PKC that 
might be activated if PA was dephosphorylated to DAG several PA-dependent 
protein kinases have been identified. In neutrophils, PA generation provokes Ser 
and Tyr phosphorylation of the p47**“ component of the NADPH complex 
(Waite et al, 1997), in HL60 cells Tyr phosphorylation of a 100-115 kDa protein 
(Ohguchi et al., 1997), and in 3T3-L1 cells Tyr phosphorylation of the 44/47-kDa 
MAP kinases (Siddiqui et al., 1995), amongst other activities. These PA- 
dependent effects give PLD an intermediary role other than its activation being 
simply a consequence of PKC activation downstream of PLC activation.
Even though a conclusive effect of PKCa on PI(4)P5K could not be 
demonstrated with the approach described in this thesis, a further more relevant 
role for DAG in the control of the activity of this lipid kinase by a dual 
mechanism is impled. This is important because in most models of signalling to 
PI(4)P5K assume that PA is exclusively the lipid responsible for the feedback 
activation of the PIP kinase (see Figure 1.4). A revised model must include both 
PKC-dependent and -independent PI(4)P5K activation by DAG.
It is conceivable that both PA and DAG could work as a coupled pair and 
both have similar properties in terms of PI(4)P5K activation. The generation of 
DAG or PA as a consequence of stimulation of surface receptors is generally
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linked to situations where the sustained synthesis of PI(4,5)P2 is also critical. This 
is because, the second messengers DAG, IP3 or PIP3, are produced from PI(4,5)P2 
but also this lipid anchors a plethora of proteins involved in vesicle trafficking or 
actin remodelling, amongst other processes, that generally accompany receptor 
stimulation. Therefore, an effective, potent and rapid mechanism for PI(4,5)P2 
replenishment and overproduction, necessary to support simultaneous 
processes, has to be triggered as soon as consumption starts. DAG is the direct 
hydrolysis product of PI(4,5)P2 and so represents a more direct stimulus to 
replenishment than the later generation of PA by DGK or following PLD- 
activation by PKC. A direct effect on PI(4)P5K reinforced by an activating 
dephosphorylation achieved through PKC/PP1 would serve as a quick and very 
powerful mechanism to increase PI(4,5)P2 regeneration during the initial phase of 
DAG-production (see Figure 5.10).
Recently Nielssen et al. (2004) found that in hepatocytes, certain GPCR- 
agonists provoke a prolonged synthesis of DAG through PI(4,5)P2 hydrolysis by 
PLC without a contribution from PLD. Upon vasopresin stimulation the level of 
PIP2 declined, but only transiently, while increases in IP3 and DAG mass were 
sustained, suggesting that efficient resynthesis of PIP2 allows sustained PLC 
activity. The use of wortm annin (to block PI(4)P and PI(4,5)P2 synthesis) 
impaired this accumulation. Therefore, as no PA-driven stimulation of PI(4)P5K 
could be taking place to stimulate the regeneration of the hydrolysed PIP2, the 
activation of PI(4)P5K by DAG could effectively and rapidly support that 
resynthesis, necessary for the prolonged accumulation of DAG in these systems. 
These data would clearly support the positive feedback model presented on 
Figure 5.10.
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Another im portant conclusion is that factors like lipid-vesicle 
composition, the nature of the fatty-acyl chains, the presence of detergents 
and/or carrier lipids and the origin of the recombinant enzymes can dramatically 
influence results. Consequently, conclusions must be drawn cautiously and 
preferably after comparing all these variables and their differential effects.
P I(4 )P 5 K
PI(4,5)P y DAG
PP1 PKC
F ig u re  5 . 10  Direct positive feedback regulation of PI(4)P5K by DAG.
The dual feedback activation of PI(4)P5K by DAG, through direct stimulation of PI(4)P5K-activity and 
through activation of c/nPKCs that can indirectly provoke an increase in PI(4)P5K-activity by 
dephosphorylation of the lipid kinase by menas of the phosphatase P PI.
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6.1 INTRODUCTION
In this final chapter I made an attempt to characterise a novel mechanism 
of regulation of the production of PI(3,4,5)P3 in cells by a completely ignored 
group of small GTPases: ADP-ribosylation factors. This approach was 
undertaken after the discovery of the existence of variations in the levels of this 
polyphosphoinositide within permeabilised HL60 cells upon readdition of 
members of this group of GTPases.
There is no previous evidence in the literature of direct interplay between 
this group of small G proteins and phosphatidylinositol 3-kinases. Class I PI3Ks 
have previously been shown to be subject to regulation by members of several 
related groups of GTPases. G(3y subunits of heterotrimeric G proteins are 
responsible for the activation of the sole member of Class IB PI3Ks upon their 
dissociation from the Ga subunit, but also of one of the members of Class IA 
PI3Ks, the p isoform (Maier et al, 1999). Ras binds to Class I PI3Ks through their 
Ras-binding domain and stimulates the level of lipid kinase activity of at least 
p i 10a and pllOy (Vanhaesebroeck et al, 2001). In the case of the Rho family of 
small G proteins, both Rac and Cdc42 can bind and stimulate the activity of 
PI3Ka (Tolias et al, 1995). PI3Kp can also be activated by Rab5, a member of Rab 
family of small G proteins (Kurosu and Katada, 2001).
The discovery of an interaction between ARF proteins and some members 
of Class I PI3Ks adds complexity to the already intricate mechanisms that 
regulate the generation of this polyphosphoinositide in biological systems and 
the functions that depend on it, albeit at the same time, it opens an exciting line 
of study that needs further elucidation to reach a better understanding of such 
processes.
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6.2 RESULTS
Both ARF I and ARF6 Promote The Synthesis Of PI(3t4t5)P3 
In Permeabilised HL60 Cells
While performing permeabilised HL60 cells experiments where the ability 
of exogenously added ARF proteins to promote PI(4,5)P2 synthesis was studied, 
a fourth spot on the TLC plates used to analyse the lipid contents of the cells 
appeared to change upon addition of ARF proteins and GTPyS. This spot 
corresponded to PIP3, as seen by comigration studies, and figure 6.1 shows its 
variation with time. GTPyS on its own appeared capable of increasing the 
production of this polyphosphoinositide marginally, between 1.22 and 1.32-fold 
compared to the control over 5 and 20 minutes of the time course (no statistical 
significance). This probably indicates the activation of residual GTPyS-responsive 
GTPases inside the cells that would have an effect on the production of PIP3 
regardless of the readdition of further proteins. After 10 minutes, the maximal 
activation with mARFl was attained, a 1.98-fold increase of the unstimulated 
control (p<0.001/n=7) (1.41-fold over of GTPyS) and at 15 minutes with mARF6, 
1.63-fold activation (p=0.02/n=7) (1.36-fold of GTPyS). In both cases, the increase 
in PIP3 diminished after 20 minutes to levels similar to those with GTPyS (1.32- 
fold of control), 1.48-fold for mARFl and 1.59-fold for mARF6 (no statistical 
significance). This shows that the effect of both myristoylated ARFs in promoting 
PIP3 formation was only transient and was attenuated after 20 minutes of 
incubation. This is to be anticipated since PIP3-degrading enzymes such as the 
phosphoinositide phosphatases SHIP and PTEN which dephosphorylates 
PI(3,4,5)P3 to generate PI(3,4)P2 and PI(4,5)P2, were likely to still be active (Damen 
et al, 1996; Nakashima et al, 2000)
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Comparison of the PIP2 and PIP3 generation curves allows direct 
comparison of the different polyphosphoinositide-synthesis patterns. PIP3 levels 
in response to ARF1 rise rapidly from the start of the reaction and reach higher 
levels than those with ARF6. This is in direct contrast to the situation with PIP2 
where ARF6 promoted a faster and remarkably higher synthesis than ARF1.
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Figure 6.1 Effect of 
th e readdition of 
recombinant 100%
myristoylated ARF I or ARF6 
and GTPyS on PIP3 
production on
permeabilised HL60 cells. 
After 10 minutes of 
permeabilisation with
streptolysin O  (0.4 lU/ml) at 
37°C, cytosol-depleted HL60 
cells w ere  recovered by 
centrifugation and resuspended 
in buffer containing 50 pM 
MgATP/[y-32P]ATP final
concentration (added last to  
sta rt th e  reaction), I pM ARF I 
o r  ARF6 and 10 pM GTPyS. 
Reactions w ere  run at 37°C 
and sampled at each tim e point 
by removal of 3x50 pJ identical 
triplicate samples of each 
reaction m ixture and
transferred into new  tubes 
containing 80 pi of 10% (v/v) 
HCI. Lipid levels w ere
m easured as described in the 
Materials and M ethods section. 
Data shown are mean ± 
S.E.M. of 7 separate 
experiments within which
measurements were made 
in triplicate. Data have been 
plotted relative to the 
maximum value of the 
control curve. The statistical 
significance of the data was 
evaluated using Student’s t 
test.
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ARF Proteins Inhibit p85/p 11 Op
A direct reading of the previous results might imply the activation of one 
or more isoforms of PI(3,4,5)P3-synthesising enzymes and/or the inhibition of a 
PI(3,4,5)P3-phosphatase i.e. Type I PI3Ks and SHIP/PTEN respectively. It is 
probable that the observed increase in PIP3 levels following the addition of ARF 
proteins was purely a consequence of the increase in the levels of PIP2, or an 
indirect effect on PIP3 generation rather than a direct activation of PI3Ks. The 
measured levels of PIP3 in HL60 cells are about one order of magnitude smaller 
than those of PIP2, consequently, significant variations in the generation of PIP2 
could be indirectly forcing the changes in PIP3. PI(3,4,5)P3 levels are known to 
only vary upon stimulation (Vanhaesebroeck et al, 2001), and in this case, 
although no receptors have been expressly stimulated, the addition of GTPyS 
should serve to promote the dissociation of a considerable number of GPy 
subunits from heterotrimeric G proteins, with the consequent activation of some 
of the cellular PI3Ky (see GTPyS curve in Figure 6.1). Of course, this might not be 
as significant as after stimulation of GPCRs, or further more, a combination of 
the two, as previously reported in the same system (Kular et al, 1997). As for 
feed-through from PIP2 synthesis, even though the patterns of increment of the 
two inositol lipids are not correlated for PIP3 levels in the presence of mARFl 
peak faster and higher than those with mARF6, another contrast to the case with 
changes in PIP2, this possibility cannot be completely ruled out from the 
permeabilisation experiments. Therefore, a more direct approach was pursued 
by testing for activation in vitro using recombinant lipid kinase proteins.
For this work, the four known isoforms of mammalian Type I PI3K were 
obtained and tested in combination with fully myristoylated ARF proteins in 
vitro. Authentic purified p i 10a, (3 and 6, plOl/pllOy protein (crystallographic
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grade) and monomeric pllOy were obtained from from Prof Mike Waterfield 
(Ludwig Institute for Cancer Research, UCL, London), Dr Len Stephens 
(Babraham Institute, Cambridge) and Prof Peter Shepherd (Department of 
Biochemistry, UCL, London), respectively. Given the small sample size, their 
authentic validated catalytic activity and their reliable provenance, the purity of 
these enzymes was not checked further. Figure 6.2 illustrates the effect of both 
ARF1 and ARF6 on the activity of the three Type IA PI3K isozymes a, p and 8.
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F igu re  6 .2  In vitro effect of recombinant 100% myristoylated ARF I and ARF6 on 
recombinant pi 10a, (3 and 5.
Recombinant p 110a, P and 5 together with p 85a  w ere expressed in Sf9 insect cells and 
imm unoprecipitated using anti-p85-N-SH2 antibody-coated protein A agarose beads, washed and 
stored in frozen aliquots. A sample of the kinase was taken and diluted in kinase buffer to  obtain 
detectable phosphorylation levels. The kinase was mixed with final 0.2 mg/ml PI, 90 pM MgATP, 5 
pCi/reaction [y-32P]ATP, 10 pM GTPyS and I pM recombinant ARF I o r ARF6. The samples w ere 
preincubated in ice for 40 minutes and after 30 minutes at 25°C, the phosphorylation reaction was 
stopped by the addition of 80 pl of 10% (v/v) HCI. PI(3)P levels w ere measured as described in the 
Materials and M ethods section.
Data shown are mean ± S.E.M. of 3 separate experim ents within which measurem ents w ere made in 
triplicate. For comparison, data are shown relative to  the appropriate internal control. The statistical 
significance of the data was evaluated using Student’s t test.
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The three pllO catalytic subunits had been expressed in Sf9 cells together with 
the p85a regulatory subunit; the heterodimers were recovered on beads coated 
with polyclonal anti-p85 antibody, raised against the N-terminal SH2 domain. 
The assays were performed with the enzyme bound to the beads. In the case of 
the a  and 8 isoform there was no significant change in activity if compared with 
the control samples or with GTPyS. However, in the case of the (3 isoform, the 
presence of both ARF1 and ARF6 provoked a decrease in the levels of PI(3)P 
generated. ARF1 reduced the amount of PI(3)P to 69 ± 8% of the control 
(p<0.05/n=3 against GTPyS) and ARF6 down to 58 ± 3% of the control 
(p=0.001/n=3 against GTPyS). This result was completely unexpected given the 
previous results on HL60 cells were ARF proteins stimulate the production of 
PI(3)P.
ARF Proteins Activate pl lOy But Inhibit plOI/pl IOy
Similar in vitro experiments were carried out using the remaining Type I 
PI3K, the sole member of the Type IB group, pllOy. A polyhistidine-tagged form 
of this protein had also been expressed in Sf9 cells and was recovered through its 
interaction with Ni2+-containing affinity media. This preparation did not contain 
the regulatory subunit plOl. Figure 6.3 reflects the significance of the activation 
of this isoform by both ARFs. Both ARF1 and ARF6 in the absence of GTPyS were 
capable of stimulating the generation of PI(3)P to 247 ± 16% and 245 ± 22% of 
control respectively (p<0.0018/n=5). The inclusion of GTPyS increased the amount 
of PI(3)P quite modestly where it was not present, up to 284 ± 17% and 339 ± 49% 
of control; nevertheless, this small increase was also forced by GTPyS on its own 
in the absence of ARF proteins, up to around 140%. This implies that such effect 
in the presence of ARF proteins is most certainly not due to the added GTPases
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Figure 6.3 In vitro effect of recom binant 100% m yristoylated ARF I and ARF6 on 
recom binant pl lOy.
Recombinant His-tagged pl IOy was expressed in SF9 insect cells and recovered using Ni2+-agarose 
beads, washed and stored in frozen aliquots. 10 pl of 130 nM pl IOy was mixed in 50 pl final volume 
with final 0 .2  mg/ml PI, 90  p.M MgATP, 5 pC i/reaction  [y-32P]ATP, 10 p.M GTPyS and I pM 
recom binant ARF I o r  ARF6. T he sam ples w e re  preincubated in ice for 40 minutes and after 
30 m inutes at 25°C , th e  phosphorylation  reaction  was stopped  by th e  addition of 80 pJ of 
10%  (v/v) HCI. PI(3)P levels w e re  m easured  as described in th e  Materials and M ethods 
section.
D ata show n are  m ean ±  S.E.M. of 5 separa te  experim ents within which m easurem ents w ere  
m ade in triplicate. For com parison, data  a re  show n relative to  the  appropriate  internal control. 
T h e  statistical significance of th e  data  was evaluated using S tudent’s t test.
by GTP-loading, but due to some indirect effect of GTPyS on the lipid kinase 
preparation probably mediated by trace contaminants.
Moreover, since the effect on members of Type IA PI3Ks had been 
performed using both the catalytic and the regulatory subunits, the equivalent 
heterodimer of Type IB PI3K, i.e. plOl and pllOy, was obtained in order to make 
a direct comparison. Strikingly as seen in Figure 6.4, the stimulation of the kinase 
activity completely disappeared and in fact the opposite effect was attained, that 
is, a potent inhibition of the enzyme. ARF1 was capable of reducing the activity
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F ig u re  6 .4  In vitro  effect o f recom binant 100% m yristoylated ARF I on
recom binant p10 l/pI IOy.
Recombinant p lO I/p l IOy w ere  expressed in Sf9 cells, recovered and frozen after elution from 
the beads. A sample of the kinase w as taken and diluted in kinase buffer to  obtain detectable 
phosphorylation levels. T he kinase was mixed with final 0.2 mg/ml PI, 90 pM MgATP, 5 
pCi/reaction [y-32P]ATP, 10 pM GTPyS and I pM recom binant ARF I. The samples w ere 
preincubated in ice for 40 minutes and after 30 minutes at 25°C, the  phosphorylation reaction 
was stopped by the addition of 80 pl of 10% (v/v) HCI. PI(3)P levels w ere  measured as 
described in the Materials and M ethods section.
Data shown are mean ± S.E.M. of 3 separate experim ents within which m easurem ents w ere 
m ade in triplicate. The statistical significance of the data was evaluated using Student’s t test.
of the phosphoinositide kinase down to 15 ± 1% of control in the absence of 
GTPyS and down to 17 ± 7% when GTPyS was included (p<0.0002/n=3).
Testing The Effect Of GTPyS On The Activation Of pl IOy 
By ARF Proteins In Vitro
ARF proteins need to be GTP-loaded in order to exert their regulatory 
effect onto other proteins, as it was the case of the interaction with PI(4)P5K 
described in Chapter 3. The fact that pllOy could be activated by both ARF1 and 
ARF6 in the absence of GTPyS came as a surprise, for that should not be the
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Figure 6 . 5  Tim e course of th e  in vitro  effect of recom binant 100% m yristoylated ARF6 
on recom binant p 11 Oy at 25°C and at 37°C.
Recom binant His-tagged pi I0y w as exp ressed  in SF9 insect cells and recovered using Ni2+-agarose 
beads, w ashed  and s to red  in frozen  aliquots. 10 pi of 130 nM pi I0y was mixed in 50 pi final volume 
w ith final 0.2 mg/ml PI, 50 pM MgATP, 5 pC i/reaction [y-32P]ATP, 10 pM GTPyS and I pM ARF6 in 
ice. T he sam ples w e re  preincubated at 4°C  for 60 minutes and then  transferred  th em  to  25°C o r 
37°C to  s ta rt the  phosphorylation. Reactions w ere  sampled at each tim e point by removal of 3x50 pi 
identical triplicate sam ples of each reaction  m ixture and transferred  into new  tubes containing 80 pi of 
10%  (v/v) HCI. PI(3)P levels w e re  m easured  as described in th e  Materials and M ethods section.
D ata show n are m ean ± S.E.M. o f triplicate sam ples within a single experim ent. T h e  statistical 
significance of the  data was evaluated using S tudent’s t test.
physiological scenario. For this reason, different assay conditions were tested to 
try to determine whether the lack of further activation in the presence of GTPyS 
was an artefact or a bona fide effect.
Temperature Dependence
Initially, the possible influence of temperature was examined. As seen in 
Chapter 3, preincubation of PI(4)P5K increased the stimulatory effect of ARF 
proteins on phosphatidylinositol 4-phosphate 5-kinase. Part of that effect may
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F igu re 6 .6  In v itro  effect of recombinant 100% myristoylated ARF I and ARF6 on 
recombinant pi 10 y.
Recombinant His-tagged p 11 Oy w as expressed in SF9 insect cells and recovered using Ni2+-agarose 
beads, washed and stored in frozen aliquots. 10 pi of 130 nM pi I Oy was mixed in 50 pi final volume 
with final 0.2 mg/ml PI, 50 pM MgATP, 5 pCi/reaction [y-32P]ATP, with (■) o r w ithout ( • )  50 pM 
GTPyS and logarithmic dilutions of recom binant ARF I and ARF6 in ice. The samples w ere 
preincubated at room  tem peratu re  for 60 minutes and after 20 minutes at 37°C, the  phosphorylation 
reaction was stopped by the addition of 80 pi of 10% (v/v) HCI. PI(3)P levels w ere measured as 
described in the  Materials and M ethods section.
Data shown are mean ±  S.E.M. of 3 separate experim ents within which measurem ents w ere  m ade in 
triplicate. The statistical significance of the data was evaluated using Student’s t test.
arise from heat-denaturation of the lipid kinase, although there is previous 
evidence of temperature facilitating the binding of ARF proteins to membranes 
as well (Haun et al., 1993). However, pllOy proved not be as heat-labile as 
PI(4)P5K, as seen in Figure 6.5 where the control curve at 37°C runs just slightly 
higher than that at 25°C (all values plotted relative to the maximum point in the 
control line at 25°C which is the 30 minutes point). A one-hour preincubation at 
4°C was performed in the absence of MgATP to allow for the components of the 
mixture to interact, followed by the transfer of the samples to a 37°C-water bath
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or to the bench with the subsequent addition of MgATP. When the 
phosphorylation reaction was performed at 37°C, ARF6 was capable of further 
stimulating pllOy in the presence of GTPyS in comparison to those samples were 
it was absent. When the reaction was performed at room temperature, there was 
no differential effect with or without the guanosine nucleotide, and both 
increased the levels of PI(3)P to an approximate 270% of the control after 30 
minutes (p<0.05/n=3). At that same time point at 37°C, in the absence of GTPyS 
there was a 155% (p=0.033/n=3) increase in the production of PI(3)P if compared 
with the control values at that same temperature, and a 235% (p=0.003/n=3) 
increase in the presence of the nucleotide. Therefore, an increase in the reaction 
temperature seemed to improve the activation by ARF upon GTPyS-binding.
Figure 6.6 shows a titration curve of ARF and its influence on the activity 
of pllOy performed at 37°C. The stimulation on PI(3)P generation became 
significant at around 1 pM concentration of myristoylated ARF proteins, with 
little differences between the two isoforms and with no apparent influence of 
GTPyS on the stimulation despite the change in the temperature of the assay. The 
activation reached very high levels at 10 pM ARF proteins. Only at that point, 
ARF6 seemed to diverge on the activation of pllOy and exceed that of ARF1. In 
the presence of GTPyS, ARF6 yielded a 1530 ± 225% increase in PI(3)P levels 
(p=0.042/n=3) whereas ARF1 yielded a 877 ± 128% increase (p=0.047/n=3). 
Without the nucleotide the values were similar in the case of ARF6, and slightly 
lower in the case of ARF1 (the difference was not statistically significant). 
Although the previous approach pointed at a possible improvement on the 
activation of pllOy by ARF by means of raising the temperature of the reaction, 
in practical terms this did not take place, or not consistently enough to be 
reflected in the titration experiment.
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Figure 6.7 Titration curve of th e  activation in vitro by recom binant 100%
m yristoylated ARF6 and GTPyS of recom binant p 11 Oy at 37°C.
Recom binant His-tagged p i I Oy w as expressed in SF9 insect cells and recovered  using Ni2+- 
agarose beads, w ashed  and s to red  in frozen  aliquots. 10 pi o f 130 nM pi I Oy was mixed in 50 pi 
final volum e w ith final 0.2 mg/ml PI, 50 pM MgATP, 5 pC i/reaction [y-32P]ATP, different 
concen tra tions of GTPyS and of ARF6 in ice. The samples w ere  preincubated at 4°C  for 60 
m inutes and then  transferred  th em  to  37°C to  sta rt th e  phosphorylation. Reactions w e re  stopped  
after 20 m inutes by addition of 80 pi o f 10%  (v/v) HCI. PI(3)P levels w ere  m easured as described 
in th e  Materials and M ethods section.
D ata show n are  m ean ±  S.E.M. of triplicate sam ples within a single experim ent., The statistical 
significance of the  data w as evaluated using S tudent’s t test.
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C on cen tra tion  o f  GTPyS
Since in the last experiment the amount of GTPyS was raised from 10 pM 
to 50 pM to maintain a saturating concentration of the nucleotide against the 
elevated ARF protein levels, I tried to determine whether using different 
concentrations of GTPyS could serve to maximise the activation of ARF by the 
nucleotide. Figure 6.7 shows how the activation of pllOy by 10 pM ARF6 at 50 
pM concentration of GTPyS is lower than that at 10 pM and especially lower than 
at 25 pM. This means that the use of 50 pM GTPyS was perhaps not the most 
appropriate working concentration in order to distinguish the small activating 
effect of GTPyS on ARF. The strongest effect seemed to be achieved at 25 pM 
nucleotide when using 10 pM ARF6 concentrations. However, at other 
concentrations of ARF6, either 10 or 25 pM GTPyS seemed to yield similar results. 
The inset above the main figure compares the activation of pllOy at increasing 
concentrations of ARF6 in the absence and in the presence of 25 pM of GTPyS, the 
concentration which exerted the most noticeable effect. The activation by ARF6 
was very strong just on its own, and the addition of GTPyS seemed to activate the 
GTPase even further as the amount of ARF6 was increased. 10 pM ARF6 and 25 
pM GTPyS were capable of stimulating the generation of PI(3)P a 40% more than 
ARF6 alone (p=0.035/n=3).
P reloading o f  ARF P rotein s w ith  GTPyS
Finally, the possibility of improving the GTPyS-loading of ARF was tested 
using three different approaches.
The first one was by controlling the amount of Mg2+ present in solution to 
facilitate the spontaneous loading of the nucleotide. The magnesium ion found in
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solutions to the structure of ARF proteins is unambiguously mandatory for GTP 
(or GTPyS) binding, but not for GDP (Amor et al, 1994; Greasley et al, 1995; 
Menetrey et al, 2000). Thus, depleting the medium of Mg2+ before adding the GTP 
may facilitate the uptake of the nucleotide by ARF as the release of GDP is 
usually the rate limiting step in exchange reactions. However, when this process 
was performed prior to the interaction between the lipid kinase and the small G 
protein, no improvement was observed in comparison to the control.
Another approach was made by using an ARF-exchange factor, 
specifically Cytohesin-1. This was the same tactic used when assessing the 
activation of phosphatidylinositol 4-phosphate 5-kinase by ARF proteins. Yet, 
and as occurred in the previous instance, no improvement was achieved.
Finally, the same recombinant nonmyristoylated ARF proteins used on 
chapter 3 to study the activation of PI(4)P5K that were 100% preloaded with 
either GDP or GppNHp were used. It needs to be highlighted once again that 
although this eliminates ambiguities due to GTP-loading, the proteins are not 
myristoylated and hence a cautious interpretation of the data needs to be made, 
as this is not the physiologically relevant state of these small G proteins. 
Nevertheless, Figure 6.8 illustrates how both GDP- and GppNHp-loaded ARF1 
and ARF6 increase the production of PI(3)P by pllOy. Once again and confirming 
the behaviour reported when interacting with PI(4)P5K, the nonmyristoylated 
GDP-loaded forms of both ARF1, up to 323 ± 49% of control, and ARF6, up to 397 
± 68 (p<0.010/n=3), are more efficient in activating pllOy than the GppNHp- 
loaded forms. GppNHp-loaded ARFs, increase the PI(3)P levels up to 181 ± 0% 
and 226 ± 18% of control respectively (p=0.002/n=3). The better performance of
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Figure 6.8 In vitro activation of recombinant pllOy by recombinant preloaded
nonmyristoylated GDP/GppNHp-ARFI and ARF6.
Recombinant His-tagged p 11 Oy w as expressed in SF9 insect cells and recovered using Ni2+-agarose 
beads, washed and stored in frozen aliquots. 10 pi of 130 nM pi lOy was mixed in 50 pi final volume with 
final 0.2 mg/ml PI, 90 pM MgATP, 5 pCi/reaction [y-32P]ATP and 10 pM recom binant preloaded 
GDP/GppNHp-ARF I o r ARF6. T he samples w ere  preincubated at 37°C for 30 minutes, the ATP added 
and after 20 minutes at 25°C, th e  phosphorylation reaction was stopped by addition of 80 pi of 10%  
(v/v) HCI. PI(3)P levels w ere  m easured as described in the Materials and Methods section.
Data shown are  mean ± S.E.M. of 3 separate experim ents within which m easurem ents w ere  made in 
triplicate. The statistical significance of the data was evaluated using Student’s t test.
the GDP-loaded forms with both isoforms of ARF is also statistically significant 
(p<0.05/n=3). In contrast to what happened when using PI(4)P5K as the effector 
of preloaded nonmyristoylated ARF proteins, there is no apparent preference for 
ARF6 over ARF1.
In conclusion, there were certain conditions where the effect of GTP 
(analogues) on the activation of pllOy by ARF proteins could be maximised in 
order to demonstrate that GTPyS could further stimulate such interaction in vitro.
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However, the potency of ARF proteins by themselves, without the need of GTP- 
binding was almost as strong, implying that the interaction between these two 
enzymes is not completely dependent of the activation state of ARF, albeit it can 
improve it.
Readdition of p 11 Oy into Permeabilised HL60 Cells together 
with ARF Proteins Augments the Generation of PIP2 and 
PIP3
An indirect method to confirm that the registered increase in PIP3 as a 
consequence of the readdition of ARF proteins in the presence of GTPyS was 
caused by the activation of Type I PI3K, was developed. To do this, pllOy was 
introduced into the permeabilised HL60 reconstitution assay in combination 
with fully and nonmyristoylated ARF proteins and GTPyS. Figure 6.9 reflects the 
PIP2 and PIP3 levels generated after 10 minutes of the readdition of the 
components.
Looking at the Control data for the PIP3 graph, it is apparent that neither 
GTPyS nor PI3K were capable of significantly altering the cellular contents of 
PIP3. This would mean that the mere enrichment of the cellular contents of Type 
IB PI3K by exogenous addition is not sufficient to increase PIP3 levels in cells, 
since physiological activation of this class I PI3K is dependent on its interaction 
with an activator in response to a stimulus, and the presence of its regulatory 
subunit, p i01, seems mandatory by mediating membrane recruitment (Brock et 
al, 2003). However, when both agents were used in conjunction, PIP3 levels rose 
to 135 ± 9% of control, statistically significant with respect to both control and 
GTPyS stimulation (p<0.023/n=3). This could reflect a situation where addition of 
GTPyS could be activating some of the membrane bound heterotrimeric G
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Figure 6.9 Effect of the readdition of recombinant ARF proteins, pi I Oy and GTPyS on
PIP2/PIP3 production after 10 minutes on permeabilised HL60 cells.
After 10 minutes of permeabilisation with streptolysin O  (0.4 lU/ml) at 37°C, cytosol-depleted HL60 
cells w ere  centrifuged and resuspended in buffer containing 50 pM MgATP/[y-32P]ATP final 
concentration (added last to  start the reaction), I pM nonmyristoylated ARF I, AI7ARFI o r ARF6, o r 
fully myristoylated ARF I o r ARF6, 26 nM p 11 Oy and 10 pM GTPyS. Reactions w ere  run at room  
tem perature for 10 minutes and stopped by addition of 80 pi of 10% (v/v) HCI. Lipid levels w ere 
measured as described in the  Materials and Methods section.
Data shown are mean ± S.E.M. of 3 separate experiments within which measurements w ere made in 
triplicate. Data have been plotted relative to  the maximum value of the control curve The statistical 
significance of the data was evaluated using Student’s t test.
proteins to release py subunits and these in turn stimulate the reintroduced 
pllOy. However, this would have to be an interaction in the absence of its
207
Regulation of PI3K pl lOy  by ARF Proteins
membrane-recruiting subunit plOl, perhaps due to intrinsic membrane binding 
properties of the catalytic subunit. In any case, this result does indicate that the 
pllOy subunit can function in the absence of plOl. Fully myristoylated ARF1 and 
ARF6 in the presence of GTPyS were both capable of stimulating the production 
of PIP3 up to 153 ± 8% (p=0.0023/n=3) and 157 ± 20 (p=0.046/n=3) respectively 
after 10 minutes. When pllOy was included in the mixture, a further increase was 
registered up to 213 ± 16% and 239 ± 12% (p<0.0023/n=3) respectively. This 
increment was only seen in the presence of GTPyS, for in its absence there were 
no significant differences. There was also a small increase when 
nonmyristoylated ARF1,127 ± 6% and ARF6,146 ±11% were used (p=0.012/n=3). 
However, once more this effect was only observed in the absence of GTPyS. In 
the case of the N-terminal truncated A17ARF1, PIP3 levels rose to 128 ± 8 without 
GTPyS (p<0.022/n=3) and to 137 ± 13% in its presence (p=0.043/n=3).
As expected, the PIP2 graph reflects the raised levels of the 
polyphosphoinositide after readdition of both fully myristoylated ARF1 and 
ARF6, in the presence of GTPyS, to 135 ± 3% and 214 ± 9% respectively 
(p<0.002/n=3). Curiously, the amount of the bisphosphoinositide was also 
influenced by pllOy when myristoylated ARF proteins exclusively in 
combination with GTPyS were present, further rising to 192 ± 20% (p=0.001/n=3) 
and 276 ± 20% (p=0.0009/n=3). This could point at an activation of PI(4)P5K by 
collaboration of both PIP3 lipids and GTP-loaded ARFs, conceivably through 
increased ARF-GEFs activation. It was again intriguing to see that 
nonmyristoylated ARF1, 117 ± 1%, and ARF6, 126 ± 3% (p<0.0006/n=3), were 
capable of slightly increasing the levels of PIP2 in the absence of GTPyS, an 
increment that was abolished in the presence of the nucleotide. A17ARF1 had no 
effect on the levels of PIP2.
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Brefeldin A Inhibits the Migration of Neutrophils in 
Response to fMLP
Another approach to examine whether ARF proteins have a real 
involvement in the control of pllOy in a more biological context was pursued by 
trying to disrupt indirectly the performance of ARF in a process dependent on 
PI3Ky. One such process is the migration of neutrophils towards a source of the 
tripeptide N-formyl-Methionyl-Leucyl-Phenylalanine (fMLP) where pllOy is 
known to be a key player (Rickert et al., 2000). For this, the effect of brefeldin A, a 
known inhibitor of most of the so called "Big ARF-GEFs" (Donaldson and 
Jackson, 2000), was tested side-by-side with wortmannin, a extensively used 
PI3K inhibitor. The experimental approach allowed quantification of the relative 
migration of neutrophils situated in an upper chamber, separated by a cellulose 
nitrate filter from a lower chamber where the source of fMLP was located. In an 
attempt to reach the source of bacterial peptide, neutrophils migrated towards it, 
becoming embedded inside the filter at different depths. Counting all cells that 
had progressed past a given migration depth (20 pm from the top surface of the 
filter) indicated the degree of migration thus assaying normal chemotaxis and 
the disruption caused by the compounds mentioned. Figure 6.10 illustrates how 
the inclusion of the source of fMLP (10 nM) in the bottom chamber increased the 
migration of cells by 49.3 ± 2.9% and that this was insensitive to the presence of 
dilute DMSO (p<0.01/n=3), the solvent vehicle used for drug additions. That 
value can be considered as the amount of neutrophils attracted by the peptide, 
rather than by randomised movement. When wortmannin was included in the 
upper chamber, the number of cells embedded deep in the filter was diminished 
to values closer to control, 111 ± 8.6%, which means an elimination of migration
209
Regulation of P B K pllO yby ARF Proteins
160 - |
DMSO b - t t t
C ontrol fMLP
Figure 6 .1 0 Effect of different com pounds in the migration of neutrophils towards an 
fMLP source.
.Neutrophils w ere  ex tracted  and introduced in the  top  com partm ent of a tw o-cham ber container 
w here the  tw o  cham bers w ere  separated  by a sem iperm eable m em brane. Neutrophils in the  top  
cham ber w ere  left to  migrate random ly (Control) o r after addition of fMLP peptide in the  bottom
cham ber (fMLP) which should a ttract them  tow ards the m em brane and penetrate  it to  different
degrees. Different com pounds w ere  te sted  in their ability to  hinder the directional migration tow ards 
the  stimulus, namely, brefeldin A, wortm annin, butano-1 -ol o r butan-2-ol, by their addition in the top  
cham ber. Controls with DMSO in th e  bo ttom  (b) o r top  (t) cham ber w ere used to  reject any influence 
of this com pound in th e  migration, as brefeldin A and wortmannin are diluted in this solvent. After X 
minutes, th e  m em brane was ex tracted , washed and the am ount of neutrophils inserted into the
m em brane w ere  counted  across 6 different optical fields and averaged.
Data shown are m ean ± S.E.M. of 3 separate experim ents within which m easurem ents w ere  m ade with 
6 different samples. The statistical significance of the  data was evaluated using Student’s t test.
towards fMLP (p=0.014/n=3). When Brefeldin A was used, migration was 
eliminated as effectively as with wortmannin, down to 101 ± 6% (p=0.002/n=3).
For comparison, PLD-dependent PA-production was inhibited (but not 
eliminated) with dilute primary aliphatic alcohol butan-l-ol in order to assess the 
involvement of the phospholipase in the process. The secondary alcohol 
butan-2-ol was used as a control as it does not participate in the
210
Regulation o fP I3K pllO yby ARF Proteins
transphosphatidylation reaction but it can give an idea of the general effect of the 
presence of alcohol in the assay. A reduction was also observed; however, it was 
caused by both types of alcohol, therefore the effect was not exclusively caused 
by disruption of the activity of PLD but certainly includes a component due to 
more general toxicity.
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6.3 DISCUSSION
The main focus of this chapter has been to establish and characterise the 
novel activation of one of the isoforms of Class I PI3K, PI3Ky, by small G proteins 
of the ARF family.
PI3Ks have long been known to be regulated by several members of the 
Ras superfamily of small G proteins, as well as by Gpy subunits of heterotrimeric 
G proteins. GTP-loaded Ras, but not GDP-Ras, interacts with class LA PI3Ks and 
famesylation of Ras at C l 86 is crucial for PI3Ka activation. Ras interacts with the 
catalytic subunit p i 10, although only PI3Ka is demonstrated to be activated by 
this interaction (Rodriguez-Viciana et al., 1994,1996) although the sole member of 
Class IB, pllOy (Pacold et al., 2000; Suire et al., 2002) also interacts with Ras. 
Alternatively, Ras and possibly other small G proteins, can bind to the p85 
regulatory subunit and activate PI3K in exclusive conjunction with 
phosphotyrosine-peptides (Jimenez et al., 2002; Chan et al., 2002).
Rac and Cdc42, two of the various members of the Rho family of small 
GTPases, are capable of interacting and activating PI3Ka (Tolias et al, 1995; 
Bokoch et al., 1996) and can bind the Rho-GAP homology domain of p85 (Zheng 
et al., 1994). PI3Ks become activated downstream of Rac (Genot et al, 2000; 
Rickert et al, 2000), despite the fact that these small G proteins, and others such 
as ADP-ribosylation factors, appear to function downstream of PI3K as well. 
Obviously, these seeming contradictions might be reconciled if these G proteins 
and the kinase are part of a positive feedback loop. There is evidence showing 
that PI3K can activate Rac, and other small G proteins, indirectly via PI(3,4,5)P3- 
sensitive GEFs (Welch et al, 2003), thus the activation of PI3K by Rho GTPases is 
considered to be generally the consequence of a positive feedback loop that
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results in an enhanced production of PI(3,4,5)P3 at particular sites on the 
membrane. This would be the case at the leading edge of migrating neutrophils 
(Weiner et al., 2002; Srinivasan et al., 2003).
Additionally, PI3Kp has also been found to be activated by Rab5, one of 
the members of the extensive Rab family, which binds to the catalytic subunit 
pllOp (Kurosu et al, 2001).
Finally, both pllOy (Stoyanov et al., 1995; Stephens et al., 1997; Leopoldt et 
al., 1998) and pllOp (Kurosu et al., 1997; Katada et al., 1999; Maier et al., 1999, 
2000) can also be activated by Gpy subunits of heterotrimeric G proteins liberated 
upon activation of G-protein coupled receptors (GPCRs). In the case of pllOp, the 
presence of p85 is not necessary, although its presence in combination with the 
binding of phospho-tyrosine peptides enhances the activation. In the case of 
pllOy, plOl is not necessary either for its activation by Gpy, albeit its presence 
seems to sensitise PI3Ky to phosphorylate PI(4,5)P2 rather than PI (Maier et al.,
1999).
The appearance of a radioactive PIP3 spot in the TLC during the HL60 
reconstitution assays, which appeared to vary in response to the presence of ARF 
proteins, led to an in-depth study of the causes of this variation. Class I PI3Ks, 
the only enzymes thought to be responsible for the generation of this second 
messenger in vivo (Carpenter and Cantley, 1990) are cytosolic proteins that are 
recruited to membranes upon stimulation (Klippel et al., 1996). Hence, 
permeabilisation of unstimulated cells should have depleted the cell content of at 
least part of the PI3Ks; as previously reported. After 10 minutes approximately 
75% of the cellular PI3Ky-content leaks out of permeabilised HL60 cells (Kular et 
al., 1997), but even after longer permeabilisation there is some remaining kinase
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within the cells that does not leak out. I assume that the process is similar with 
the remaining Class IA isoforms that are also present in this particular cell type 
and which are also cytosolic. Thus, there would still be enough PI3Ks to generate 
PIP3. As seen in Figure 6.1, the increase in the levels of PIP3 was transient and 
decreased after approximately 20 minutes of readdition of the different proteins 
however the change was not as prominent as that seen with the levels of PIP2. 
This is probably foreseeable as no stimulus had been given to the cells in order to 
fully activate PI3K enzymes, and no inhibition of PIP3-phosphatases, such as 
PTEN or SHIP, had been implemented either. Therefore the limited activation 
registered was probably caused by the few remaining PI3K enzymes that could 
become activated in the absence of stimulation and whose product became 
degraded after a few minutes.
Assessment of the in vitro activation of the diverse isoforms of Class IPI3K 
by ARF proteins could help establish direct activation of the kinase. Class LA 
enzymes were tested as heterodimers, i.e. the catalytic subunit pllOa/p/5 
together with the regulatory subunit p85a all immobilised on beads. This is 
essential as the catalytic subunits are extremely unstable in the absence of its 
regulatory adaptor (unlike pllOy, see below). Class I enzymes a  and 6 were not 
affected by the presence of ARF proteins. However, the p isoform was partially 
inhibited by the presence of both ARFs.
It is conceivable that an effect of ARF on the other isoforms of Class IA 
PI3Ks is still plausible. It has been demonstrated that p85 inhibits p i 10 when 
associated (Yu et al., 1998). This inhibition is released when p85 binds, via its SH2 
domain, tyrosine-phosphorylated proteins (Jimenez et al., 2002) and may be 
enhanced by phosphorylation at Y688 (Chan et al., 2002). Further investigation of
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the effect of ARF proteins should include tyrosine-phosphorylated proteins or 
peptides to which p85 could bind, after elution from the recovery beads to fully 
assess this possible interaction as it happens.
On the other hand, when pllOy was tested separately from its regulatory 
subunit p i01, a potent increase in the phosphorylation of PI was observed. 
Consequently, my main efforts were centred in the characterisation of this 
interaction. Later I tested the effect of ARF proteins in the plOl/pllOy 
heterodimer with the intention of making a comparative analysis of its influence 
in relation to Class LA enzymes. Strikingly, not only did ARF not stimulate the 
activity of the PI3Ky heterodimer but it strongly suppressed it. It is interesting 
how both heterodimeric PI3Kp and PI3Ky reacted in a similar manner to the 
presence of ARF. PI3KP is the only isoform of Class IA PI3Ks that can be 
activated by Gpy subunits of heterotrimeric G proteins in the same way as PI3Ky. 
Class IA enzymes become activated by the binding of p85 to growth factor 
receptors or associated proteins that become phosphorylated upon stimulation, 
at pYxxM motifs. The p isoform however, can also be activated by Gpy subunits 
released upon activation of GPCRs (which is the typical activation mechanism of 
PI3Ky) and this such activation is further enhanced by the presence of phospho- 
tyrosine peptides derived from RTK stimulation in the case of PI3Kp (Kurosu et 
al., 1997; Katada et al., 1999; Maier et al., 1999, 2000). It is intriguing to see that the 
two isoforms that can be regulated by heterotrimeric G proteins can both be 
inhibited by ARF when in their heterodimeric form. This further raises the 
question on whether monomeric pllOp may also be activated by ARF, and if so, 
whether it has any biological relevance. Again further investigations of ARF 
effects on these kinases may benefit from the inclusion of Gpy subunits in the 
assay.
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Although it became clear from the in vitro pllOy activation assays that the 
catalytic subunit could be strongly stimulated by ARF, the fact that this 
activation was independent of the nucleotide-bound state of ARF was not at all 
expected. Variations in the temperature and duration of the preincubation, in 
the temperature of incubation and the concentration of GTPyS, improved GTPyS- 
loading or the use of fully nucleotide-loaded nonmyristoylated ARF proteins, 
proved to be moderately helpful, but in no instance definitive proof that GTP- 
ARF could activate pllOy significantly better than GDP-ARF. There is one report 
by Rubio et al. (1999) showing that post-translationally, i.e. famesylated, 
modified Ras associates with pllOy independent of GTP, whereas non- 
famesylated Ras only does it upon GTP binding; nevertheless, GTP-Ras forms a 
much tighter complex with pllOy. This behaviour is not shared by p i 10a, which 
only binds to GTP-Ras. Despite these data, there is strong evidence showing that 
catalytic activation of pllOy is exclusively GTP-Ras dependent (Pacold et al., 
2000; Suire et al., 2002). It is possible that the observed GTP-independent 
activation by ARF is an artefactual consequence of using lipid vesicles containing 
excessive amounts of PI. Kirsch et al. (2001) presented strong evidence that 
membrane tethering of pllOy may involve association with anionic 
phospholipids and Krugmann et al., (2002) in in vitro conditions, showed that 
most of PI3Ky is already associated with lipid vesicles in the absence of Gpy. 
These reports taken together could mean that pllOy, in the exclusive presence of 
PI, is already vesicle-bound and therefore the GTP-dependent association to 
membranes characteristic of ARF would have been overcome by its binding to 
the already lipid-associated pllOy. In a way, it would be as if the roles of the two 
proteins would have been inverted. Since either GDP-ARF or GTP-ARF provokes 
a clear increase in the activity of pllOy, an allosteric activation of the enzyme
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ARFs. This seems to be a recurring behaviour of nonmyristoylated forms of 
ARF. When nonmyristoylated (not preloaded) ARFs were used in the 
permeabilisation cell reconstitution assay with pllOy, there was always a small 
increase in the levels of PIP3 in the absence of GTPyS or pllOy, and also in the 
levels of PIP2; this effect was suppressed upon addition of GTPyS. In chapter 3, 
Figures 4.14 and 4.17 also show, although more moderately, how the effect of 
nonmyristoylated ARF proteins on PI(4)P5K in the absence of GTPyS is always 
relatively higher than in its presence. These different assays highlight once again 
a peculiar characteristic of ARF proteins out of which a conclusion must be 
drawn: the use of nonmyristoylated or partially myristoylated preparations of 
the recombinant protein should be avoided due to the complicated and often 
opposing effects upon GDP- or GTP-binding. In biological terms, it is 
unnecessary and probably irrelevant to analyse the consequences of this odd 
behaviour in depth, as nonmyristoylated forms of this small GTPase do not occur 
in living cells. Another conclusion that can be extracted from this experiment is 
that in the case of pllOy there was not a marked preference for any of the two 
isoforms of ARF, as was already apparent from the other in vitro and 
reconstitution assays. This lack of preference throws into stark relief the 
selectivity of PI(4)P5K for ARF6 (Chapter 3, Figure 4.15), as they are both parallel 
activation assays of phosphoinositide kinases using the same recombinant ARF 
proteins.
Finally, I attempted to imply the involvement of these small G proteins in 
one of the most studied cell biological processes where PI3Ky is involved, the 
migration of neutrophils. Leukocytes are capable of detectings gradients of 
chemoattractant, allowing them to move towards injured or inflamed tissue.
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would be taking place as a consequence of their association, rather than the 
recruitment of the lipid kinase to membranes. In line with this, famesylated Ras 
is thought to promote a conformational change in the structure of pllOy upon 
association and this is thought to allosterically activate the enzyme. Indeed, 
structural studies reveal a direct interaction of Ras with the COOH-terminal part 
of the catalytic domain of pllOy and a difference in the conformation of the 
catalytic domain between pllOy and Ras-pllOy (Pacold et al., 2000). In the 
permeabilised-cell system however, it was obvious that PIP3 generation, both in 
the presence and absence of reintroduced pllOy, was conditional to the presence 
of GTPyS. Hence in cells, the basal recruitment of pllOy to membranes may be 
minimal, and the activation by ARF dependent on its GTP-bound state and 
consequent membrane relocation of the two proteins. What cannot be inferred 
from the results in this system is whether ARF is solely responsible for the 
increased pllOy membrane relocation, as supposed from the higher yield of PIP3 
obtained, or whether another parallel mechanism is facilitating the colocalisation 
of the two proteins on the membrane. GTPyS on its own does not stimulate a 
significant increase in PI(3,4,5)P3 levels unless accompanied by myristoylated 
ARF, therefore the activation of Gpy subunits by readdition of GTPyS is not 
sufficient to activate pllOy. Ras does not drive membrane translocation of PI3Ky 
either in vivo or in vitro (Suire et al., 2002). This might be the case with ARF as 
well, although important differences in the functional behaviours of these two 
small G proteins could allow for this mechanism.
The use of fully GDP- or GppNHp-loaded nonmyristoylated ARFs did not 
reveal the GTP-dependent activation of pllOy. In accordance with effects on 
PI(4)P5K, but in an even more pronounced manner, GDP-loaded ARFs 
stimulated the activity of pllOy almost twice as potently as GppNHp-loaded
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Neutrophilic leukocytes orient their polarity in response to such a gradient and 
migrate in the right direction up the concentration gradient. Chemoattractants 
such as fMLP stimulate GPCRs, which upon activation of a heterotrimeric Gi 
protein, release the Gpy subunit. Amongst many downstream effectors, which 
include Rho GTPases, MAP kinases, PKC£, cytosolic tyrosine kinases and cPLA2, 
there is a key role for PI3Ks. PI3K inhibitors reduce chemotaxis of four types of 
leukocytes, neutrophils, macrophages, T cells and natural killer cells (Rickert et 
al, 2000). Use of PBKy7 mice has revealed that the chemotaxis of neutrophils is 
severely impaired in the absence of PI3Ky, both in vitro and in vivo (Li et al, 2000; 
Sasaki et al, 2000; Hirsch et al., 2000; Hannigan et al., 2002). However, little effect 
is observed on random movement of these cells suggesting that PI3Ky regulates 
chemotaxis primarily by controlling the direction of cell migration and the 
intracellular colocalisation of Akt and F-actin to the leading edge (Hannigan et 
al., 2002). In neutrophils, PI3K activity is required for attractants to activate two 
GTPases directly responsible for cytoskeletal changes leading to cell movement, 
Rac and Cdc42 (Benard et al., 1999). Asymmetric accumulation of PI(3,4,5)P3 and 
actin at the leading edge, with the consequent formation of pseudopods, depends 
upon a positive feedback loop in which accumulation of the lipid activates Rho 
GTPases, whereas activated Rho GTPases and (probably) polymerised actin in 
turn increase accumulation of the lipid (Wang et al., 2002; Weiner et al., 2002).
Recognising that some ARF-GEFs can be inhibited by Brefeldin A (BFA) 
then tbis reagent can indicate the involvement of ARF proteins in the migration 
process. It is a limited result, however, as BFA exclusively inhibits the BIG family 
of ARF-GEFs (with the exception of GBF1). It does not affect the function of other 
ARF-GEFs from the Cytohesin family or others, which are thought to be located 
at the plasma membrane, as opposed to the BIG GEFs which are believed to be
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Golgi-based (Donaldson and Jackson, 2000). To my knowledge, there is no 
available information on the location of these big ARF-GEFs in neutrophils.
In spite of these limitations, directional migration of neutrophils can be 
impaired by the use of BFA to the same extent as wortmannin. This would imply 
that if inhibition of the nucleotide-exchange reaction of ARF by ARF-GEFs and 
hence its activation provokes an arrest in the directional migration of these 
leukocytes, ARF proteins must be involved in the control of some aspect of the 
process. ARF might have a very specific function, as Rac and Cdc42 have 
(Srinivasan, 2003), and the coordinated activation and regulation of all these 
different GTPases will translate in the chemotactic movement of the cell. This 
assay might help to reveal the role of a completely disregarded albeit vital group 
of small G proteins involved in vesicle trafficking and actin regulation, in 
processes such as leukocyte chemotaxis.
There is previous evidence of ARF proteins being involved in motility of 
cells. For instance, ARF6 and its exchange factor ARNO have been implicated in 
epithelial cell scattering. Wounding or cell stimulation by HGF (scatter factor) 
triggers the activation of the ARF-GEF ARNO, resulting in the activation of both 
ARF and Rac (Turner and Brown, 2001). In other cases, ARF6 has been 
implicated in the formation of lamallipodia-like membrane protrusions, possibly 
through the ability of ARF6 to facilitate recruitment of active Rac to the plasma 
membrane (Radhakrishna et al, 1999; Boshans et al, 2000) and in other cases 
independently of Rac (Honda et al, 1999). In macrophages, intact ARF6 function 
is required for coupling activated Rac to one of several effector pathways and 
suggests that a principal function of ARF6 is to coordinate Rac activation with 
plasma membrane-based protrusive events (Zhang Q. et al, 1999). Expression of
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a dominant negative mutant of ARF6 in HeLa cells has been shown to inhibit cell 
spreading (Song et al., 1998).
From this set of experiments it can be deduced that ARF proteins could be 
directly involved in the regulation of the activity of at least PI3Ky. This 
interaction seems to be restricted to the monomeric form of the enzyme. If 
proven to take place in vivo, ARF could conceivably be responsible for one of the 
two distinctive mechanisms for pllOy-activation that may occur in cells.
One would be the classic sequence of events: activation of a GPCR, GTP- 
loading of Ga and dissociation of Gpy, recruitment of plOl/pllOy via binding of 
the complex to Gpy (primarily through plOl) and enhanced production of 
PI(3,4,5)P3.
As already noted, plOl is responsible for the recruitment of pllOy to the 
plasma membrane upon stimulation, which is equivalent to the function of p85 
in Class IA enzymes. Brock and colleagues (2003) have shown that pllOy is not 
capable of binding to membranes unless plOl binds first to it and consequently 
brings it to the plasma membrane where it can be activated by Gpy subunits and 
colocalise with its substrate. Gpy subunits by themselves are not capable of 
recruiting pllOy probably because their interaction is weak, as opposed to that of 
GPy and p i 01 (Stephens et al., 1997; Krugmann et ah, 1999; Maier et al., 1999). 
They also showed that by mutating pllOy and including, for instance, an 
isoprenylation signal in its sequence, they could relocate the otherwise cytosolic 
monomeric pllOy to membranes where it is activated by Gpy, even in the absence 
of p i01. What is clear then is that forcing membrane localisation is sufficient to 
activate this enzyme but it is not clear how biologically relevant this is. Does 
pllOy occur in cells in the absence of plOl? In the case of Class IA enzymes, p85
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stabilises the catalytic subunit (Yu et al., 1998) and so it is assumed that Class IA 
p i 10 subunits are only found together with their regulatory pairs. Conversely, 
pllOy seems to also occur in the absence of its regulatory counterpart (Baier et al,
1999), and in fact pllOy is stable monomerically in cells whereas plOl is not 
(unless pllOy is present) and seems to be degraded rapidly (Brock et al, 2003). 
Taken together, these data could grant the possibility of the existence of pllOy as 
a monomer, even if only transiently, and that it would be capable of functioning 
in cells apart from its regulatory subunit. This might provide an alternative 
mechanism of recruiting the catalytic subunit to membranes where its substrate 
is found. Indeed, there are reports that point at the downstream regulation of 
GPCR-dependent signal transduction pathways in cells by monomeric pllOy 
(Lopez-Ilasaca et al., 1997, 1998; Bondeva et al., 1998; Murga et al., 1998; Baier et 
al, 1999).
The second mechanism would therefore be the recruitment of pllOy 
independently of p i 01. Different mechanisms can be envisaged. As previously 
mentioned, in vitro evidence points at a possible anionic lipid-dependent 
association of pllOy to membranes, especially PI(4,5)P2, PA and PS through a 
phospholipid binding domain (Kirsch et al, 2001). Conversely, like all other 
PI3Ks, pllOy binds and is directly activated by GTP-bound Ras (Pacold et al,
2000). GTP-Ras cannot recruit pllOy to membranes and binding of the enzyme to 
lipids seems to be an in vitro mechanism not reported in vivo and not observed 
when pllOy is overexpressed. As a result these two mechanisms could assist but 
not fully explain p i01-independent pllOy-recruitment. The activation of ARF 
proteins could represent a additional means of tethering pllOy to the plasma 
membrane through direct binding and catalytic activation of the monomeric lipid 
kinase, although this would only be part of the mechanism of ARF activation.
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The cellular control of the performance of ARF proteins is tightly 
dependent on PI3Ks and their lipid products. Several ARF-GEFs and ARF-GAPs 
possess PH domains that bind to PI(3,4,5)P3, as well as other 
polyphosphoinositides such as PI(3,4)P2 or PI(4,5)P2, or phospholipids such as 
PA (Randazzo et al, 2000). In many cases but not all, it has been demonstrated 
that the activation of ARF proteins via their GEF is dependent on PI3K activity 
(Klarlund et al., 1998; Langille et al., 1999; Venkateswarlu and Cullen, 2000; 
Bourgoin et al, 2002). Also ARF inactivation is sensitive to PI3K activity (Vitale 
et al, 2000; Miura et al, 2002; Krugmann et al, 2002; Venkateswarlu et al, 2004). 
Indeed, readdition of pllOy together with ARF proteins and GTPyS into 
permeabilised HL60 cells caused a clear increase in the levels of PIP2 as well as a 
rise in PIP3. This is a clear demonstration of an improvement in the performance 
of the reintroduced ARF proteins conceivably through the activation of ARF- 
GEFs via association with the newly sythesised PIP3. This cascade of events 
results, in all probability, in a better activation of PI(4)P5Ks, amongst other ARF 
effectors, and the consequent boost in PI(4,5)P2 generation.
In parallel to what happens with GEFs for the Rho family of small G 
proteins, where disassociation of Gpy subunits provokes their activation through 
PI(3,4,5)P3 produced by PI3Ky, tyrosine kinase-dependent phosphorylation of the 
GEFs or through downstream activation of Class I PI3K enzymes giving a 
positive feedback loop that further increases the levels of PI(3,4,5)P3 produced, so 
it could happen with ARF-GEFs.
In conclusion, even though still unclear and with abundant questions and 
paradoxes to answer, it seems likely that ARF proteins are directly involved in 
PI3K metabolism. Extensive work needs to be done to clarify the remaining
223
Regulation ofP I3K pllO yby ARF Proteins
questions and to assign correct functions and interrelation roles to these group of 
small G proteins within the already extremely intricate PI3K-metabolism field. It 
is striking that the involvement of these GTPases has been overlooked for so long 
when they are so closely related, functionally and metabolically, to all other 
constituents of the PI3K signalling cascades.
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The principal theme of this thesis has been the study of the regulation of 
two of the enzymes involved in the synthesis of polyphosphoinositides, namely, 
Type I PI(4)P5K and consequently its product PI(4,5)P2, and a Class IPI3K and its 
product PI(3,4,5)P3. More precisely, I have attempted to characterise the influence 
of members of the ADP-ribosylation factor family of small G proteins, PKC and 
certain lipids on these kinases. Initially, an in-depth study of the preference of 
Type I PI(4)P5K isoforms for different isoforms of ARFs, the need for post- 
translational modification of the GTPases and a direct proof of protein-protein 
interaction was attempted. For this matter, in vitro, permeabilisation/ 
reconstitution in HL60 cells and direct protein-protein interaction pull-down 
assays were used to try to establish a strong basis from which to draw 
conclusions by using diverse but complimentary techniques. Furthermore, based 
on a bioinformatic analysis of the sequence of Type I PI(4)P5K and the prediction 
of the existence of a potential phosphorylation site for cPKCs, detection of such 
protein-modifying reactions in vitro was attempted but failed to provide 
conclusive results. Nonetheless, during the course of these experiments I 
discovered the overlooked stimulation of PI(4)P5K-activity caused by an 
important second messenger, diacylglycerol. Finally and completely accidentally, 
evidence of a possible novel control mechanism of PI(3,4,5)P3-generation was 
found and further characterisation was attempted. This chapter will summarise 
the new findings, including their originality, and discuss their implications and 
contributions to the overall picture of polyphosphoinositide metabolism.
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The data presented in this thesis indeed confirmed the well-established 
view that N-terminal myristoylation of ARF proteins plays a crucial role in ARF- 
function. More accurately, it demonstrates the requirement for this post- 
translational modification for the correct membrane-recruitment of the GTPase 
together with its effectors and subsequent stimulation on the activity of these 
enzymes. With the apparent exception of the plasma-membrane located isoform 
(murine) PI(4)P5K ip, which seemed to be less strict in its necessity for this lipid- 
modification and even GTP-dependent activation, solely in combination with 
ARF6, the control of all other isoforms of this particular lipid kinase by ARF were 
absolutely dependent on the presence of the myristate group. Likewise, the 
activation of Class IB PI3K as deduced from the permeabilised-cell assays, was 
also contingent on the presence of the N-terminal myristate.
Even more remarkable is the constant effect of nonmyristoylated forms of 
the protein under some of the conditions regarding their nucleotide-dependent 
activation. Recurrently, nonmyristoylated ARF proteins seemed to cause 
stimulation on its effector proteins in the absence of GTP to a higher extent than 
in conjunction with the nucleotide. This behaviour, as well as unpredicted, is 
usually thought to be completely unproductive in the normal function of ARF 
proteins. However, the effect was seen in vitro exclusively at high concentrations 
of ARF and at 37°C, and at more standard physiological concentrations in 
permeabilised cells, with both lipid kinases under study. Moreover, in biological 
terms, this scenario is artefactual as ARF proteins are always myristoylated. 
However, it is an extremely important insight that needs to be considered when 
judging or reviewing the information obtained in all of those studies that 
routinely use partially myristoylated populations of ARFs.
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Furthermore, the use of fully-myristoylated ARFs made it possible to 
show a clear-cut difference between ARF6 and ARF1 in PI(4)P5K regulation. This 
is the first time a rigorous side-by-side assessment of the ARF isoform selectivity 
of PI(4)P5Ks has been achieved and is the direct result of avoiding partially 
myristoylated preparations of the GTPase. A wide range of approaches was used 
throughout this thesis in order to allow the evaluation of potential artefacts e.g. 
differences in the efficiency of GTP-loading or membrane-tethering as causal 
determinants of the improved activation of PI(4)P5K by ARF6 versus ARF1. As a 
result this investigation conclusively points to this isoform as the favoured 
activator of PI(4)P5K. Further support for this preference comes from the 
comparative use of the same fully-myristoylated ARF isoforms in the activation 
of pllOy in this same thesis and by studies of PLD by others. I found no 
significant preference between ARFs 1 and 6 for pllOy and in additional studies 
carried out in our lab on PLD (Ha, 2003), conversely it was established that ARF1 
was the preferred activator using the same or identical preparation of protein.
The only problematic data was thrown-up while assessing the protein- 
protein interaction between PI(4)P5K and the two ARFs 1 and 6 along with their 
mutants. In this case, the preference for ARF6 was suppressed, and in activity 
terms it was inverted. Due to the more extensive persistent preference for ARF6 
in all other approaches, including cell-free and cell-based assays which could be 
considered to be close to in vivo conditions, it seems wise to assume that in the 
case of the coprecipitation assay the discrepancy is an artefactual consequence of 
the overexpression system utilised to determine the existence of interaction, 
and/or the use of mutants. Further experimentation using a co-expression system 
(which was attempted but with no success due to technical difficulties) or co­
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precipitation of endogenous proteins should help clarify this paradox and 
perhaps reveal an interaction more in accord with the rest of data.
Another original finding presented in this thesis is the existence of 
activation of PI(4)P5Ks by diacylglycerol. Although this discovery might seem to 
be of little immediate significance, for it might just be yet another lipid of the 
many that influence the activity of a wide range of enzymes in vitro, it must be 
remembered that DAG is generated by the direct degradation of PI(4,5)P2. 
Besides, much work (and much presumption) has been made on the activation of 
this enzyme by an extremely closely related lipid, phosphatidic acid. This 
discovery should give plenty of reasons to rethink and redraw the pathways and 
interplay diagrams that define the control of the metabolism of this 
polyphosphoinositide and the multiple functions associated with it. 
Consequently, the results presented in many reports where PA is thought to be 
the direct activator of PI(4)P5K and thus its presence is used to explain certain 
behaviours and activities, need to also be reassessed. This finding situates DAG 
alongside PA in the control of the activation of PI(4)P5K, allowing for an even 
more powerful and straightforward activating machinery, as it elevates the 
activation of PI(4)P5K from being downstream of PLD (which is generally 
downstream of PLC) to being directly downstream of PLC as well. This 
activation by DAG is very much in line with standard, established biochemistry 
in that it is an example of product feedback, a well-demonstrated principle. 
Together with the confimed existence of a mechanism of activation of PI(4)P5K 
upon PKC activation, once again downstream of PLC activity, offers the 
possibility of strong collaborative reinforcement as part of a precise and potent 
regulatory mechanism. The demonstration of the existence of this dual, mutually
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supportive feedback mechanism (direct activation by DAG and indirect via PKC) 
in living cells will be worth verifying but probably very difficult to demonstrate, 
because of the intricate interrelations of both PI(4)P5K and DAG with other 
enzymes and lipids, making it hard to isolate this process with certainty from the 
surrounding influences.
At the same time, exhaustive exploration of differences in the in vitro 
activation of PI(4)P5K by different lipids during this thesis calls for the careful 
consideration of conclusions drawn from these type of experiments using lipid 
metabolising enzymes, as factors such as the precise composition of substrate 
vesicles, which include the enclosure of carrier lipids and the molar ratios in use, 
the nature of the side chains of the lipids under study, the inclusion of detergents 
and the origin of the enzyme, can all alter the result and lead to divergent 
inferences unless careful comparative consideration of all these variables is 
undertaken.
Finally the striking novel discovery that ARF proteins could activate a 
specific PI3K (or inhibit both the P and y isoforms in the presence of their 
regulatory subunits) was made completely fortuitously. ARF proteins have 
already been shown to activate some PI4Ks and PI(4)P5Ks, thus controlling all 
the previous steps necessary for the ultimate generation of the second messenger 
PI(3,4,5)P3 under the control of Class I PI3Ks. Hence, the possibility of at least 
part of the PI(3,4,5)P3-production being subject to ARF-regulation does not sound 
outlandish. Moreover, since the activity of ARF seems to be closely linked to the 
presence of this polyphosphoinositide through its GEFs, and as seen in the 
permeabilised-cell assays its own presence not only reinforces its generation in
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the presence of ARF but also that of its precursor PI(4,5)P2, it seems plausible that 
a set of interrelations link all these kinases together with ARF. This way, a 
precise polyphosphoinositide-generating mechanism could be created and hence 
the cell-physiological functions that are PI(3,4,5)P3-dependent can be tightly 
managed and co-ordinated.
Further characterisation of this effect led to the finding that pllOy the only 
isoform of Class I PI3Ks whose activity can be stimulated by the presence of the 
small GTPase. However, it is still possible that other isoforms can also be 
influenced by ARF proteins, as the assay conditions might be optimised in order 
to fully assess the possibility of interaction. In vitro study of the activation of 
pllOy could not establish a difference between GDP- and GTP-loaded ARF, 
although this was probably due to the precise in vitro conditions, as in cell-based 
assays there was a clear preference for GTP analogues. On the other hand, the 
activation of pllOy by ARF was limited to its monomeric state as the presence of 
its regulatory subunit exerted the opposite effect, making ARF-driven 
recruitment of pllOy a conceivable alternative to the well-known plOl- 
dependent tethering of the lipid kinase. However, if other adaptors for pllOy are 
discovered then the effects of ARFs on the new kinase heterodimers will need to 
be evaluated.
An interesting idea is that, ARF-dependent activation of pllOy, 
independent of plOl and therefore Gpy dissociation, could situate monomeric 
PI3Ky downstream of Class I PI3Ks. However, to my knowledge, there is no 
evidence of such an event occurring in cells.
The studies undertaken in this thesis have focused mainly on in vitro 
assessment of the activation of phosphoinositide kinases by different ARF
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proteins and lipids. This is a solid foundation on which to build hypotheses 
regarding ARF regulation of phosphoinositide metabolism. However in 
physiological terms, there are limitations to the scope of these studies. In the case 
of the preference of phosphatidylinositol 4-phosphate 5-kinases for ARF6 over 
ARF1, although a clear biochemical difference has been shown in cell-free and 
broken cell systems, confirmation of this effect in intact cells needs to be 
obtained. Other factors such as the presence of GEFs/GAPs, the lipid composition 
of the membranes in which they act and other effectors and regulators might 
reveal that this natural preference is subject to further controls. In those cases 
where both ARF isoforms coincide spatially and temporally within a region of 
the cell, this preference might have sufficient weight to determine the 
preferential interaction of these isoforms with their different effectors, for 
instance ARF6 acting on PI(4)P5K while ARF1 acts on a different effector such as 
PLD. Alternatively, other factors that control the activity of the lipid kinases 
might overcome this natural preference and determine the real inclination within 
cells. In those cases where these isoforms do not colocalise in specific cellular 
regions, recruitment of the specific isoforms by GEFs or other mechanisms might 
be the real determinant of such activation, allowing for the possibility of ARF1 
acting on PI(4)P5K regardless of its reduced effect if compared with ARF6.
Due to the high complexity of the cell environment, these simplified 
biochemical studies are a necessary first step towards the elucidation of the 
patterns of interaction of these proteins in vivo. Nonetheless, further work needs 
to focus on the confirmation of such natural preferences within cellular systems. 
So is also the case with regards to the activation of PI(4)P5K by DAG or the 
activation of monomeric pllOy by ARF proteins. Strong proofs are difficult to 
obtain in whole cells again because of the complexity of the system and also
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because of redundancy in signalling pathways and so both approaches are 
mutually complimentary. For example biochemical studies can accurately guide 
the creation of effective genetic or pharmacological interventions.
Continuation of the work described here might focus on the following
issues:
Confirmation of the preference of ARF6  over ARF1 on the activation of 
PI(4)P5Ks in cells. For this matter, different approaches could be used such as the 
use of RNAi. Elimination of a specific ARF isoform, such as ARF6 , and 
measurement of the cellular levels of PI(4 ,5 )P2 or the influence of this exclusion in 
processes where ARF and PI(4)P5Ks are known to be involved, such as the 
formation of membrane ruffles or Golgi function, could give an idea of whether 
one isoform can efficiently substitute for the other or whether their cellular roles 
are clearly distinguished as well as which processes depend on which isoforms. 
Additionally, the same could be done with the different PI(4)P5K isoforms and 
combinations of the isoforms of the two proteins. PI(4 ,5 )P2 levels could be 
monitored using radioactive methods or a fluorescent probe, such as a GFP- 
fusion protein with the PH domain of PLC81 which specifically binds PI(4 ,5 )P2.
Another approach would be the use of knockout or knockdown mice 
where the exression of ARFs or PI(4)P5Ks could be eliminated/downregulated in 
order to examine the requirement for these enzymes in ARF1 or ARF6  dependent 
processes. PI(4)P 5-kinase a  and y knockout mice have already been produced 
and may be effective and valuable tools.
Indication of linkage between ARF and pllOy could be studied by 
monitoring the increase in PI(3 ,4 ,5 )P3 generation in living cells when they are 
transfected with constitutively active or dominant negative ARF mutants.
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Preliminary experiments indicate that cotransfection of ARF1(Q71L), pllOy and 
Grpl-PH domain-eGFP fusion protein (a fluorescent marker of PI(3,4,5)P3 
synthesis) produces a profound increase in the fluorescence of the plasma 
membrane.
Permeabilisation assays using cell types where pllOy is absent, such as 
HEK293 cells or other fibroblasts, could clarify whether the increase in PIP3 levels 
registered after re-addition of ARF proteins are solely caused by pllOy activation 
or whether there is any input from the other isoforms.
Interaction studies by coexpression and coprecipitation of PI3Ks and ARF 
proteins in order to demonstrate a direct interaction between the two proteins 
would also be valuable and RNAi of ARF isoforms in cell types where pllOy 
function is well established, such as neutrophil migration or platelet aggregation, 
could help determine whether there is any involvement of ARF proteins in such 
processes.
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